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RÉSlTMÉ 
But: L'hormonothérapie (HT) aux estrogènes, seuls ou combinés aux progestatifs, est 
prescrite aux femmes pour contrôler les symptômes reliés à la ménopause. Puisque l'HT 
augmente le débit sanguin dans les organes non reproducteurs et protège contre 
l'atrophie du tissu cérébral dans certaines régions du cerveau, et que les récepteurs aux 
estrogènes et à la progestérone sont présents dans la rétine chez l'homme, nous avons 
étudié si l'HT améliore le débit sanguin de la rétine et de la tête du nerf optique (TNO), 
et protège la topographie du TNO et la fonction des cellules ganglionnaires (CGs) de la 
rétine chez les femmes ménopausées. De plus, les récepteurs aux estrogènes étant 
présents dans la rétine du rat, nous avons développé un modèle de rate ménopausée afin 
d'évaluer si l'estradiol altère le débit sanguin de la rétine. 
Méthodologie: Soixante-cinq femmes ménopausées d'âges similaires ont été évaluées, 
vingt-neuf n'ont jamais utilisé l'HT (0HT) et trente-six ont utilisé l'HT (+HT) depuis le 
début de leur ménopause. Le débit sanguin de l'artère inféro-temporale de la rétine 
(AITR), et des régions nasales et temporales pérripapillaires a été mesuré dans un œil à 
l'aide du "Canon Laser Blood Flowmeter" et du "Heidelberg Retina Flowmeter". Les 
douze paramètres stéréométriques de la TNO et l'électrorétinogramme évoqué par 
inversion d'un damier (PERG) ont été mesurés à l'aide du "Heidelberg Retina 
Tomograph" et du système VERIS™. Pour le modèle de rate ménopausée, des rates 
matures (Rattus norvegicus) ont subi une ovariectomie et l'implantation sous-cutanée de 
capsules silastic contenant de l'estradiol (EÛ ou placébo. Six semaines plus tard, 
l'indice de capture rétinien (ICR), un indicateur de la perfusion rétinienne, a été mesuré 
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après l'injection d'un traceur radioactif diffusible, le N-1sopropyl-p-[14C]-
iodoamphétamine ([14C]_1MP). L'1CR a été mesuré dans quatre isoptères concentriques 
à chaque quadrant, à l, 2, 3 et 4 mm de distance du centre de la TNO, de la rétine 
montée à plat. 
Résultats: Le groupe +HT a présenté des valeurs significativement plus élevées pour le 
débit sanguin de l'AITR (15.4 ± 3.4 vs 12.5 ± 2.9 !-tL/min, p=0.006) et du volume de 
l'anneau neurorétinien de la région entière de la TNO (0.438 ± 0.136 vs 0.380 ± 0.143 
mm
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, p=0.032), ainsi que pour le volume de l'anneau neurorétinien (0.066 ± 0.041 vs 
0.050 ± 0.030 mm3, p=0.042), de la hauteur de la variation du contour (0.353 ± 0.099 vs 
0.289 ± 0.101 mm, p=O.Oll), de l'épaisseur moyenne (0.l94 ± 0.053 vs 0.167 ± 0.058 
mm, p=0.033) et de la surface (0.238 ± 0.068 vs 0.l98 ± 0.073 mm2, p=0.020) de la 
couche des fibres nerveuses rétiniennes de la région inféro-temporale de la TNO 
comparativement au groupe 0HT. Chez les rates ménopausées, le traitement à l'E2 a 
induit une augmentation significative des 1CRs de 40.6% (p=0.03) pour l'isoptère à 2 
mm, 44.2% (p=0.04) à 3 mm et 31.4% (p=0.04) à 4 mm comparativement aux rates 
contrôles. 
Conclusion: Ces résultats indiquent que l'utilisation de l'HT chez les femmes 
postménopausées est associé à une amélioration du débit sanguin de la rétine, et une 
couche des fibres nerveuses rétiniennes plus épaisse. De plus, le traitement à l'E2 chez 
les rates ovariectomisées a augmenté la perfusion rétinienne. 
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ABSTRACT 
Aim: Postmenopausal honnone therapy (HT) consisting of estrogens alone or combined 
with progestagens, is prescribed to women in order to alleviate postmenopausal 
symptorris. Since HT increases blood flow in non-reproductive organs and prevents 
cerebral tissue atrophy in sorne brain regions, and estrogen and progesterone receptors 
are present in the human retina, we investigated whether HT improves retinal and optic 
nerve head (ONH) blood flow, and protects ONH topography and the function of retinal 
ganglion cells (RGCs) in postmenopausal women. Moreover, since estrogen receptors 
are present in the rat retina, we developed a menopaused ratmodel to assess the effects 
of estradiol on the retinal blood flow. 
Methods: Sixty-five healthy postmenopausal women of similar age were investigated, 
twenty-nine of them who had never used HT (0HT) and thirty-six who were HT users 
(+HT) since their ·'menopause onset. Blood flow of the infero-temporal retinal artery 
(lTRA), both nasal and temporal peripapillary retinal areas, and ONH rim were 
measured in one eye using the Canon Laser Blood Flowmeter and the Heidelberg Retina 
Flowmeter. The 12 standard stereometric parameters Of the ONH and the pattern 
electroretinogram (PERG) were measured using the Heidelberg Retina Tomograph and 
the VERIS ™ system. For the menopaused rat model, mature female rats (Rattus 
norvegicus) were ovariectomized and silastic capsules containing either estradiol (E2) or 
placebo were implanted subcutaneously. Six weeks later, the retinal uptake index (RUI), 
an indicator of the retinal tissue perfusion, was measured following the injection of the 
blood flow tracer N-Isopropyl-p-e 4C]-iodoamphetamine ([14C]-IMP). The RUI was 
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measured in four concentric isopters of aIl quadrants, at 1, 2, 3 and 4 mm away from the 
centre of the ONH, in the whole-mount retina. 
Results: The +HT group presented significantly greater blood flow of the ITRA (15.4 ± 
3.4 vs 12.5 ± 2.9 !-tL/min, p=0.006) and greater rim volume for the entire ONH region 
(0.438 ± 0.136 vs 0.380 ± 0.143 mm3, p=0.032), as weIl as greater rim volume (0.066 ± 
0.041 vs 0.050 ± 0.030 mm3, p=0.042), height variation contour (0.353 ± 0.099 vs 0.289 
± 0.101 mm, p=O.Oll), mean thickness (0.194 ± 0.053 vs 0.167 ± 0.058 mm, p=0.033) 
and cross-sectional area (0.238 ± 0.068 vs 0.198 ± 0.073 mm2, p=0.020) of the retinal 
nerve fiber layer for the infero-temporal region of the ONH compared to those of the 
0HT group. ln the menopaused rat model, E2 treatment significantly induced an 
increase in the RUIs by 40.6% (p=0.03) for the 2 mm isopter, 44.2% (p=0.04) for the 3 
mm isopter and 31.4% (p=0.04) for the 4 mm isopter compared to those in placebo 
animaIs. 
Conclusion: These findings indicate that the use of HT in postmenopausal women was 
associated with improved retinal blood flow and thicker retinal nerve fiber layer. 
Moreover, the E2 treatment in ovariectomized rats was associated with enhanced retinal 
tissue perfusion. 
Keywords: women, menopause, rats, ovariectomy, estrogens, hormonotherapy, blood 
flow, retina, retinal nerve fiber layer, neuroprotection 
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PREFACE 
Menopause is the period corresponding to the pennanent cessation of ovarian foHicular 
activity and subsequent faH in en doge nous estrogens and progesterone production in 
aging women. The average age at menopause is around 50 years. 
Women undergoing menopause experience physiological and metabolic changes that 
may or may not be symptomatic. These changes are translated into vasomotor 
instability (hot flushes, night sweats), urogenital tissue atrophy, vaginal dryness, dry 
skin, bone and collagen loss, and psychological symptoms such as insomnia, depression, 
irritability, lethargy/fatigue and loss of libido. As well, ocular changes occur such as the 
onset of dry eyes (keratoconjunctivitis sicca), senile cataract, presbyopia, ptosis of the 
eyelids, glaucoma and age-related macular degeneration (ARMD). 
Particularly in glaucoma and ARMD, recent epidemiological studies have reported that 
reduced exposure time to endogenous estrogens defined as late menarche, early 
menopause onset and decreasing duration of reproductive year increases the risk in the 
development and progression of glaucoma and ARMD in postmenopausal women. As, 
well, the use of postmenopausal honnone therapy (HT) decreases this risk. Impaired 
ocular blood flow contributes to the etiology and progression of glaucoma and ARMD. 
The apparent protective role of estrogens and HT against glaucoma and ARMD in 
postmenopausal women could result from the vasomotor effect of estrogens by 
providing a better blood flow as well as a protective effect on the optic nerve head 
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(ONH) topography. However, there is no direct evidence that estrogens and HT 
influence the retina and ONH head flow and the ONH topography. 
The research area of this thesis focuses on investigating whether estrogens and HT 
influence the blood flow in the retina and ONH, and the ONH topography. An 
introductory chapter will present the basic knowledge of the eye and histology, anatomy 
of the arterial ocular supply, control of the ocular circulation and the techniques 
employed to measure the ocular circulation. This chapter will also discuss glaucoma 
and ARMD, the estrogen and progesterone hormones and the CUITent knowledge on 
menopause and postmenopausal hormone therapy and their relation to glaucoma and 
ARMD. The second and third chapters will present the aim of two studies designed to 
investigate whether estrogens and HT influence the blood flow in the retina and ONH 
blood, and the ONH topography. An observational study investigates the long-term 
effects of estrogen depletion and the use of HT on retinal and ONH blood flow, and 
ONH topography in a group of healthy postmenopausal women. The second study 
investigates the long-term effect of estrogen depletion and estrogen treatment on the 
retinal tissue perfusion using a radioactive blood flow tracer, the N-Isopropyl-p-[14C]-
iodoamphetamine in a menopausal rat model. A fourth chapter reports the findings of 
these two studies followed by a discussion chapter on the interpretation of these 
findings. 
We hope that this postdoctoral work provides a better understanding of how menopause, 
estrogens and HT play roles in the ocular circulation and optic nerve head topography in 
an attempt to explain the link between the hormonal status of estrogens and progesterone 
27 
throughout a wornan's life and the risk of developing glaucorna and ARMD in the aging 
wornan. 
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1.0 INTRODUCTION 
1.1 The eye 
The eye is the organ of vision. The retina is the photosensitive layer in the innermost 
part of the eye responsible for the conversion of different light energy quanta into 
nervous pulses. Hs externai surface is in contact with the choroid and its internaI surface 
is in contact with the vitreous body (Fig. 1). 
Figure 1: The eye. (From http://www.basiclenses.comiimages/uploadslEye Diagram 
National Eye Institute Refno NEA08.jpg) 
The histology of the retina consists of eleven layers of cells. They are listed as follows 
along the path of the incident light: (Fig. 2): 
1) inner limiting membrane (glial cell fibers separating the retina from the vitreous 
body 
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2) nerve fiber layer (astrocytes and bundles of the retinal ganglion cells (RGCs) axons 
surrounded by neuroglia) 
3) retinal ganglion celllayer (cell nuclei) 
4) inner plexiform (synapses between the bipolar, horizontal and amacrine cells with 
RGCs) 
5) inner nuclear layer (cell nuclei of the bipolar cells, horizontal and amacrine cells) 
6) outer plexiform layer (synapses between the bipolar cells, horizontal and amacrine 
cells with photoreceptors) 
7) outer nuclear layer (cell nuclei of the photoreceptors) 
8) outer limiting membrane (sieve-like plate of the rods and cones) 
9) layer of the rod and cone outer segments 
10) retinal pigmentary epithelium 
Il) 8ruch's membrane (basal membrane separating the retina from the choroids 
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Figure 2: Histology and schematic representation of the retinallayers. (From Lang, GK. 
Ophthalmology. A Poeket Textbook Atlas. Stuttgart, Germany: Georg Thieme Verlag; 
2000:301) 
Ali the nerve fiber layer bundles converge to form the neuroretinal rim of the optic nerve 
head (ONH) (Fig. 3). The cup of the optic disc is a concave region of the optic nerve 
head. The fibers exit the eye through a sieve-like structure called the lamina cribrosa 
and form the optic nerve. 
Cilioretinal 
vessel 
Neuroretinal 
rim 
Optic cup 
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Figure 3: Fundus picture of the optic nerve head and retinal vessels. (From Lang, GK. 
Ophthalmology. A Poeket Textbook Atfas. Stuttgart, Germany: Georg Thieme Verlag; 
2000:360) 
1.2 Arterial supply to the eye 
The ocular circulation is provided by the ophthalmic artery, which is a branch of the 
internai carotid.! The ophthalmic artery enters the orbit of the eye and branches into the 
central retinal artery, two or three posterior ciliary arteries and several anterior ciliary 
arteries (Fig. 4). The central retinal artery enters the optic nerve at approximately 10 
mm behind the globe, then at the exit of the optic nerve head, is divided into four retinal 
vessels, each supplying one of the four quadrants of the retina (Fig. 3). The posterior 
ci liary arteries divide into lOto 20 short posterior ciliary arteries and, as a ruIe, two long 
posterior ciliary arteries.! The short and long posterior ciliary arteries pierce the sciera 
to supply the choroid. The short posterior ciliary arteries pierce the scIera at the 
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posterior pole, while the long posterior ciliary arteries pIerce the sciera toward the 
periphery. The circle of Zinn-Haller represents the scierai penetration of the short 
posterior ciliary arteries organized in a ring fashion around the optic nerve. 1 The outer 
portion of the optic nerve behind the lamina cribrosa is supplied by the pial vessels, 
whereas the inner portion is supplied by branches of the central retinal artery, while 
running within the nerve, and anastomose with the superficial pial vessels (Fig. 5). 
BoNEs. VESSELS. Al'ID NEIlVES 
Figure 4: Gross anatomy of the arterial suppl y to the eye showing the internai carotid 
(17), ophthalmic artery (18), central retinal artery (35), medial posterior ci liary artery 
(38) and short ciliary branches of the lateral posterior ciliary artery (39). (From Zide 
BM, Jelks GW. Bones, vessels and nerves. In Surgical Anatomy of the Orbit. New York, 
USA: Raven Press, 1985: II) 
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Figure 5: Vasculature of the optic nerve head. (From Lang, GK. Ophthalmology. A 
Poeket Textbook Atlas. Stuttgart, Gennany: Georg Thieme Verlag; 2000:362) 
1.2.1 Retinal vessels 
The retinal vessels are distributed within the inner two-third portion of the retina 
including the nerve fiber layer, with the exception of a capillary-free zone within the 
fovea. The fovea is the central region of the retina (diameter 1500 !lm) and has the 
greatest cone density. The foveal avascular zone (F AZ) is within the fovea (500 !lm) 
and comprises the foveola (350 !lm), characterized by the absence of inner retinal layers 
and the presence of cones as the only photoreceptors. The intervening capillaries of the 
retinal vessels are organized in a multilaminate fashion . In the posterior pole, the retinal 
capillaries fonn several layers and are greater in number than in the more peripheral 
retina.2 The peripapillary retina has a superficial layer of fine capillaries. If present, a 
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cilioretinal artery which may be a direct branch of the ciliary or choroidal arteries, 
supplies a variably sized region of the retina, temporal to the optic nerve.2 
1.2.2 Choroid 
The choroid supplies the outer one third portion of the retina incIuding the 
photoreceptors, bipolar cells and RPE.2,3 It extends from the ora serrata anteriorly to the 
optic nerve head posteriorly. Histologically, the choroid consists of three layers layers: 
the outermost layer of large vessels (Haller's layer), the medium vessellayer (Sattler's 
layer) and the inner choriocapillaris layer, which is the capillary layer of the choroid. 
The suprachoroidal space is a virtual space between the choroid and the sciera. The 
outer half of Bruch's membrane can be considered as part of the choroid, whereas its 
inner half can be considered as a part of the retinal pigmentary epithelium. Due to its 
avascular nature, the central fovea depends entire1y on the blood supply provided by the 
choroid. 
1.2.3 Optic N erve 
There are four anatomical regions constituting the optic nerve: 1) the surface layer of the 
nerve fiber layer, 2) the prelaminar region, 3) the lamina cribrosa and 4) the retrolaminar 
region.4 The nerve fiber layer region gets its blood supply from the retinal arterioles. 
The pre1aminar region receives blood supply from the choroid. The lamina cribrosa 
receives its blood supply from the short posterior ciliary arteries, either directly or from 
the circIe of Zinn-Haller formed by the short posterior ciliary arteries. The retrolaminar 
region gets a dual source of blood supply, from the peripheral centripetal vascular bed 
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formed by the pial vessels and from the axial centrifugaI vascular bed derived from 
branches of the central retinal artery (Fig. 5). 
1.2.4 Control of the ocular circulation 
To maintain the functional integrity of the blood flow in the vascular architecture of the 
retina, choroid and optic nerve head, several local and systemic factors regulate the 
ocular circulation. The local factors are the 1) perfusion pressure, 2) endothelium 
activity, and 3) metabolic demand. The systemic factors are the 1) innervations from the 
autonomie nervous system and 2) blood gases. I ,5-12 
1.2.4.1 Perfusion pressure 
The perfusion pressure is the entering force of the blood through the intraocular blood 
vessels. lt is determined by the difference between the two-third mean arterial pressure 
(MAP) (the diastolic pressure + 1/3 of the systemic blood pressure pulse) in the arteries 
entering the eye and the pressure in the veins leaving it. The intraocular pressure (IOP) 
is normally almost identical to the pressure in the veins. Therefore, the ocular perfusion 
pressure (OPP) is calculated using the following equation: 1 
OPP = 2/3 MAP-IOP 
where MAP = Diastolic pressure + 1 /3 (Systolic pressure- Diastolic pressure) 
Consequently, it is expected that a change in IOP or BP cou Id affect the perfusion 
pressure to the eye. However, several studies have shown that the retinal vessel 
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circulation in humans has an autoregulatory property allowing constant blood flow 
regardless of moderate changes in perfusion pressure. 13•14 This is called myogenic 
autoregulation of the perfusion pressure. Myogenic autoregulation is the maintenance of 
consistent blood flow in the presence of altered perfusion pressure. The principle is that 
myocytes sense the transmural pressure, which is the difference in pressure across the 
wall of vessel, i.e. the internaI blood pressure minus the external pressure acting on the 
vessel. 15 In the event that the internaI pressure is raised, the myocytes undergo a 
mechanical stretch and activate their stretch-sensitive non-selective cation channels and 
chloride channels. The resulting ionic currents depolarize the myocytes, which increase 
the open probability of L-type Ca2+ channels leading to the contraction of the arterial 
wall. In ocular circulation, myogenic autoregulation occurs with BP and IOP changes. 
M · 1 . . h . 1 1 16-20 ON2122 d h 'd 23-25 yogemc autoregu ahon occurs m t e retma vesse s, . an c orm . 
There is clinical evidence that points to impaired autoregulation mechanisms in patients 
who suffer of diabetes,26 glaucoma,27-30 and age-related macular degeneration.31 
1.2.4.2 Endothelium 
The blood vessel wall consists of three different layers: the intima (innermost layer also 
called the endothelium), media (middle layer also called the smooth muscle), and the 
adventitia (outer layer) (Fig 6).15 The intima is a layer offlat endothelial cells and is the 
main barrier to plasma proteins. It secretes many vasoactive products and is 
mechanically weak, while the media supplies the mechanical strength and contractile 
power. The media is made of spindle-shaped smooth muscle cells arranged circularly. 
The adventitia is a connective tissue sheath with no distinct border. It serves to secure 
the vesselloosely in place. 
Tunica 
adventitia 
Figure 6: Blood vessel wall. 
smoolh muscle cells 
Tunica media 
(From http://www.lab.anhb.uwa.edu.au/mb140/CorePagesNascularNascular.htm) 
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The endothelium controls the tone of the underlying vascular smooth muscle (VSM) by 
releasing endothelium-derived relaxing factors (nitric oxide, prostacyclin, and 
endothelium-derived hyperpolarizing factors) and endothelium-derived contracting 
factors (endothelin-l , thromboxane A2, angiotensin (AT), superoxide anions, and 
endoperoxides).32 The VSM controls the radius of the blood vessels and consequently 
the blood flow running through it. The VSM contraction is triggered by a rise in Ca2+ 
ion concentration in the cytoplasm leading to the activation or shortening of the actin 
and myosin filaments. 15 
Nitric oxide (NO), prostacyclin (PGh) and endothelin (ET) are strong vasoactive factors 
(see reviews).33,34 Nitric oxide is an endothelial vasodilating compound and is believed 
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to be involved in the basal blood flow in the retina, choroid and optic nerve.33 AIso, 
nitric oxide acts as a vasodilator mediator for acetylcholine, bradykinin, histamine, 
substance P and insulin. Prostacyc1in is also present in the retina and intravitreal 
injection of prostacyc1in has been shown to increase retinal blood flow. 35,36 Endothelin 
is a vasoconstrictive peptide released by the endothelium. Its vasoconstrictive effect has 
been observed in ophthalmic, ciliary and retinal arteries in animal studies?4 In humans, 
systemic injection of endothelin induces a reduction of the pulsatile blood flow in the 
choroid and optic nerve.37 
1.2.4.3 Metabolic demand 
The retina, choroid and optic nerve head induce changes in the ocular circulation in 
response to dark or light stimulation in order to meet the metabolic demand. Human 
studies have shown that blood flow at the optic disk surface increases from dark to light 
condition,38 and that choroidal blood flow decreases from light to darkness.39 
Moreover, the diameter of retinal arteries and veins, blood velocity in the macular 
capillary and blood flow at the optic disc surface have been shown to increase during a 
flicker4o-43 or a pattern stimulation.44 Therefore, retinal vessels, the choroid and the 
optic nerve head circulation have an autoregulatory metabolic property in order to meet 
the physiologic demand in response to the level of ambient light or light stimulation. 
1.2.4.4 Nervous control 
Sympathetic and parasympathetic innervation are present in the choroid1,45-48 but not in 
the retinal vessels.47,48 Sympathetic innervation of the choroid decreases choroidal 
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blood flow.3 The sympathetic adrenergic innervation is present in the central retinal 
artery but absent in the retinal vessels.47,48 It has been postulated that the presence of 
cholinergic innervation in the central retinal artery plays a role in protecting the fragile 
capillaries of the retina in situations of marked increase of blood pressure. A sudden 
increase in sympathetic activity, as may occur during stress, causes a marked increase of 
blood pressure. It is believed that the constriction of the extraocular part of the central 
retinal artery increases resistance and limits the increase of the intravascular pressure in 
the fragile capillary bed.9 The role of parasympathetic innervation of the choroid is less 
known, other than that parasympathetic innervation seems to increase choroidal blood 
flow possibly via the vasoactive intestinal peptide (VIP) and nitric oxide (NO).1,46 
1.2.4.5 Blood gases 
Ambient oxygen (02) and carbon dioxide (C02) are also contributing factors changing 
the ocular blood flow to the retina, choroid and optic nerve head in humans. In the 
presence of elevated O2, blood flow decreases in the retinal vessels and macular 
capillaries causing a reduction of blood velocity and constriction of the vessels,49-53 
while elevated CO2 causes an increase of the velocity and dilation of the blood 
vessels.50,51,54 Pulsatility, velocity, volume and flow of the neuroretinal rim decrease in 
the presence of O2 and increase in the presence of CO2. 55-57 Finally, 02 has been shown 
to have very little effect on choroidal pulsatility, while CO2 induces an increase on 
choroidal pulsatility55,56,58 and flow. 59 
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1.3 Techniques employed to assess ocular blood flow 
Several techniques have been developed to measure ocular blood flow so as to 
understand the vascular supply of the retina, choroid and optic nerve as well as the 
underlying mechanisms of impaired ocular blood flow in eye diseases. 
1.3.1 In humans 
Techniques to assess ocular blood flow in humans are: fluorescein angiogram (FA), 
indocyanine angiogram (ICG), pulsatile ocular blood flow (POBF), laser interferometry, 
blue field entoptic simulation, color Doppler imaging (CDI), laser Doppler velocimetry 
(LDV), retinal vessel analyzer (RVA), laser Doppler flowmetry (LDF), scanning laser 
Doppler flowmetry (SLDF) and Canon laser Doppler flowmeter (CLBF). 
Fluorescein angiography (FA) is a technique consisting of injecting a bolus of 10 mL of 
5% fluorescein sodium into one of the patient's cubital veins.60-62 The sodium 
fluorescein has a peak of absorption at 490 nm and emission at 530 nm. Blue and 
yellow-green filters are positioned along the optical axis of a single-Iens reflex camera 
for viewing and documenting the fundus fluorescence. As the fluorescein dye reaches 
the retinal and choroidal circulation, it is photographed at several time intervals while 
the circulation of the fluorescein dye progresses in time. The fluorescein angiogram is a 
technique which qualitatively assesses blood flow in the retina and optic nerve head and 
localizes the regions of ischemia and leakage. 
The indocyanine green angiography (ICGA) consists of injecting indocyanine dye using 
the same technique as for the sodium fluorescein dye. It is used for assessing the 
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choroidal circulation. The indocyanine dye has several advantages over the sodium 
fluorescein dye. Its fluorescence is near-infrared spectrum. Unlike sodium fluorescein, 
which absorbs and emits light in the visible portion of the spectrum, indocyanine dye has 
a peak absorption (805 nm) and fluorescence (835 nm) in the near-infrared range.62 
Light at a wavelength in the near-infrared spectrum penetrates deeper in tissue than light 
in the visible spectrum.62 Therefore, light at wavelengths in the near-infrared spectrum 
penetrates the pigmented layers of the fundus allowing to assess deeper structures of the 
retina (RPE and Bruch's membrane) and choriocapillaris. Similar to FA, ICG is used 
for qualitative assessment of the blood flow and localizes the regions of ischemia and 
leakage. 
The pulsatile ocular blood flow (POBF) is the pressure change of the eye in response to 
the bolus of blood from each heartbeat. Each heart contraction causes a bolus of blood 
to flow into the ophthalmic artery from the internaI carotid artery (ICA) and then spreads 
rapidly forward through the retinal vessels and choroidal vascular network. The entry of 
blood into the eye increases the ocular volume with a proportionate increase of the IOP 
to reach a maximum IOP, which corresponds to the systolic IOP. Following relaxation 
of the heart and closure of the aortic valve, the IOP falls gradually to a minimal value, 
which corresponds to the diastolic IOP. The observed changes in pressure reflect the 
fact that the eye volume must change in response to accommodate changes in the 
intraocular blood volume induced by the arterial pulse. A re1ationship between 
pressure/volume has been established by Silver et al. (1989,1994) from living human 
eyes.63,64 From this relationship, the volume of blood ente ring the eye can be estimated 
from the corresponding and measured IOP. The total ocular blood flow consists of 
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pulsatile and non-pulsatile components. In healthy eyes, the pulsatile component is 75% 
to 85% of the total flow. 65,66 It has been estimated that from the total ocular circulation, 
95% is constituted from the choroidal circulation and 5% from the retinal circulation.65. 
68 Therefore, POBF is essentially the measurement of blood flow circulating in the 
choroid with each heartbeat, and is a reliable parameter for evaluating the status of the 
choroidal circulation, and consequently the overall ocular circulation. However, the 
POBF technique does not account for the sc1eral rigidity, which has an impact on how 
rigid or elasticthe eye is and affects its mechanical property to pulsate from each bolus 
of blood. Sc1eral rigidity' extremes might not reflect the "true" representation of the 
volume of bolus of blood. As explained before, POBF is used to mainly assess the 
overall choroidal circulation. Therefore, it does not provide any information on the 
retinal and optic nerve head circulation and it does not give information on particular 
regions of the retina, optic nerve or choroid. 
Laser interferometry is another technique that has the capability of measuring the 
pulsatility of the ocular blood flow by measuring fundus pulsation of the eye. It uses an 
infrared single-mode laser diode (780 nm) integrated to a fundus camera.69,70 The 
fundus camera permits the visualization and control of the region of the fun dus to be 
investigated, i.e. the retina, the choroid or the optic nerve head. The principle of this 
technique is that it measures the distance changes between the fundus and the cornea, 
called the fundus pulsation. The laser beam is reflected at the front side of the cornea 
and at the retina. Distance variations between the cornea and the retina lead to a 
corresponding variation L1N(t) of the interference order in the interference pattern 
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resulting from the two reflected beams.71 The advantage of this technique compared to 
the pulsatile ocular blood flow system is that no contact is required with the comea and 
no topical anaesthesia is needed. The instrument allows the operator to locally measure 
the pulsatility at a discrete region of the fundus, either at the retina, the macula, or the 
neuroretinal rimlcup. However, as for the pulsatile ocular blood flow, it does not account 
for scleral rigidity, and a relatively clear media is necessary for performing this test. 
The blue field simulation technique consists of illuminating the eye fundus with an 
intense blue light from a narrow optical spectrum centered at a wavelength of 430 nm.72 
Under this condition, bright corpuscles can be seen "flying" in an are a of 10 to 15° of 
arc radius centered at the fovea. These corpuscles correspond to the white blood cells 
(leukocytes) circulating in the macular capillaries. The leukocytes do not absorb short 
wavelength as the red blood cells do, therefore they are perceived as shadows on the 
background of the continuous blood stream. Because the fovea is avascu1ar, the entoptic 
phenomenon is absent. There are two physical properties drawn from the blue field 
perception of the leukocytes in the blood stream: one is the velocity and the other is the 
density. Therefore, based on these two properties, the blue field perception of the 
leukocytes is a close index of the blood velocity, volume and flow. 73 During the blue 
field entoptic simulation, one of the subject' s eyes is stimulated by the intense blue light 
at a wavelength of 430 nm, while the subject is asked to observe a CRT screen with the 
other eye, which is also illuminated with a blue light but at a wavelength of 450 nm to 
prevent the perception of the entoptic phenomenon. The CR T screen displays computer 
simulated leukocytes and the subject adjusts the velocity pulsatility, me an velocity and 
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number of the simulated leukocytes with control buttons in order to match with his own 
leukocyte motion in the stimulated eye. This is a very subjective technique used to 
measure retinal blood flow and cannot be used in the presence of opaque media. 
The optical property of laser light and the property of ultrasound to shift at a frequency 
(Doppler shift) corresponding to a specific velocity of a moving particle, for instance the 
blood cells, have led to a series of new techniques for assessing blood flow in various 
vascular structures, including the ones from the eye. Color Doppler ultrasound imaging, 
laser Doppler velocimetry, retinal vessel analyzer, laser Doppler flowmetry, confocal 
scanning laser Doppler flowmetry techniques and Canon laser Blood Flowmeter have 
been developed to study the vascular and microvascular (capillary) beds of the retina, 
choroid and optic nerve head. 
The color Doppler ultrasound imaging (CDI) is the only non-invasive system that 
records the blood circulation from the retrobulbar vessels. It uses ultrasound 
scanners/transducers (5-10 MHz) which are applied with contact jelly through the closed 
upper eyelid.74 Blood flow in the retrobulbar vessels is detected by the production of 
colour pixels (representing Doppler frequency shifts) on a visual display unit. Pulsed 
Doppler ultrasound is thereby aimed at the vessel of interest (ophthalmic artery, central 
retina artery and vein, posterior ciliary artery), and spectral analysis of the resultant 
Doppler frequency shift is used to obtain a velocity waveform. Peak systolic (PSV) and 
end diastolic velocities (EDV) are obtained from the signal and are used to calculate two 
indexes, i.e the resistivity (Rl=(PSV -EDV)/PSV) and pulsatility (PI=(PSV -EDV)/Tmax) 
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indexes. These two indexes provide a measure of peripheral resistance to flow. The 
resistance index ranging from 0 to 1, where 0 represents no resistance and 1 represents 
high resistance, is also called the Pourcelot's index. High velocity readings provide 
better reproducibility than low velocity readings. It has been shown that the coefficient 
of variation with either the Acuson 128 System or the Siemens Q2000 System varies 
from 4.0% to 4.8% for the ophthalmic artery, 6.4% to 11.0% for the central retinal 
artery, and 10.0% to 38.0% for the posterior ciliary artery.74 Therefore the cor 
technique is not a reliable technique for measuring the posterior ciliary arteries. CDr has 
a limited resolution range for detecting velocity as low as 1-3 cm/s. The angle of 
incidence between the scanner/transducer and the measured vessel is normally very low 
as most of the vessels have an antero-posterior orientation. However, in situations 
where the blood vessels present a tortuosity, the measurement is unreliable. 
Laser Doppler velocimetry (LDV) permits the measurement of red blood cell velocity in 
retinal vessels. A helium-neon laser beam (632 nm) incorporated to a fundus camera is 
focused on a retinal vessel (50 to 150 um diameter) and illuminates the entire lumen 
over a short vessel segment. 75 This vessel segment contains many RBCs moving at 
different velocities aIl in one direction. The scattered laser light is detected by a detector 
(optical fiber) located in the retinal image plane of a fundus camera. Two components 
of this light, one originating from the moving RBCs, the other from the vessel wall, are 
optically mixed by a photomultiplier tube (PMT). The resultant photocurrent contains a 
whole spectrum of different frequencies (~fs) corresponding to the spectrum of different 
RBC velocities. The power of the photocurrent at a given frequency is proportional to 
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the number of RBCs moving at the corresponding velocity. A good analogy is that the 
power spectrum of the photocurrent represents several histograms of RBC velocities. 
From Poiseuille's mathematical model of the flow, the distribution of the RBC velocities 
within the vessels is a parabolic function of the radial distance from the vessel axis with 
an equal number of RBCs flowing at each velocity from V=O to V=Vmax. Vmax is the 
maximum (centre line) velocity of the RBCs. 72 In order to increase the accuracy and 
reproducibility of Vmax at the centre line of the blood vessel and to obtain an absolute 
measurement ofVmax, a bi-directionallaser has been developed.76 In the bi-directional 
technique, one incident beam is used to illumina te a site along a retinal vessel. The light 
scattered by the blood cells at the illuminated site is detected simultaneously in two 
distinct directions separated by a known fixed angle. Two Doppler shift frequency 
spectra are measured, each with a particular value of ~f max. The difference of the two 
values is used to ca1culate the Vmax in units of speed, i.e. cm/s. By determining the 
vessel diameter from photograph or laser measurement (CLBF technique described 
later), the retinal blood flow can be ca1culated. LDV requires relatively clear media and 
good fixation from patients. 
The retinal vessel analyzer (RVA) is a fundus camera (FF450, Zeiss Jena, Germany). It 
allows on line measurement of the diameterof a retinal vessel of interest. The diameter 
measurement is obtained with a charged-coupled device (CCD) camera mounted in the 
fundus camera. The CCD camera measures diameters of ~90 ' . .un 77 on a vessel segment 
which can be up to 1 mm maximum length. The CCD camera and analysis software 
camera de termine the diameter using a contra st analysis technique of the column of red 
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blood cells. Temporal resolution is 40 ms and the diameter resolution is 1 !lm. One 
interesting feature of the RV A system is that it permits the recording of the video signal 
of the eye fundus (30°) for :::;10 minutes using an SVHS recorder. This feature gives the 
opportunity to recall data and to analyse different vessels after data acquisition. Since 
the RV A only gives information on retinal vessel diameter, it does not provide 
quantitative data ofblood flow of the vessel investigated. 
Laser Doppler flowmetry (LDF) is a technique that measures the relative velocity, 
number and flow of red blood cells in the vascular network embedded in tissue. It is 
used for measuring blood flow in a discrete area of the choroid, the optic nerve 
superficiallayer or retina, where blood vessels are absent. The laser wavelength chosen 
for the site of measurement determines how deep the measurement is done in the tissue. 
The longer the laser wavelength is, the deeper is the tissue sampled. The principle of 
LDF is that the incident laser beam illuminates a small region i.e. the retina, choroid or 
the optic nerve head free of surface vessels. As the light penetrates the tissue, it is 
randomly scattered both by nonvascular tissue elements and by blood cells circulating 
through the capillaries embedded in the tissue. In this situation, each blood cell receives 
light from a multiplicity of directions. Moreover, the Doppler shifted light scattered by 
each cell is again randomly scattered by the surrounding nonvascular tissue prior to 
detection. The power spectrum depends not only on the blood cell speed as for retinal 
vessels, but also on the light scattering property of the tissue. The Doppler shift power 
spectrum is recorded via a photodetector placed near the site of illumination of the 
incident laser. The shape of the power spectrum is logarithmic. The logarithmic fit of 
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the power spectrum where it meets the baseline is proportional to the velocity of the red 
blood cells. Bonner and Nossa178 developed the mathematical model of the broadened 
Doppler shift spectrum to quantify the total number of blood cells moving in the 
illuminated tissue volume (X), and to quantify the flux or flow rate of the moving cells 
(w). The mean blood cell speed is th en related to the quotient w/x. In the Occulix 
system, which is an LDF system, the volume sample corresponds to the area of the laser 
beam reaching the tissue. The Occulix records in real time, which allows applying stress 
tests such as the cold provocative test, breathing of different CO2/02 mixtures and light 
stimulation. However, the output measurements of velocity and flow are in arbitrary 
units (AU) and therefore it does not allow comparing inter-session measurements. Like 
the LDV, the Occulix requires relatively clear media and good fixation from patients. 
The choice of laser wavelength used will determine the depth of the blood flow 
sampling. The LDF is a single point laser and does not allow the measurment of blood 
flow in different regions simultaneously. 
Scanning laser Doppler flowmetry is the combination of laser Doppler flowmetry 
(described above) and a scanning laser device. This system has been developed by 
Heidelberg Engineering.79 The principle of this system is that the direction of the laser 
beam (780 nm) entering the eye is periodically changed in two orthogonal directions by 
means of two oscillating mirrors, so that a two dimensional region is scanned line by 
line. The scanned field is 100 wide by 2.5 0 (2.88 mm x 0.72 mm). During the scan 
along one line, the reflected light intensity at 256 equidistant locations (pixels) is 
measured and digitized. The pixel distance is 11.2 !lm. Each line is scanned 128 times, 
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th en the next line goes through the same process up to a total of 64 lines. The total 
acquisition time is 2.05 seconds. A discrete fast Fourier over the 128 intensity values for 
each pixel is performed for generating the power spectrum of the Doppler shift. An 
automatic full-field perfusion image analysis software (AFFPIA, v3.3),80,8\ is used to 
determine perfusion analysis of the pixels of the entire image and to obtain the overall 
volume, velocity and flow. It improves data quality by removing over-exposed pixels 
and saccades, vessels greater than 30 /lm and allows the analysis of large regions of 
tissue such as the neuroretinal rim. When the acquired image con tains the neuroretinal 
rim area surrounded by the peripapillary retina, inner and outer circles can be drawn by 
the operator to delimit the neuroretinal rim. 
The depth of penetration of the SLDF measurement has been estimated to be 300 to 400 
/lm. 82 This estimate has been obtained from a monkey model where the central or 
posterior ciliary arteries were ligatured. Following the occlusion of the central retinal 
artery, which provides the blood supply to the retinal nerve fiber layer (300 to 400 um 
thickness), a 51 % decrease of the blood flow measured with the SLDF was observed. 
Following the occlusion of the posterior ciliary arteries, which supply the laminar and 
retrolaminar region of the ONH, no change in the blood flow was observed. 
In nonnal subjects, SLDF intra-session coefficient of variations for the mean of 5 
images of same centration, brightness, and absence of movement, ranges from II.4% to 
16.4%, and the coefficient ofreliability ranges from 0.93 to 0.95. Regarding the inter-
session, the coefficient of variation ranges from 9.8% to 12.5%, and the coefficient of 
,( 
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reliability ranges from 0.80 to 0.87 respectively.83 Since it is necessary to obtain at least 
three good images without blinking and eye drifting, the SLDF system is not a simple 
test for patients and requires very good cooperation and fixation. Like any other laser 
Doppler technique, it is necessary to have a relatively c1ear media. 
In order to de termine accurate1y the blood flow from a retinal vessel at a giventime, it is 
necessary to record simultaneously the velocity of the centre line blood colurnn of the 
vessel and its corresponding width (diameter). The Canon Laser Blood Flowmeter 
(CLBF) has been developed to achieve this. It uses a bi-directional red diode laser (675 
nm, 80 ~m x 50 ~m oval) that measures the centre line blood colurnn velocity, and a 
green diode laser (543 nm, 1500 ~m x 150 ~m) that measures the blood vessel diameter 
and also serves as a vessel trac king system. These two lasers are mounted in a fundus 
camera. Refer to the section above describing the principle of the bi-directional laser 
system. The vessel tracking system corrects for small eye movements. It allows a 
graph of eye position to be superposed oyer the velocity time curve to aid in artefact 
rejection. Two sequent bi-directional readings (i;e. path 1 and path 2) are takenand 
averaged to give one reading. Multiple diameter readings are simultaneously acquired 
during the first and final 60 ms of the 2-second velocity measurement window. The 
CLBF software calculates the blood flow of the vessel of interest once the mean vessel 
diameter and centre blood velocity are obtained from two paths (2 measurements), using 
the following fonnula: 
Flow (~L1min)= Velocitymean(7tDiameter2/8) 
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where Velocitymcan is the time averaged centre line blood velocity (mm/s) during the 
cardiac cycle and nDiameter2/8 is the cross-sectional area of the measurement site (J.!m2). 
The CLBF software takes into consideration the axial length. The CLBF accuracy relies 
on the possibility of rejecting or accepting the reading of the path based on visual 
inspection of the signal in terms of its stability. From our lab experience, we have 
obtained a coefficient of variation of3.2 +/- 1.9% for the diameter, 6.7 +/- 3.2% for the 
velocity, and 7.1 4.4% for the flow following a standard protocol (paper in 
preparation). AIso, the system keeps in memory the location of the measurement site for 
follow-up investigations. The CLBF system is user friendly for both technician and 
patient, but it has minor limitations. lt does not allow for measures of an artery if too 
close to a vein as the laser beams are dragged away from the arterial measurement site 
by the vein signal. To be performed on patients, CLBF requires a good dilation of at 
least 7 mm of diameter as the iris blocks the incident laser coming superiorly. 
Therefore, droopy eyelids or long eyelashes cause problems as the laser signal is 
blocked. In the presence of lens opacities, the power of the laser can be increased to the 
next level from 200 to 300 J.! W for the velocity measurement laser, and from 4 to 6 Il W 
for the trac king and diameter measurement laser. 
1.3.2 In animaIs 
An the techniques mentioned in the previous section can be performed on monkeys or 
other large animaIs under anaesthesia, which can alter basal hemodynamics and normal 
physiologie levels. For smaller animaIs such as rodent s, laser Doppler techniques have 
, 
, 
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been adapted to the confined working area present in the eye, but they still present sorne 
limitations. 
The laser Doppler flowmetry technique usmg an intraocular probe can be used to 
measure retinal blood flow in rodents.84-86 However, this technique is invasive as it 
requires one to position the probe near the retinal surface while the IOP has to remain 
constant. AIso, it has to be performed under anaesthesia, which can alter basal 
hemodynamics and normal physiologic levels. The scanning Laser Doppler Flowmetry 
(SLDF) (HRF, Heidelberg Engineering, Germany, vl.02) technique can be used in small 
rodents, but again it must be used in animaIs under anaesthesia. Moreover, comeal 
dryness under anaesthesia is a limiting factor. Finally, the SLDF cannot be applied in 
small rodents for capillary blood flow measurements as it does not have the ability to 
visualize the capillary layers and it detects blood flow signal from the choroid. 87 
The microsphere technique consists of injecting radioactive microspheres (MS) of a 
known dosage and size into the left ventricle. MS have been used to measure the retina, 
optic nerve head and choroidal blood flow. 88 ,89 As the MS circulate in the blood stream, 
they become entrapped within the vascular bed in proportion to its regional blood flow. 
The regional blood flow is determined by calculating the ratio of total MS in the tissue 
in reference to the arterial contamination obtained from blood samples collected during 
MS injection. The MS technique presents sorne limitations, which can over- or und er-
estimate blood flow. 90-92 A too high or too low dose may lead to over or under MS 
entrappement. A large size of MS can alter hemodynamics resulting from a blockage of 
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large vessels. Axial streaming of the MS is also another limiting factor. In the retina, 
optic nerve and choroid of rats, 8 !lm and lO !lm MS are optimal sizes to estimate blood 
flow in the retina/optic nerve head and choroid respectively.89 However, since MS are 
entrapped with the microvascular space and not in the tissue, measurement of the blood 
flow of the tissue is missed. 
Diffusible blood flow tracers su ch as [14C]-iodoantipyrine,93 [14C]diazepam,94 or n-
[14C]butanol,95 have been developed to measure regional blood flow in a tissue of 
interest. The use of a diffusible tracer avoids inaccuracies of the retinal blood flow 
measurement due to axial streaming, plugging or permeability changes as reported with 
the classical microsphere technique.89,92 However, post-mortem intraparenchymal 
diffusion occurs, which results in weakening the local tracer spatial gradients as 
observed in the brain,96 retina, optic nerve and choroid.92 ,97-IOO The [14C]_ 
iodoamphetamine ([14C]_IMP) is a blood flow tracer, which has been developed and 
proven to be ideal in measuring blood flow several reasons. First, the [14C]-IMP binds 
to the amine sites lOI ,I02 and has a very high extraction at the first pass through the 
microvasculature, which aUows a non-restrictive diffusion from blood to tissue despite 
the blood-retinal barrier. Second, [14C]_IMP has a very low clearance rate and low post-
mortem diffusion,lo3 due to its high affinity for cerebral tissue. Third, [14C]-IMP is 
chemicaUy and biologicaUy inert for the duration of the measurement period. I03 These 
properties have aUowed the IMP to be successfuUy used for measuring cerebral blood 
flow in smaU animal research,96,I03,I04 and in humans using Single Photon Emission 
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Computed Tomography. The principle of blood flow evaluation of the [14C]-IMP is 
identical to that of micrometric microspheres89 except that molecular microspheres 
diffuse within the tissue, whereas micrometric microspheres are trapped inside the 
microvascular space. As yet, there are no published studies reporting the use of IMP in 
measuring retinal, optic nerve and choroidal blood flow. We have developed a new 
technique where we used IMP to assess retinal blood flow in a menopause rat model. 
This is the first time the IMP has been used to measure ocular circulation. 105 Details of 
the study protocol and findings are presented in the methodology section and paper #2 of 
the present thesis. 
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1.4 Glaucoma 
Glaucoma affects the retinal ganglion cells and their axons, leading to the excavation of 
the optic nerve head (ONH) and constriction of visual fields. Recent prevalence 
estimates conclude that glaucoma is the second leading cause ofblindness worldwide. I06 
It is also the second leading cause of blindness in the Canadian population aged 50 and 
over. I07 At least 300 000 Canadians are affected with this disease, and since it is 
asymptomatic, 50% of patients are unaware that they have it. I08 The three clinical 
signs of glaucoma are optic nerve head excavation, visual field deterioration and 
elevated intraocular pressure. There are two causes involved in the aetiology and 
progression of glaucoma: elevated intraocular pressure (IOP) and/or impaired ocular 
hemodynamics.I09-111 Elevated intraocular pressure (IOP) results from a poor draining 
of the aqueous through the angle between the iris and cornea (irido-corneal angle), 
among other proposed mechanisms, is thought to lead to a mechanical compression of 
the RGCs and retinal vessels and RGC death. Patients with an open irido-corneal angle 
and elevated IOP are classified in the open-angle glaucoma (OAG) category, while 
patients with narrow or closed irido-corneal angle and elevated IOP are classified in an 
angle-closure glaucoma (ACG) category. Finally, patients with normal IOP, but still 
present visual field constriction and abnormal excavation of the ONH, fall in the normal 
tension glaucoma (NTG) category. 
There is a large body of evidence indicating impaired ocular blood flow in glaucomatous 
patients. llo For example, clinical features indicative of impaired ocular blood flow in 
glaucomatous patients can be observed through funduscopy. Patients may present pallor 
of the neuroretinal rim,II2-115 flame haemorrhages of the optic disc 116 and focal 
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narrowing of the retinal vessels. ll7,118 Angiographic studies have demonstrated reduced 
blood flow, 1 19-121 filling defects,120-124 and delayed filling time in glaucoma 
patients. 125,126 lmpaired ocular blood flow demonstrated by quantitative methods has 
been documented in glaucomatous patients. Color Doppler lmaging technique has 
demonstrated increased resistivity indexes in the central and short posterior ciliary 
arteries. 127,128 Pulsatile ocular blood flow findings have indicated reduced flow in 
. l l 65 129 dl' l 130 131 S . l pnmary open-ang e g aucoma' an norma tensiOn g aucoma.' canmng aser 
Doppler flowmetry studies have reported reduced blood flow of the peripapillary and/or 
. l . .. l l 132-137 dl' neuraretma nm m pnmary open-ang e g aucoma, an norma tensiOn 
glaucoma. 137,138 A recent study conducted in our laboratory has reported reduced blood 
flow in the infera-temporal retinal artery measured with the Canon Laser Blood 
Flowmeter (paper in preparation). 139 
Abnormal peripheral blood circulation underlines the raIe of impaired ocular blood flow 
in the aetiology of glaucoma. 
Normal systemic blood pressure (BP) and ocular perfusion pressure (OPP = mean BP -
lOP), (systolic BP-lOP and diastolic BP-PP) are important hemodynamic factors in 
providing normal blood perfusion to the retina and optic nerve. Clinical evidence 
indicates that altered BP and OPP affect the ONH blood flow. First of all, glaucomal4o 
and OHT patients l40,141 have reduced OPP and ONH blood flow compared to control 
subjects as documented by laser Doppler flowmetry and scanning laser Doppler 
I~ flowmetry studies. Moreover a significant positive correlation between mean blood 
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pressure (mean BP) and ONH blood flow exists in glaucomal4o and OHT patients,14o,141 
while ONH blood flow remains stable in control subjects despite the BP changes. 141 
These findings underline a possible impaired autoregulation to maintain a constant blood 
flow to the ONH regardless of changes in systemic BP in glaucoma and OHT patients. 
As weU, it indicates that a reduced BP has a stronger negative effect on the ONH blood 
flow compared to those with a higher BP. This strongly suggests that a higher BP 
provides a better blood perfusion to the ONH in glaucoma patients. This hypothesis is 
supported by ONH tomography and visual field studies. Glaucoma patients with 
normalized diastolic BP resulting from systemic hypertension present a significant 
decrease of the neuroretinal rim area and an increase in both cup area and cup-to-disc 
ratio (cid) of the ONH. 142 ln normal tension glaucoma patients, larger circadian OPP 
and me an BP variations are predicting factors for visual field deterioration. 143,144 
Several population-based studies have linked reduced BP and OPP to the glaucoma 
prevalence and incidence. Low OPP, systolic OPP (systolic OPP = systolic BP-IOP) 
and/or diastolic OPP values (diastolic OPP= diastolic BP-PP) have been reported to 
increase significantly the odds ratio of glaucoma prevalence as reported in the Baltimore 
Eye Survey,27 Barbados Eye Study,145 Long Island Glaucoma Case-control Study,146 
Egna-Neumarkt Study,147 and the Barbados Family Study,148 and to increase 
significantly the relative risk ratio of glaucoma incidence as documented in the Barbados 
Incidence Study of Eye Diseases,149 Early Manifest Glaucoma Trial/ 50 and in the 
Barbados Eye Study.151 
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Migraines and vasospasticity have been associated with the development and 
progression of glaucoma. 152 ln the Collaborative Normal-Tension Glaucoma Study, it 
has been reported that glaucomatous female patients who suffered from migraines 
presented visual field deterioration 2.6 times faster compared to those of females who 
did not suffer from migraines. 153 In a study involving patients suffering from low-
tension glaucoma, reduced finger flow at baseline and following the co Id provocation 
test, which asses ses vasospasticity, has been shown. 154 
Finally, and not the least interesting, single photon emission computed tomography 
(SPECT) studies have been conducted in 31 normal-tension glaucomatous patients. 155 
Blood flow measures have reported cerebral blood flow perfusion patterns similar to 
those of Alzheimer's disease (AD)-like perfusion patterns in seven normal-tension 
glaucoma patients, while the other NTG patients presented a normal perfusion pattern. 
Interestingly, the visual field deterioration of the NTG group with an AD-like perfusion 
pattern had progressed more rapidly than in the group with normal perfusion pattern. 
1.5 Age-related macular degeneration (ARMD) 
Age-related macular degeneration (ARMD) is thought to be related to the accumulation 
of metabolite products in the retinal pigmentary epithelium (RPE) of the macular region. 
The clinical signs are the appearance of drusen (yellow spots) and pigmentation 
abnormalities (hyper- or hypo-pigmentation), which occur in the early stage, white 
geographic atrophy and subretinal neovascularization occurs in the later stage. ARMD 
is the most common cause of vision impairment and blindness worldwide,106 and in the 
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Canadian population. 107 The number of ARMD cases is predicted to grow at a rate of 77 
000 per year. 108 The accumulation of metabolites may result from impaired choroidal 
hemodynamics failing to clear the metabolites discharged in the macular region although 
multiple mechanisms are likely. 156,157 
Angiographie studies have reported a slowl58 and prolonged choroidal filling l59,I60 in 
patients with ARMD. Color Doppler studies have documented higher pulsatility indexes 
for the ophthalmic,161 central 162,163 and both nasal and temporal ciliaryl62 arteries in 
ARMD patients. Reduced choroidal blood flow has been documented in ARMD 
patients with the laser Doppler flowmetry.156 As well, impaired autoregulation of 
choroidal blood supply in isometric conditions has been reported. 31 Autoregulation is 
the ability of a vascular bed to maintain constant blood flow despite changes in 
perfusion pressure. In normal subjects, subfoveal choroidal blood flow has been shown 
to remain constant between rest and isometric exercise despite an increase in systemic 
blood pressure and ocular perfusion pressure, while choroidal blood flow has been 
shown to increase in ARMD patients with neovascular ARMD. 31 This increase in 
choroidal blood flow indicates altered autoregulation in response to increased ocular 
perfusion pressure in ARMD patients. 
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1.6 Estrogens 
Estrogens are a family of hormones which are synthesized in a variety of tissues, such as 
ovary, placenta, and adipose tissue. 164 Estrogens are responsible for cyclic changes in 
the vaginal epithelium and the endometrium of the uterus. 
There are three kinds of endogenous estrogens; estradiol (E2), estrone (Et) and their 
metabolite product estriol (E3). Estrogens are formed by the aromatization of 
testosterone or androstenedione (androgens).164,165 The aromatization is achieved by the 
cytochrome P450 enzyme (P450 aromatase) using 02 and NADPH. In the presence of 
the testosterone as a substrate, the P450 aromatase leads to the formation of 17~­
estradiol, while for the androstenedione it leads to the formation of estrone. 
There is a mutual interconversion between estradiol and estrone, and between estrone 
and estrone sulfate. 166,167 Estrone is then metabolized by two metabolic pathways, the 
A-ring hydroxylation pathway and the D-ring hydroxylation pathway, each having its 
own and separate enzyme systems. The two metabolites formed by A-ring 
hydroxylation are 2-hydroxyestrone and 4-hydroxyestrones, also called 
catecholestrogens, which can be further metabolized into 2-methoxyestrone and 4-
methoxyestrone metabolites. The two metabolites formed bythe D-rihg hydroxylation 
are 16a-hydroxyestrone and estriol. Figure 7 illustrates the chemical structures of the 
parent hormone 17l3-estradiol and its main A- and D-ring metabolites. 
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Figure 7: Chemical structures of the parent hormone 17B-estradiol and its main A- and 
D-ring metabolites, The cited estrogen metabolites can undergo an additional 
degradation step by conjugation, either by glucuronidation, sulfation, or methylation, 
(From Mueck AO, Seeger H, Lippert TH, Estradiol metabolism and malignant disease, 
. Maturitas, 2002;43: 1-10) 
P450 aromatase rnRNA and expression are found in several regions of the brain in 
d'f'C ,\68 d b' h' f l7 A d' l 'h b ' \69 \70 1 lerent specles an IOsynt eSls 0 t-'-estra 10 occurs m t e ram, . 
Recently, Cascio and al. (2007)\7\ also found P450 aromatase mRNA and expression in 
the adult male rat retina and confirmed that the biosynthesis of 17p-estradiol occurs as 
weIl. It is unknown what functional role local estrogen biosynthesis plays in the retina, 
62 
In the brain, the proposed role of estrogen biosynthesis is thought to play a role in local 
trophic and protective effects on neurons. 168 This is discussed in the section 1.6.2. 
In the premenopausal period, estradiol and estrone are secreted by the ovaries. Estrone 
is less biologically active than estradiol and is produced in adipose tissue from 
androstenedione. Prior to menopause, levels of estradiol are higher than levels of 
estrone. This is reversed after menopause because estrone continues to be produced in 
adipose tissue. When released in the blood stream, the estrogens are bound to sex 
hormone-binding globulin (SHBG).164 17~-estradiol, estrone and estriol is 37%, 16% 
and 1 % bound to SHGB respectively, while 61 %, 80% and 91 % to albumin. 167 
Although the role of estrogens is primarily in reproductive organs, they exert important 
effects in non-reproductive organs inc1uding the bone, the cardiovascular system and 
neural sites in the brain. The action of estrogens throughout the body is mediated via 
estrogen receptors (ER) alpha and beta (ERa and ER~), 172-174 which have been localized 
throughout the body inc1uding the central nervous system, heart and vascular tree, 
respiratory system, alimentary canal, endocrine system, bone, urinary system and male 
and female reproductive systems. See reviews for exhaustive list of specific locations of 
ERs in humans. 167,175,176 In addition to ER, recent studies have reported that estrogens 
activity is also mediated via the transmembrane G protein-coupled receptors GPR30, 
which are found in the ovaries, lung, liver, heart breasts, lymphomas and brain. 177 
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Estrogen receptors (ERs) have also been localized in the different structures of the eye. 
This includes the lacrimal gland, meibomian gland, lid, palpebral and bulbar 
conjunctiva, comea, lens, iris/ciliary body, lens, uvea, choroid and retinal pigmentary 
epithelium of rats, rabbits or humans.178-184 As well, ERs are present in the 
human,179,180,185-187 rat,179,180,188 rabbit 179,180 and bovine retinas. 188 In the human retina, 
both ERa and ER~ have been identified. ERa are present across the retina, mostly in 
the inner and outer nuclear layers, in a few cells of the outer plexiform layer and in sorne 
nuclei of the ganglion cells layers. A strong presence of ERa has been detected in the 
axon the RGCS. 186 ER~ are present in the ganglion cell layer and in the choroid. 187 
Based on a small sample of eye donors, ERa has been detected in the retina and RPE of 
two young female eyes still having estrous cycles, but not in eyes from one 
postmenopausal woman and one elderly man. 186 This indicates a possible age and 
gender effect on the presence of ERa. 
The binding affinity of en doge nous estrogens to both ERa and ER~ is greater for the 
17~-estradiol, followed by estrone and th an estriol. I67 
1.6.1 Vasomotor effect 
There is much evidence demonstrating that estrogens have a vasomotor effect by having 
the ability to influence the vascular tone and blood flow via genomic or non-genomic 
pathways in reproductive and non-reproductive organs and tissues including the brain 
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parenchyma. See reviews.189-191 Experimental studies conducted in female rats showed 
that 17~-estradiol treatment increased blood flow in sorne regions of the brain especially 
the hypothalamus,192 the frontal cortex, hippocampus, basal ganglia and cerebellum. 193 
The vasomotor effect of estrogens is mediated by a stimulating action on the 
endothelium-derived relaxing factors, such as ni tric oxide (NO),194-196 prostacyc1in 
(PGh),197-199 pathways and endothelium-derived hyperpolarizing factors (EDHFs), such 
as potassium (K+).191,200,201 The vasomotor effect of estrogens is also mediated by an 
inhibiting action on the endothelium-derived contracting factors, such as the endothelin 
(ET),202-2o4 angiotensin (AT)/o5-207 thromboxane A2 (TXA2)32,191,208 and Ca2+ 
pathways.191,209 Figure 8 illustrates sorne of these key players on which estrogens 
induce vasomotor on the blood vessel wall. Here we are going to review sorne of those 
key players. 
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Figure 8: Putative mechanisms for the action of estrogens on the vascular system. (From 
Tostes RC, Nigro D, Fortes ZB, Carvalho MHC. Effects of estrogen on the vascular 
system. Braz J Med Biol Res. 2003 ;36: 1143-58. 
1.6.1.1 Nitric oxide 
Nitric oxide (NO) is agas that is normally produced in the human body. It is 
endogenously synthesized from the L-arginine via the nitric oxide synthase (NOS). 
There are three isoforms of NOS, the neuronal NOS (nNOS or NOS-l), endothelial 
(eNOS or NOS-III) and inducible (iNOS or NOS-II). The e- and nNOS are normally 
present while the iNOS is present in pathologie conditions. 
NO causes vasodilation by inhibiting contraction of the vascular smooth muscle the 
following way.15 Once diffused from the endothelial cells to the cytoplasm of the 
smooth cell layer, NO stimulates the cytoplasmic enzyme guanylate cyclase. This 
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enzyme catalyzes the production of cyclic guanosine monophosphate (cGMP) from the 
guanosine triphosphate (GTP). The cGMP activates the protein kinase P, which then 
reduces the cytosolic Ca2+ that is required for the contraction of the smooth muscle cell. 
In sorne arteries, NO induces hyperpolarization by directly activating the potassium 
channels. 15,32 The hyperpolarization reduces the probability of the Ca2+ voltage-gated 
channels to open and consequently reduces the availability of Ca2+ necessary for 
contraction. 
Because NO has a short half-life and cannot be store d, its bioavailability is critical. NO 
production accounts for most of the enqothelium-dependent relaxation activity, and there 
is extensive evidence showing estrogen-induced up regulation of NO production in 
endothelial cells. The proposed me chanis ms are 1) transcriptional regulation of eNOS 
gene expression; 2) prolongation of the mRNA half-life of eNOS; 3) post-transcriptional 
modifications and co-factor availability; 4) increase of substrate availability, the L-
Arginine; 5) and protection ofNO.2lo 
Both estrogens receptor u and ~ are expressed in endothelial and vascular smooth 
muscle ceIls.211 It is believed that ERu are implicated in the increase of nitric oxide 
synthase III expression and production.194.196 Little is known of the role of ER~. The 
ER~ do not appear to participate in NO production as documented in the mouse aorta. 194 
However, it has been reported that ER~ participate in the eNOS activity in endothelial 
ceIls212 and in the vascular smooth muscles.213 
.[ 
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1.6.1.2 Prostacyclin 
Prostacyclin (PGIz) is produced by arachidonic acid by the cyclo-oxygenase (COX) in 
the endothelial cells. 15 Arachidonic acid is an unsaturated fatty acid that is generated 
from the cell membrane phospholipids by the action of another enzyme, phospholipase 
A2, which is the rate-limiting step in prostacyclin production.15.214 
In the vascular smooth muscle, prostacyclin receptors are coupled to adenylate cyclase 
(AC) 1eading to an increase of cyclic adenosine 3' ,5' -monophosphate (cAMP). 34 The 
cAMP is involved in two vasodilatory mechanisms by: l)increasing the extrusion of the 
cytoplasmic Ca2+ 32 that is normally necessary for contraction; and 2) stimulating ATP-
sensitive K+ channels causing hyperpolarization of the cell membrane?2 Consequently 
this inhibits the contraction of the vascular smooth muscle. 
Clinical studies indicate that estrogens have a beneficial effeet on prostanoid production. 
For example, in post-menopausal women, it has been shown that inhibition of COX-l 
and COX-2 abolishes skin blood flow after 17p-estradiol administration. 197 In 
ovariectomized rats treated with 17 p-estradiol, the levels of prostacyclin, phospholipase 
A2 and COX-l increase compared to those of non-treated ovariectomized rats. 198 
Moreover, in cultured aortic endothelial cells from piglets, rats, and human umbilical 
vessels, 17 p-estradiol stimulates prostacyclin synthesis, and this was also observed in 
cultured and fresh umbilical vein endothelial cells. 199 To date, there are no published 
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findings explaining exactly how estrogens are interacting with prostacyclin and whether 
estrogens receptors are involved. 
1.6.1.3 Potassium 
Extracellular potassium (K+) is known to induce hyperpolarization and relaxation in 
cells. Studies suggest that estrogens interact on the potassium level and channels in 
vascular smooth muscles. It has been shown that ACh-induced hyperpolarization and 
relaxation of mesenteric arteries are reduced in ovariectomy (OVx) female and intact 
male rats compared to intact females and that the differences in the ACh responses in 
OVx female compared to intact rats were eliminated in the presence of K+ channel 
blockers?OO Moreover, in OVx rats the hyperpolarization and relaxation were restored 
following 17p-estradiol treatment. In porcine coronary arteries, it has been shown that 
17p-estradiol stimulates K+ channel gating from the smooth muscle leading to K+ efflux 
and relaxation. 191 Single-channel and whole ceIl recording studies performed on 
isolated human coronary smooth muscle indicate that 17p-estradiol increases the who le-
cell current over a range of membrane potentials by likely acting on the calcium- and 
voltage-activated potassium (BKca) channels inducing relaxation. 201 
1.6.1.4 Endothelin 
Endothelin (ET) is an important vasoconstrictor. It is a peptide produced and released 
by the vascular endothelium. It is synthesized from the pro-hormone big endothelin via 
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the endothelin-converting enzyme (ECE).34,208,215 There are three isoforms of endothelin 
(ET -l, ET -2 and ET -3), and the most potent is ET -1. Normally, the plasma level of ET 
is low (1.5 pg/mL) and has either no direct contractile effect or acts as a vasodilator.34 
During pathological condition, ET production is enhanced by angiotensin II, arginine-
vasopressin, thrombin, transforming growth factor, interleukin, epinephrine, calcium 
ionophore, and phorbol ester, inducing a powerful and sustained vasoconstriction. 15,32,34 
There are two types of endothelin receptors, ET A and ET B receptors. The 1 binds to 
ET A and ET B receptors of the vascular smooth muscle to induce vasoconstriction208 by 
releasing the Ca2+ from the sarcoplasmic reticulum leading to an increase of intracellular 
Ca2+.34 ET -1 can also interact with ET B receptors on endothelial cells, triggering the 
release of nitric oxide (NO) and endothelium-derived hyperpolarizing factors 
(EDHF).208 
There is scientific evidence that estrogens interact with the endothelin system. Clinical 
studies indicate that there is a negative relationship between the levels of estrogens and 
endothelin levels in women: I)ET levels are lower in pregnant women than in age-
matched non pregnant women;216 2)ET-l levels are higher in postmenopausal women 
compared to premenopausal women;217 and 3)ET-I levels decrease in postmenopausal 
women after starting estrogens replacement therapy.217.220 In animal studies it has been 
reported that 1 )antagonist ET A decreases both mean arterial pressure and 1 plasma 
levels in ovariectomized rats;221 2)estradiol metabolites inhibit ET-release in porcine 
coronary endothelial cells;202 3)17~-estradiol attenuates the rabbit coronary arterial 
\ 
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contraction induced by ET -1 ;203 and 4) 17p-estradio1 inhibits both ET -1 production and 
its gene expression in bovine carotid arteria1 endothe1ia1 cells.204 Cu1tured bovine 
carotid endothe1ia1 cells were used to assess whether estrogen receptors interact on the 
endothe1in pathway.204 Transforming growth factor-b 1 normally stimu1ates the ET-1 
production in cell and treatment with 17p-estradio1 has shown that gene expression and 
secretion of ET -1 is inhibited. F ollowing treatment with an estrogen receptor antagonist, 
the ICI 182,780, it was observed that the beneficia1 effect of 17p-estradio1 on ET -1 was 
b10cked. This finding was a1so confirmed in a more recent study using the same 
methodo10gica1 approach and the same ER antagonist on porcine coronary endothe1ia1 
cells.202 These studies strong1y suggest the participation of estrogen receptors in 
controlling the endothe1in pathway. 
1.6.1.5 Angiotensin II 
Angiotensin II (AT-II) IS a powerfu1 vasoconstrictor. It is produced from 
angiotensinogen cleaved off by the enzyme renin (main1y secreted by the kidneys) to 
produce angiotensin 1 (AT-I).'5 Then AT-I is cleaved aga in by an enzyme situated in the 
1ungs, called angiotensin converting enzyme (ACE) to form angiotensin II. Endothelial 
cells express receptors to AT-II in sorne arteria1 beds.32 The contraction induced by AT-
II in vascu1ar smooth muscle is mediated by AT, receptors coup1ed to the activation of 
phospholipase C, the mobilization of intracellu1ar Ca2+, and the activation of mitogen-
activated prote in kinases. 
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Studies indicate that estrogens interact with the angiotensin by inhibiting its constrictive 
effect. Women on estrogen replacement therapy have a lower level of renin than women 
not on estrogen replacement therapy, and premenopausal level women have a lower 
level of renin than men and postmenopausal women. 191 In another group of 
postmenopausal women taking HRT, it has been shown that ACE activity is reduced. 222 
Moreover, women who are estrogen deficient have a higher level of mRNA for the AT1 
receptor and its density.191 Animal studies seem to confirm these findings in humans. 
For example, a study of ovariectomized rats showed that l7~-estradiol reverses the 
density and expression of AT 1 receptors in smooth muscle cells from the aorta. 205 ,206 It 
has also been reported that 17~-estradiol treatment reduces ACE mRNA concentration 
in kidneys, lungs and the aorta in ovariectomized rats. 207 So far, there is no study 
looking at whether estrogens receptors are directly interacting with the renin, ACE and 
angiotensin production. 
1.6.1.6 Thromboxane A2 
Thromboxane A2 (TXA2) is formed in platelets and is a powerful vasoconstrictor. It is 
also synthesized via the prostaglandins pathway.15 Basically, the arachidonic acid 
transformed by cyclooxygenase produces both prostacyclin (PGIz) and thromboxane 
(TX).223,224 TXA2 binds to endoperoxide/thromboxane receptors on the smooth muscle 
to induce contractions.32 ,208 Studies indicate that estrogens have an inhibitory effect on 
the vasoconstrictive property ofTXA2.191 In ovariectomized rats, it has been shown that 
estrogen treatment decreases the sensitivity TXA2 receptor. 
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1.6.1.7 Calcium 
The contraction mechanism reqmres the presence of intracellular calcium (Ca2+). 
Functional evidence has suggested that estrogens modulate Ca2+ entry or intracellular 
Ca2+ release in the vascular smooth muscle. 191 For example, 17~-estradiol has been 
shown to inhibit the barium inward CUITent through voltage-dependent L-type Ca2+ in 
cultured rat thoracic smooth muscle. AIso, in experiments caITied out using Ca2+-free 
solution in which Ca2+ storage was depleted, 1 7~-estradiol significantly reduced the 
contraction following the re-addition of Ca2+ to the Ca2+-free solution.225 This suggests 
that 17~-estradiol restricted the Ca2+ entry. ln a different experiment, Freay et al. 
(1997)209 demonstrated that 17~-estradiol inhibits Ca2+ uptake causing relaxation in 
smooth muscle in rat aorta. 
1.6.2 Neuronal effect 
As well, there is a growing body of evidence showing that estrogens have a protective 
effect on neurons. For example, estrogens have been shown to increase neuron survival 
in several toxicity models of cultured neurons, such as in glutamate, ~-amyolid, 
hydrogen peroxide, and excitatory amino acid toxicity models.226-229 
Estrogens also have a trophic effect on neurons. Experimental studies have 
demonstrated that estrogens increase dendritic spines density, which are the post-
synaptic sites of excitatory input to a wide variety of neurons in the mammalian brain. 
This has been observed in the pyramidal cells of the CA 1 region of the hippocampus in 
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rodents.230-232 As weU, estrogens stimulate ceU proliferation in the hippocampus.233 ,234 
A large body of evidence pointed out that the neurotrophic mechanisms of estrogens are 
mediated by the brain-derived neurotrophic factor (BDNF).235,236 
1.7 Progesterone 
Progesterone is a sexual hormone produced by the corpus luteum and placenta. It is 
responsible for changes in the endometrium in the second half of the menstrual cycle, 
preparatory to implantation of the blastocyte, development of the mate rial placenta and 
development of the mammary glands. Progesterone results from the conversion of 
pregnolone by the 3~-hydroxysteroid dehydrogenase.237 Progestagens is a term applied 
to hormones that produce similar effects to those of progesterone, the only natura} 
progestagen. AIl other progestagens are synthe tic and are often referred to as progestins. 
Progesterone is 36% bound to corticosteroid-binding globulin (CBG) when released in 
the blood stream. 167 
Similar to estrogens, progesterone also exerts vascular etfects in non-reproductive 
organs including the vascular system and the brain. The interaction of progesterone 
throughout the body is mediated via progesterone receptors (PRs). There are two 
isoforms of progesterone receptors termed A and B (PR-A and PR_B).238-241 The 
interaction of progestins is not only with progesterone receptors, but aiso with other 
'd h 242 S .. . h h d sterOl ormones receptors. orne progestms mteract Wlt t e an rogen, estrogen, 
glucocorticoid or the mineralocorticoid receptors. These interactions may either induce 
transactivation of a steroid receptor or prevent activation. Therefore, the resulting action 
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of a progestin may be agonistic or antagonistic based on the ratio of 
transactivationlinhibition of a steroid receptor.243 
P h b 1 1· d' h 1 244-246 k' 247 rogesterone receptors ave een oca Ize III t e centra nervous system, s Ill, 
heart and vascular tree248-250 and reproductive system251 in humans. Progesterone 
receptors have also been localized in different structures of the eye. These includes the 
lacrimal gland, meibomian gland, li d, palpebral and bulbar conjunctiva, comea, lens, 
iris/ciliary body, lens, uvea, choroid, and retinal pigmentary epithelium ofrats, rabbits or 
humans.178-181,183,184 As well, progesterone receptors are present in the human,179,180,185 
rat 179,180 and rabbit retinas. 179,180 
1.7.1 Vasomotor effect 
Contrary to estrogens, the vasomotor effects of progesterone are divergent. In animal 
models, P has been shown to either induce vasodilation,252-255 increase BF256,257 or have 
no effect.258,259 In clinical trials involving postmenopausal women, P administration has 
been shown to decrease the endothelium-dependent flow mediated vasodilatation (FMD) 
of the brachial artery,260 to have no effece61 or to increase FMD.262 
To add to the complexity of progesterone vasomotor effects, progesterone also has 
divergent vasomotor effects when administered with estrogens. In an animal model, 
progesterone was shown to antagonize the estrogen-induced BF in a combined 
therapy.258,259,263 In postmenopausal women, . . d 264 It antagomze, or did not 
. 262 265 h . d d FMD d d .. . 1 antagomze ' t e estrogen-Ill uce compare to estrogen a mImstratIon a one. 
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The vasomotor effect of progesterone is mediated by stimulating action on nitric 
oxide,266-268 and prostacyclin267,269 pathways, and inhibiting action on the thromboxane 
A2 pathway. 255 
1.7.2 Neuronal effect 
With regards to whether progesterone protects neurons, findings are also divergent. P 
has been shown to increase neuron survival in glutamate toxicity models of neurons 
from the hippocampus270 and cerebral cortex,271 and in a spinal cord genetic modet2n in 
rodents. However, an increase of neuron survival has not been observed in the 
axotomized optic nerve model in rodents. 273 
\ 
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1.8 Menopause 
The menopause is the period corresponding to the permanent cessation of ovarian 
follicular activity and subsequent fall in endogenous estrogens and progesterone 
production in aging women. Prior to menopause, the ovanes become increasingly 
resistant to hormonal stimulation. To compensate for this, the hypothalamus and the 
anterior pituitary gland increase the release of gonadotrophic hormones. Eventually, the 
remaining ovarian follicles fail to ripen despite continued secretion of follicle 
stimulating hormone (FSH) and lutenizing hormone (LH), and a subsequent fall in 
endogenous estrogens and progesterone occurs. Table 1 indicates the concentration 
ranges of endogenous estradiol, estrone and progesterone during the follicular, lute al and 
postmenopausal period in women. The average age at menopause is 51 years, although 
it commonly occurs as early as 45 years or as late as 56 years of age.274 The 
perimenopause (or climacteric) is the period immediate1y before the menopause with 
endocrinological and clinical features of approaching menopause, and at least the first 
year after the menopause. The postmenopause is the period following the date of the 
last menstrual bleed, which cannot be determined until12 months of amenorrhea. 
Symptoms related to the menopause are vasomotor instability (hot flushes, night 
sweats), urogenital tissue atrophy, vaginal dryness, dry skin, bone density loss and 
psychological symptoms such as insomnia, depression, irritability, lethargy/fatigue and 
loss of libido. 
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Table 1: Concentration ranges of endogenous estradiol, estrone and progesterone during 
the follicular, luteal and postmenopausal period in women. 
Estradiol (pmollL) 
Estrone (pmollL) 
Progesterone (nmollL)* 
Follicular 
110.3-367.1 
110.9 - 369.8 
Luteal 
257.0 - 1101.3 
332.8 - 591.7 
11.1-119.3 
* Luteal progesterone on days ranging from 17 to 23. 
(F rom http://www.esoterix.comlfiles/ expected _ values. pdf) 
1.9 Postmenopausal hormone therapy (HT) 
Postmenopausal 
< 55.1 
< 147.9 
<0.3 
Postmenopausal hormone therapy (HT) consisting of estrogens alone or combined with 
progestagens, is frequently prescribed to women in order to alleviate postmenopausal 
symptoms. The most common routes of administration are oral and transdermal, but it 
also can be administered vaginally, by injection or via nasal spray. The active 
ingredients can be bio-identical or synthetic. 
1.9.1 Estrogen therapy 
The most common forms of estrogens and equivalent doses in HT are listed in Table 2. 
Table 2: Common fonns of estrogens and equivalent doses in HT * 
Estrogens 
17~-estradiol 
Conjugated equine estrogens (CEE) 
Ethinyl estradiol (EE) 
Transdennal l7~-estradiol 
Dose 
1.0 2.0 mg 
0.625 - 1.25 mg 
5.0 Ilg 
50 - 100 Ilg 
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* Personal communication from Dr Michèle Moreau, Department of Family Medicine, 
University of Montreal 
When administered orally in its native crystalline state, 17~-estradiol is poorly absorbed 
by the gastro-intestinal tract because of its extensive first hepatic effect, but in 
micronized fonn it is weil absorbed.275 After oral administration of 17~-estradiol 70% is 
converted to estrone in the liver. Estrone is then further metabolized, resulting in 
metabolites with decreasing estrogenic activity such as estriol which is the most 
abundant end product.274 Transdennal application of 17~-estradiol avoids the entero-
hepatic pass. 
The tenn "conjugated equine estrogens" (CEE) refers to a natural mixture of water-
soluble sodium salts of estrogen sulfate esters of the ring B saturated and unsaturated 
estrogens, which are extracted from the urine of pregnant mares. 1 67,276 Since aH 
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estrogens present in CEE have estrogenic activity, the pharmacological effects of CEE 
are a result of the sum of these individual activities, which is greater than the 17~­
estradiol activity. Ethinyl estradiol is a synthe tic estrogen and is more potent than 17~­
estradiol because it is not metabolized by the liver, and it is rapidly and almost 
completely absorbed from the gastro-intestinal tract.275 
The relative potency of various estrogens is tissue-specific and cannot be generalized. 167 . 
Based on several clinical and metabolic parameters, the relative potency of CEE and EE 
ranges from 1.1 to 5.0 times and from 120 to 600 times respectively of the 17~-estradiol. 
1.9.2 Progestagens therapy 
Progestagens are prescribed as a combined HT to menopausal women with an intact 
uterus so as to regulate the action of estrogens on endometrial cells and prevent 
endometrial cancer. Progestagens can be prescribed as a cyclical treatment (the first ten 
or fourteen days of each month) or as a continuous treatment. The types of progestagens 
prescribed in combination with estrogens in HT are listed in Table 3. 
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Table 3: Types ofprogestagens used in combination with estrogens in HT 
Progestagens Cyclical dose Continuous dose 
Progesterone 200- 300 mg 100 mg 
Medroxyprogesterone (MP A) 5 -10 mg 2.5 mg 
N orethisterone acetate (NET A) 0.7-1.0 mg 0.25 - 0.5 mg 
Levonorgestrel 751lg 250llg 
Desogestrel 150 Ilg unknown 
Dydrogesterone 10- 20 mg 2.5 - 2 mg 
Cyproterone acetate 1 mg unknown 
Norgestimate 90llg 90llg 
(From Samsioe G, Lobo RA, Doren M. Menopause. London, UK: Elsevier; 2003:36) 
The bioavailability of oral progesterone is low and progesterone derivates such as MP A, 
NET A and levonorgestrel, three commonly used progestagens, have improved 
bioavailability. Similar to the estrogens, the data on the potency of the various 
progestagens are tissue-specifie. Based on the transformation dose (an indicator of the 
progestagens hormonal potency on the endometrium),167 the hormonal potency of the 
MPA and NETA is 84 times, and for levonorgestrel, it is 840 times of the 17~-estradiol. 
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1.9.3 Vasomotor effect 
The vasomotor effects of estrogens have been observed in postrnenopausal women using 
HT. Clinical studies have demonstrated that the use of HT improved blood fIow in the 
Co 1 277 db· h 278-281 d 1 ·1· dl .... d lemora artery an ram parenc yma, an pu satI lty an or reslstIvlty m exes 
( . f· fi)· h ·d 282-284 . 1 ·d285-289 d expreSSIOn 0 reslstance to ow m t e common carotI , mterna carotI an 
middle cerebral arteries286,287 in postmenopausal women. 
The beneficial vasomotor effects of HT in improving blood fIow combined with an 
improved lipid profile, su ch as decreased low-density lipoprotein and increased high-
density lipoprotein, have characterized HT as being cardioprotective. During the 
1990's, HT was increasingly prescribed to postmenopausal women to protect against 
cardiovascular disease (CVD). Observational studies pointed out that postmenopausal 
women taking HT presented a reduction in aU-cause mortality, which was be1ieved to be 
primarily due to a reduction in CVD.290-294 However, since the publication of two large 
randomized trials, the Heart and Estrogens/Progestins Replacement Study (HERSi95 
and the Women's Health Initiative Study (WHli96 indicating that HT does not offer a 
cardiovascular protection, the use of HT for controUing postmenopausal symptoms has 
raised controversies. 
The HERS295 study was the first large-scale randomized trial of HT for the prevention of 
coronary heart disease (CHD). A total of 2 763 women with coronary disease, younger 
than 80 years old (mean=66.7 years) were randomly assigned to either 0.625 mg of 
conjugated equine estrogens (CEE)) plus 2.5 mg medroxyprogesterone acetate (MPA) or 
a placebo treatment. The primary outcome measures were the occurrence of myocardial 
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infarction (MI) or CHD death. After a 4.1 year foIlow-up, there were no significant 
differences between the two groups for MI and CHD death. Women assigned to HT 
treatment significantly presented an Il % decrease in their low-density lipoprotein 
(LDL) and a 10% higher high-density lipoprotein (HDL). However they experienced 
significantly more venous thromboembolic events (odds ratio=2.9, 95% CI: 1.5, 5.6). 
The design of this study presented sorne weaknesses. First of aIl, 18% of the women, 
who were assigned to the treated group, crossed over to the placebo group during the 
study297 and both groups of women used statin, but more in the placebo group.298 
W omen enrolled in the study had CHD history and the endothe1ia1 lining in these 
women was likely damaged throughout their vascular system. Finally, the age average 
of women enrolled in the study was 66.7 years, which is too late an age to initiate HT, 
for the following reasons; the amount of ERs decreases299 and ERa gene methylation 
increases300 (an indicator of inactivation of gene transcription) in atherosc1erotic women, 
and response to vasodilatation is impaired in postmenopausal women with 
cardiovascular disease.30I ,302 Consequently, the use of HT in older postmenopausal 
women with a history of CHD would be unlikely to provide a protective effect against 
cardiovascular disease in the presence of reduced ER expression and activity, and 
impaired vasodilatation response. The scientific community started to refer to the tenn 
"the window of opportunity ,,303 which means that to be effective against cardiovascular 
disease and other menopausal symptoms, HT must be prescribed to menopausal women 
when estrogen receptors are still present and active, and that the cardiovascular system 
and endothelium are still relatively healthy and responsive to HT, i.e. in the first five 
years of the menopause. 
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The WHI study was a large multicentre study that focused on defining the risks and 
benefits of strategies that potentially could reduce the incidence of heart disease, breast 
and colorectal cancer, and fractures in postmenopausal women over a period of 8.5 years 
oftreatment.304 Between 1993-1998, a total of 161 809 women aged between 50 and 79 
years old, were enrolled into a set of clinical trials (trial of low fat dietary pattern, 
calcium and vitamin D supplementation, and two trials of postmenopausal hormone 
use). The HT trial of 27,500 women (mean age = 63.3 years old) had two arms: 45% of 
women without uterus were randomized to receive either CEE (0.625 mg/day) or a 
placebo, while 55% of those with intact uterus received CEE (0.625 mg/day) + MPA 
(2.5 mg/day). In July 2002, the interim analysis of 5.2 years follow-up of the CEE+P 
arm study was published.296 It reported the following odds ratio of 1.29 (95% CI: 1.02, 
1.63) for CHD, 1.26 (95% CI: 1.00, 1.59)for breast cancer, 1.41 (95% CI: 1.07, 1.85) 
for stroke, 2.13 (95% CI: 1.39,3.25) for pulmonary embolism, 0.63 (95% CI: 0.43,0.92) 
for colorectal cancer, 0.83 (95% CI: 0.47, 1.47) for endometrial cancer and 0.66 (95% 
CI: 0.45, 0.98) for hip fracture. In light of these findings, the data and safety monitoring 
board recommended discontinuing the CEE+MPA arm as the risks exceeded the benefits 
and the CEE+MPA did not demonstrate cardiovascu1ar protection. Then, in April 2004, 
the interim analysis of 6.8 years follow-up of the CEE arm study was published.305 The 
following odds ratio were reported; 0.91 (95% CI: 0.75, 1.12) for CHD, 0.77 (95% CI: 
0.59, 1.01) for breast cancer, 1.39 (95% CI: 1.010, 1.77) for stroke, 1.34 (95% CI: 0.87, 
2.06) pulmonary embolism, 1.08 (95% CI: 0.75, 1.55) for colorecta1 cancer and 0.61 
(95% CI: 0.41, 0.91) for hip fracture for the treatment group. In this second interim 
analysis, the use of CEE significantly increased stroke risks, but did not affect the 
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incidence of CHD. Because CEE did not of fer any overall benefit, the CEE study ARM 
was discontinued. However, the outcomes of the WHI study were also controversial. 
As in the HERS Study, the WHI Study presented similar weaknesses in its design: the 
average age of the study participants at the initiation of HT was 63.3 years old, which 
again, is too late an age to initiate HT. As weIl, sorne women already had CHD history 
prior to the study enrolment. Interestingly, when looking at the odds ratio of CHD for 
different age-groups, the odds ratio were 0.93 (95% CI: 0.65, 1.33) for age group 50 to 
59,0.98 (95% CI: 0.79, 1.21) for 60 to 69 and 1.26 (95% CI: 1.00, 1.59) for 70 to 79 age 
group.306 This finding indicated that younger women tended to have reduced CHD risks 
compared to oIder women. Moreover, when looking at the odds ratio of CHD risk when 
HT was initiated at different postmenopausal times, the odds ratio were 0.76 (95% CI: 
0.50, 1.16) for less than 10 years of menopause, 1.10 (95% CI: 0.84, 1.45) for 10 to 19 
years and 1.28 (95% CI: 1.03, 158) for 20 years or more (p for trend = 0.02, but this 
trend did not meet the criterion for statistical significance as stated by the investigators 
of this study). Therefore, women who initiated HT sooner after menopause onset tended 
to have a reduced CHD risk compared with the increased CHD risk among women who 
initiated HT later after menopause onset. These two latest observations underline the 
importance of the "window of opportunity" in prescribing HT in postmenopausal women 
as explained earlier. 
In response to both HERS and WHI design weaknesses, another randomized trial, the 
Kronos Early Estrogen Prevention Study (KEEPS), was designed in 2005, which tested 
whether the use of HT had cardiovascular benefits.307 The KEEPS was designed with 
major improvements of inclusion/exclusion criteria and interventions. Women were 
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recently menopaused and assigned to oral CEE (0.45 mg/day) + Progesterone (200 mg), 
transdermal estradiol (50 Ilg/day) or placebo treatment. The choice of a lower CEE 
dosage compared to the usual 0.625 mg/day was decided based on the fact that a CEE 
dose of 0.625 mg may induce a prothrombotic or inflammation effect.308,309 AIso, the 
choice of ad ding a transdermal HT treatment group was to eliminate the prothrombotic 
effect reported with the use of oral CEE.309-311 Finally, women could not have taken any 
estrogens- and progestagens-containing medications (contraceptive and HT) within 6 
months of randomization and must have presented reduced estradiol levels <91.75 
pmol/L as well as FSH 2:1.16 nmollL. This clinical trial is still in progress and no 
findings have been published yet. 
1.9.4 Neuronal effect 
The protective effect of HT on brain tissue has been reported in postmenopausal women 
using HT. Observational studies using magnetic resonance indicated that women on HT 
presented larger volumes of sorne brain regions such as the hippocampus,312-314 and the 
lateral prefrontal, fusiform and entorhinal cortex.314 
1.9.5 Guidelines and recommendations for UT use 
In January 2006, the Society of Obstetricians and Gynaecologists of Canada (SOGC) 
published several general and specifie recommendations on HT.315 The first three 
general recommendations are listed as follows: 
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1) Health care providers should discuss and encourage initiation of healthy lifestyle 
choices in menopausal women 
2) The primary indication for hormone therapy (HT) should be for the management 
of moderate to severe menopausal symptoms 
3) HT should not be prescribed for primary or secondary prevention of 
cardiovascular disease (CVD) or for primary prevention of dementia 
These first three general recommendations should guide the reader to understand the 
SOGC position following the controversial findings of the HERS and WHI clinical 
trials. In 2007, the International Menopausal Society also pub lished their 
recommendations on HT.316 The IMS recommendations reflect those of the SOGC. 
Both documents listing these recommendations are found in the annex section of the 
present thesis. 
The general message from SOGC and IMS guidelines and recommendations is that HT 
may still be cardioprotective, but HT should not be prescribed for primary and 
secondary prevention of cardiovascular disease. . 
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1.10 Relationship between estrogens and HT with glaucoma and ARMD 
Recently, population-based studies indicated a possible link between estrogens and the 
use of HT with glaucoma and age-related macular degeneration. In the Rotterdam Study 
(n=3 078),317 it was reported that women who experienced early menopause onset before 
the age of 45 (odds ratio=2.6, 95% CI: 1.5,4.8) had a significantly greater odds ratio of 
developing open-angle glaucoma. The Blue Mountain Eye Study (n=2 072 women)318 
reported that women who experienced menarche at 2:13 aiso presented a significantly 
greater odds ratio (odds ratio=2.1, 95% CI: 1.1, 3.8) of developing glaucoma. AIso, in 
the same Blue Mountain Eye Study,319 it was reported that an increasing amount ofyears 
from menarche to menopause significantly decreased the odds ratio of early ARMD 
(odds ratio=0.97, 95% CI: 0.95, 0.99). Interestingly, it has been shown that the use of 
HT in postmenopausa1 women significant1y decreased the odds ratio of developing 
advanced (odds ratio=0.62, 95% CI: 0.39, 0.96),320 and neovascular ARMD (odds 
ratio=0.29, 95% CI: 0.90, 0.92).321 In the Rotterdam Study, the odds ratio of open-
angle glaucoma was lower in women who had used HT than in women who never had 
used HT, but this was not significant (odds ratio=0.54, 95% CI: 0.17, 1.74).317 These 
observations underline that short exposure to endogenous estrogens and depletion of 
estrogens throughout menopause might be risk factors in the development and 
progression of glaucoma and ARMD and that the use of HT seems to play a protective 
role. 
This apparent protective role of estrogens and HT against glaucoma and age-related 
macular degeneration observed in postmenopausal women could result from vasomotor 
and protective effects of estrogens. Clinical studies reported that postmenopausal 
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women taking HT presented improved pulsatility and/or resistivity indexes in the 
retrobulbar vessels, such as the ophthalrnic,288,289,322,323 short posterior324 and the central 
retinal arteries,324-327 as demonstrated by color Doppler Irnaging. However, there is no 
direct evidence that estrogens and HT have a vasornotor effect on the retinal and ONH 
circulation in postmenopausal wornen. Additionally, since estrogens have a protective 
effect on neurons, as HT has been shown to prevent cerebral tissue atrophy in sorne 
brain regions and as ERs are present in the ganglion cell layer and axons in hurnan 
retinas,186,187 it is unknown whether HT rnay present a protective effect on optic nerve 
head (ONH) topography as well as on the function of the retinal ganglion cells (RGCs). 
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2.0 AIM OF THE STUDY 
In an attempt to investigate whether estrogens and HT have a vasomotor effect on the 
retinal and ONH circulation, as well as a protective effect on the ONH topography and 
the retinal ganglion cell (RGC) function, we designed two studies. One observational 
study investigated the retinal and ONH blood flow, ONH topography and the function of 
RGCs,which were measured in healthy postmenopausal women who were HT users 
(+HT) since their menopause onset. Results were compared with those obtained from 
healthy postmenopausal women of similar age and characteristics who had never used 
HT (0HT) since their menopause onset. The advantage of this approach over a 
prospective drug trial is that we could ascertain a potential effect of several years of 
estrogen therapy. It also would have been impossible to recruit patients for a 
prospective estrogen trial in the wake of the 2002 report of the Writing Group for the 
Women's Health Initiative Randomized Controlled Trial,296 which is wh en this study 
was being initiated. Retinal blood flow measurements were obtained at three different 
sites: 1) in a major retinal vessel, the infero-temporal retinal artery (ITRA) , using the 
Canon Laser Blood Flow Meter (CLBF, Japan) and in both peripapillary 2) nasal and 3) 
temporal areas using the Heidelberg Retina Flowmeter (HRF, Germany). For the ONH, 
the blood flow of the rim was also measured using the HRF. The ONH topography was 
assessed by measuring the 12 standard stereometric parameters using the Heidelberg 
Retina Tomograph (HRT I), and the function of RGCs was measured with the pattern 
electroretinogram (PERG) using the VERIS™ system. 
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In a second study, we investigated the vasomotor effect of 17p-estradiol (E2) treatment 
on the retina in a menopause rat model. In vivo retinal tissue perfusion was quantified 
by autoradiography using the diffusible tracer N-Isopropyl-p-[14C]-iodoamphetamine 
([14C]_IMP) in the conscious rat. This methodological approach provided the ability to 
distinguish the local effects of E2 on tissue perfusion in different isopters and quadrants 
of whole-mount retinas. This second study was designed for the purpose of developing 
a menopause rat model: 1) to confirm our retinal blood flow findings in postmenopausal 
women on HT, 2) to isolate the estrogen component on retinal blood flow changes by 
exposing ovariectomized rats to 17p-estradiol treatment only, and 3) to prospectively 
study the possible vasomotor pathways of estrogens on retinal circulation and protective 
effect on the ONH and RGCs. 
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3.0 METHODOLOGY 
3.1 Observational study in postmenopausal women 
Subjects 
This study was approved by the locallnstitutional Review Board (IRB) of Maisonneuve-
Rosemont Hospital and adhered to the tenets of the Declaration of Helsinki. A signed 
informed consent was obtained from aU subjeets before enrolment in the study. Subjects 
were tested in the Ocular Blood Flow Laboratory at the Ophthalmology Research Unit, 
Maisonneuve-Rosemont Hospital Research Centre. 
Eligibility criteria 
Healthy postmenopausal women were recruited from both Notre-Darne and 
Maisonneuve-Rosemont Hospital Menopause Clinies, Montreal, Quebec by personal 
interview and by posting advertisements in both hospitals and in the local newspaper. 
To be eligible for the study, aIl pre-screened healthy menopausal women had to meet the 
following inclusion criteria: not HT (0HT) or HT (+HT) users (as prescribed by a 
physician) since their menopause onset, 45 years of age or oider, naturaIly or surgically 
menopaused, amenorrhea for at least one year, body mass index equai or Iess than 30 
and non or former smoker. Menopausal women had to be free of systemic and central 
nervous system diseases and to present normal ocular histories and eye exams. Subjects 
on vasoactive or anti-inflammatory medications, and allergie to eye drops were 
excluded. The 0HT postmenopausal women served as control group. 
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Study visit 
Twelve hours prior to the study visit, subjects were asked to avoid caffeine and alcohol 
so as not to alter their basal hemodynamic level. As well, they were asked to avoid food 
with high fat content, which alters the serum estradiol assays. AIso, so as to confirm the 
use of HT and rule out the effects of vasoactive drugs, subjects were asked to bring an 
their medications, including any herbai medicine with them. The type of HT in terms of 
their active ingredients was documented. 
Medical, gynaecological and ocular histories, and eye exam 
At the time of the study visit, demographic, medical, gynaecological and ocular histories 
were obtained from each subject using a standardized questionnaire administered by one 
examiner (MCD), who determined the eligibility of the subjects for the study. Medical 
history included measures of the blood pressure (BP)(mmHg) at rest for 30 minutes, 
height (m), and weight (kg). These measures were used for calculating the body mass 
index (BMI=weight/height2) and mean BP «BPdiastolic + l/3(BPsystolic 
BPdiastolic». Gynaecological history included the following variables: age at 
menarche, age at last menses (natural or induced by ovariectomy) and duration of 
reproductive years (RY) (age at last menses minus age at menarche). Menopause 
duration (age at study visit minus age at last menses) and HT duration (age at study visit 
minus age at initiation of HT) were calculated. For women who had hysterectomies, the 
age at last menses could not be determined. Therefore, age at last menses, reproductive 
year and menopause durations were tabulated as missing values. Ocular histories and 
eye exams were obtained, which included best corrected visual acuity using the Snellen 
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chart (V A expressed by its numerator divided by its denominator), refraction (expressed 
in spherical equivalent), and biometry (OcuScan, Alcon® Surgical Inc., USA v3.02). 
Slit-Iamp examination, evaluation of peripheral anterior chamber depth, tonometry (IOP 
mmHg), and ophthalmoscopy were performed by one ophthalmologist (DD). Ocular 
perfusion pressure (OPP mmHg) was calculated using the foUowing formula: OPP= 2/3 
BPrncan-IOP.l 
Selection of the investigated eye 
AU retinal and ONH blood flow measurements, as weU as ONH topography and PERG 
measurements were conducted in one eye only, i.e. the eye with the c1earest media, 
better fixation and least lid ptosis. When both eyes were eligible for the study, one eye 
was randomly chosen. The chosen eye was tested first undilated for the PERG testing, 
then dilated with tropicamide (Mydriacyl® 1 %, Alcon Canada Inc.) for the HRT, SLDF 
and CLBF testing. 
Serum estradiol and progesterone assays 
A blood sample was obtained from aIl subjects and analyzed by the local hospital 
laboratory service for documenting the total serum estradiol (E2) and progesterone (P) 
concentrations by chemiluminescent immunoassay technique (ADVIA Centaur®, Bayer 
HealthCare Diagnostic, USA). These assays were obtained to confirm the hormonal 
status of estrogens and progestagens in aU postmenopausal women. Sorne active 
ingredients present in the HT regimens and used by postmenopausal women were not 
17p-estradiol- and/or progesterone-based. Therefore, measures of the serum estradiol 
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and progesterone concentrations by the hospitallaboratory service were not appropriate. 
Consequently, low serum concentrations of estradiol and progesterone not detected by 
the assay technique were tabulated as zero. As well, for sorne postmenopausal women 
who were not HT users, the endogenous serum 1 7~-estradiol and progesterone 
concentrations were below the level of detection by the assay technique. Consequently, 
their serum concentrations were also tabulated as zero. 
Infera-temporal retinal artery 
Blood flow (Flow) of the infero-temporal retinal artery (ITRA) was measured using the 
Canon Laser Blood Flowmeter System (CLBF model 100, Japan). The CLBF is a 
unique system that quantifies blood flow in retinal vessels by simultaneously measuring 
both diameter (D) and velocity (Vel) of the blood column in a vessel of interest.328 To 
achieve this, the CLBF system is equipped with a dual laser system mounted in an eye 
fundus camera and an acquisitionlanalysis software (v2.1.23). An oval (8 !-lm x 50 !-lm) 
red diode laser (675 nm) measures the mean centre line blood column velocity (Velmcan) 
of the vessel of interest by using a bi-directionallaser Doppler velocimetry, the principle 
ofwhich has been described elsewhere.329-331 Briefly, the Doppler-shifted light scattered 
from the flowing blood cells in the targeted vessel is detected simultaneously in two 
directions by two photomultiplier tube detectors positioned at a fixed angle. The signaIs 
from two photomultiplier tube detectors undergo computer-controlled spectrum analysis, 
and sequential measurements of ve10cities are performed automatically at every 20 ms 
(50 Hz sampling rate) over a period of 2 sand time-averaged velocity (Velmcan) is 
determined. The D is measured by a rectangular (1500 !-lm x 150 ""m) green diode laser 
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(543 nm) manually positioned perpendicular to the vessel of interest. The laser 
measures the blood column width by transmittance profile method, the principle of 
which has been described elsewhere.332 The D is determined automatically by computer 
analysis of the signal produced by the image of the vessel on a charge-coupled device 
(CDD) sensor using the half-height of the transmittance profile to define the blood 
column edge. It is measured for the first and last 60 ms of the 2 s velo city measurement 
period, at every 4 ms (250 Hz sampling rate). The D measurement is corrected for the 
axiallength of the eye (operator input) and refractive error of the eye, which is measured 
by the CLBF itself. To compensate for microsaccade of the eye, the green diode laser 
also serves as a tracking system by scanning repeatedly and rapidly the intensity profile 
produced by the rectangular green diode laser and by analyzing the scanned intensity 
profile. The analyzing electronics automatically reposition/stabilize the incident laser to 
the vessel centre.333 Since both lasers operate simultaneously, D and Velmcan are 
obtained in the same time frame. 
The CLBF acquisition software has been designed so that one measurement of D and 
Velmcan obtained by the operator corresponds to one Path. After the acquisition of one 
Path, the software displays 4 parameter windows allowing the operator to visually 
inspect the quality of the Path obtained and it is either saved or discarded. The 
parameter windows are: 1) stability of the relative velocity over the 2 s period, 2) the 
stability of Q-index over the 2 s period and the overall Q-index (an indicator of the 
signal quality intemally determined by the software), 3) the stability of the vessel 
tracking over the 2 s period, and 4) the coefficient of variation of the vessel diameter. 
For accuracy, the CLBF software operates by measuring two Paths (Pathl and Path2), 
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th en automatically calculates the flow following the Poiseuille's law, according to the 
following equation: 
Flow (IlLlmin)= Velocityrncan(nDiameter2/8) 
where VelocitYrncan is the time averaged centre line blood velocity (mmls) during the 
cardiac cycle and nDiameter2/8 is the cross-sectiona1 area of the measurement site (11m2). 
Since study participants underwent several tests during the study visit, retinal blood flow 
measurements were only obtained from one site, the ITRA. By inference, the blood 
flow measures from the ITRA can be used as an indicator of the overall retinal arterial 
circulation. There are two motives for choosing the main retinal artery from the infero-
temporal region. First, it is a region that is technically accessible to obtain CLBF 
measurements, and second, the infero-temporal region is the most common site of early 
glaucomatous damage. The location of the measurement on the ITRA was done on a 
straight section of the vessel before the first bifurcation between 0.5 and 2.0 dise 
diameters from the edge of the optic dise. Ten consecutive high quality Path 1-Path2 
pairs and calculated Flow values were obtained. After excluding the incomplete 
measures (the CLBF automatically rejected flow measurements wh en one of the two 
paths was unreplicable) and discarding the highest and lowest flow values, the three 
closest flow values calculated by the CLBF software were used for averaging D, Velrncan, 
and Flow. This recording protocol gave us an intra-session coefficient of variation of 
3.2+/-1.9% for D, 6.7+/-3.2% for Velrncan, and 7.1 +/-4. % for Flow obtained from the 
ITRA in 19 normal women (manuscript in preparation). Figure 9 illustrates an example 
of a CLBF recording from a normal subject. 
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B 
Figure 9: Example of a CLBF measurement obtained from a nonnal subject. The panel 
(A) illustrates the position of the red diode laser (675 nm) that measures the me an centre 
line blood colurnn velocity of the infero-temporal retinal artery (ITRA) and the 
\ 
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orientation of the green diode laser (543 nm) that measures its diameter. The right panel 
(B) shows both Path measurements, Path 1 and Path 2, with their respective parameter 
windows. For one Path, the top window displays the relative velocity over a 2 s period, 
followed by a window, which displays the Q-index over a 2 s period and the overall Q-
index (an indicator of the signal quality intemally determined by the software). Then a 
third window displays the stability of the vessel tracking over the 2 s period, and finally 
the last window displays the coefficient of variation of the vessel diameter. For this 
particular subject, four Flow measurements (ranging from 3. 7 to 5.2 flL/min) were 
acquired with their respective D (ranging from 90.5 to 94.4 flm) and Vel (ranging from 
19.2 to 24.6 mmls) as shown on the bottom left ofpanel B. 
Peripapillary retinas and ONH rim areas 
The capillary blood flows of the ONH rim and both nasal and temporal peripapillary 
retinal areas were measured by Scanning Laser Doppler Flowmetry (SLDF) (HRF, 
Heidelberg Engineering, Germany, v1.02). Briefly, the Heidelberg Retina Flowmeter 
combines a confocallaser scanning technique and laser Doppler flowmetry. It measures 
the amount of back scattered light at different locations (pixels) in the region of interest. 
A parallel infrared laser beam of 3 mm diameter (780 nm, 180 fl W) scans line by line a 
two-dimensional region of the retina. The scan field is 100 wide by 2.50 height, 
corresponding to a size of 2.88 mm x 0.72 mm. Detailed description of the instrument 
and measurement technique has been described elsewhere?34,335 During the scan along 
one line, the reflected light intensity at 256 equidistant locations (pixels) is measured 
and digitized (pixel distance Il.2 flm) sequentially. Each line is scanned 128 times at 
'\ 
) 
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4000 Hz, which takes 0.032 s. Then, the next line is scanned 128 times until a total of 
64 equidistant lines (line distance 11.2 ~I.m) are scanned. Thus, the reflected light 
intensities of each pixel are obtained as a function of time (fluctuation time curve). The 
total acquisition time is about 2.5 s. The automatic full-field perfusion image analysis 
software (AFFPIA, v3.3)80,81 improved data quality by removing over-exposed pixels, 
and saccades, and allowed the analysis of large regions of tissue such as the neuroretinal 
rim. The collected intensity data of each pixel was then analyzed by a discrete Fourier 
transformation, thus calculating the laser-Doppler frequency shift for each pixel. The 
data of the laser Doppler frequency shift of the 64 x 256 pixels is the base to generate 
the perfusion image, and the AFFPIA computes flow (distance travelled by aIl moving 
red blood cells per unit of times), volume (number of moving blood cells), and velo city 
(mean of blood cell speed) for each pixel, aIl expressed in arbitrary units (AU). For 
valid capillary blood flow measurement at each pixel, the AFFPIA uses an algorithm to 
exclude over- or under-exposed pixels, retinal vessel tree and eye saccades (which is 
identified by the operator). Moreover, the AFFPIA permits an interactive marking of the 
rim are a of the optic nerve head allowing the output of the three hemodynamic 
parameters, flow (Flow), volume (Vol) and velocity (V el) for each region of interest, i.e. 
the nasal peripapillary retina (n), temporal peripapillary retina (t) and neuroretinal rim (r) 
areas. Figure 10 illustrates an example of a SLDF perfusion image and automatic full-
field perfusion image analysis obtained from a normal subject. 
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Figure 10: Example of a SLDF perfusion image obtained from a normal subject. The 
left side shows the marking circle delimitating the rim and both nasal and temporal 
retina of the optic nerve head region from a normal subject. The right side shows the 
Flow, Vol and Vel values obtained with the full-field perfusion image analysis 
(AFFPIA). For this particular subject, the Flow, Vel and Vol values obtained by the 
AFFPIA for the temporal retina ofthis SLDF image corresponded to 271.7 AU, 0.9 AU, 
and 20.7 AU respectively. 
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Our HRF images were centered on the optic nerve head, optimizing the photodetector 
sensitivity to obtain a strong signal from both nasal and temporal peripapillary retinas, 
while avoiding overexposure. Ten SLDF images were obtained from each subject and 
the five best images in terms of focussing, ONH centration, optimum exposure, 
brightness, and lack of major eye saccades were kept for full-field perfusion image 
analysis. The obtained Flow, Vel and Vol from these 5 images for the nasal (n), 
temporal(t) and rimer) areas were th en averaged. This SLDF measurement protocol 
developed in our lab yields intra-session coefficients of reliability ranging from 0.93 to 
0.95, and coefficients of variation ranging from II.4% to 16.4% for the Flow among the 
three regions of interest.83 
ONH topography 
The optic nerve he ad topography was evaluated by measunng the 12 standard 
stereometrie parameters (i.e. dise area, cup area, cid, rim area, cup volume, rim volume, 
me an cup depth, maximum cup depth, cup shape measure, height variation contour, 
mean retinal nerve fiber layer (RNFL) thickness and the R1\IFL cross-sectional area) in 
all subjects. This was achieved by using the Heidelberg Retina Tomograph 1 (HRT l, 
Heidelberg Engineering, Heidelberg, Germany, v2.01). The HRT 1 is a confocallaser 
scanning ophthalmoscope operating three-dimensionally. A diode laser (670 nm) scans 
the optic nerve he ad (along the z-axis) in a series of 32 consecutive and equidistant two-
dimensional optical section images (x-axis and y-axis of 10° x 10° (256 x 256 pixels). 
Each pixel is approximately 1 0 ~m. The reflected light at each pixel is measured by the 
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eonfoeal optieal deteetor system and is used for generating a topography and refleetivity 
image. The topography image is the location along the z-axis where the maximum 
refleetivity registered is assumed to be the height of the location and the refleetivity 
image is the sum of the refleetivity measurements along the z-axis. Between five to ten 
ONH images were obtained and the average of the three closest images in terms of 
alignment, brightness and clarity was obtained. With the aid of fundus pietures, the 
extemal contour of the optie nerve rim was manually drawn and the Heidelberg Retina 
Tomograph interactive software automatieally ealeulated the twelve standard 
stereometrie parameters. The stereometrie parameters were obtained for the entire ONH 
(0°-360°) and for the infero-temporal reglOn (270°-360°), whieh is a reglOn most 
eommonly affeeted by early glaueomatous damage. Figure Il illustrates the topography 
and refleetivity images, and an output of the stereometrie parameters ealeulated by the 
HRT software from a normal subjeet. 
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Figure Il: Example of ONH topography measurement obtained from a normal subject. 
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using the Heidelberg Retina Tomograph I (HRT I). The topography image (panel A) 
represents the maximum reflectivity registered along the z-axis at each pixel, and the 
reflectivity image (panel B) represents the sum of aIl the reflectivity measurements 
along the z-axis. The 12 standard stereometric parameters from the entire ONH (0-360°, 
panel C) and the infero-temporal region (270-360°, panel D) are automatically calculated 
by the HR T software after manually marking the external contour of optic nerve head 
nm. 
Functionality of the RGC 
The pattern electroretinogram (PERG) represents an objective and direct measure of 
retinal ganglion cell function.336-338 It is a retinal biopotential evoked when a high 
contrast patterned stimulus (alternating stripes or checkerboards) is viewed. The PERG 
waveform signal begins with a negative deflection called N35, followed by a positive 
deflection called P50, and th en a second negative deflection called N95. Smaller PERG 
amplitudes and delayed latencies are indicative of RGC loss. Clinical studies where loss 
of RGCs occur such as in OHT and OAG, have demonstrated that N95 amplitude is 
reduced and P50 latency is increased,339 and that N95 amplitude significantly and 
positively correlates with RNFL thickness while P50 latency negatively correlates.340,341 
The PERG was recorded using the VERIS™ Multifocal System (Electro-Diagnostic 
Imaging, Inc., USA, v5.0) following the Guidelines of the International Society for 
Clinical Electrophysiology of Vision (ISCEV).342 Transient (4.7 reversalls (rps)) 
PERGs (bandwidth 1-100 Hz) were evoked by a black and white reversing checkerboard 
stimuli of 50° x 38° with checksize of 0.8° generated by a 9-inch monochrome monitor 
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(75 Hz frame rate). The luminance of the white squares was set at 353 cd/m2 and for the 
black squares, it was set at 30 cdlm2, (of 192 cdlm2 average luminance, 84% contrast). 
A sterilized and disposable silver DTL Plus ™ (Diagnosys LLC, USA) electrode placed 
in the lower conjunctival sac served as the active electrode in reference to a gold cup 
electrode (Grass Technologies, USA) placed at the ipsilateral outer canthus. Subjects 
were grounded through the forehead with a go Id cup electrode. Electrode impedances 
were checked for 5kn or less. The recording session was devided in segments, i.e. 32 
segments, each lasting 3.41 s for a total of 109.1 s. This corresponded to an average of 
514 responses obtained. During one segment recording, the subject was asked not to 
blink to minimize artifact since there is no artifact rejection capability built into the 
system. Two replicable PERG waveforms were obtained. The N35, P50 and N90 
waveform components were identified, and latency (N35 lat, P50 lat, N95 lat) and 
amplitude (P50 amp, N95 amp) were measured. Figure 12 illustrates a transient PERG 
waveform and measured components obtained from a normal subject. 
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Figure 12: Example of a transient pattern electroretinogram (PERG) obtained from a 
normal subject. The PERG was evoked by a checkerboard pattern of 50° x 38° with a 
checksize of 0.8° set at a contrast of 84% (white square luminance of 353 cd/m2, black 
square luminance 30 cd/m2). The PERG was recorded at 4.7 reversal/s. The three main 
waveform components were identified, N35, P50 and N90, and both latency (N35 lat, 
P50 lat, N95 lat) and amplitude (P50 amp, N95 amp) were measured as indicated. 
Estimation of sam pie size 
The calculation of the sample size was based on a power of 0.80 with an a=0.05 for 
comparing two means of two normally distributed samples of equal sizes using an 
unpaired two-sided t-test. The following formula to de termine the sample size is: 
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where 
cr represents a known standard deviation 
il represents a known change il = 1 ).12-).11 1 
For our study design we used the following information to determine our sample size: 
In postmenopausal women who have been on 2 mg of micronized 17p-estradiol for 2 
months, the resistivity index in the central retinal artery has been shown to significantly 
decrease from 0.73 ± 0.08 to 0.66 ± 0.01.325 Although this central retinal artery 
resistivity index was not an outcome variable for this observational study, it provided 
sorne guidance in calculating the sample size and we predicted we would find 
approximately the same magnitude of change of blood flow in the retina and optic nerve 
head. Therefore, 
n (0.082 + 0.01 2)(1.96+ 0.84/ 
(0.73 - O.66i 
n Il patients in the el HT (control group) 
n Il patients in the +HT (treated group) 
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We decided to include 25 subjects in each group hoping to gain power analysis. 
Statistical analysis 
Unpaired Student t-tests were performed for clinical, gynecological and 
ophthalmological variables between 0HT and +HT post-menopausal women. Linear 
regression analysis was performed for the out come variables for the blood flow, ONH 
stereometrie parameter and PERG between 0HT and +HT post-menopausal women. As 
postmenopausal women on HT were either on estrogens alone or combined with 
progestagens, subsequent linear regression analysis was performed to compare the effect 
of the type of HT treatment (estrogen therapy vs 0HT, estrogen + progestagen therapy 
vs 0HT and estrogen vs estrogen + progestagen therapies) in an attempt to evaluate the 
effects of estrogen therapy only. Statistical analysis was done using STAT AlIC 
software (Stata Corp LP, Texas, vI 0.0). A significance level of a = 0.05 was chosen. 
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3.2 Menopaused rat model 
AnimaIs 
Ali experimental methods and animal care procedures were approved by the local 
institutional animal care committee, "le Comité de Déontologie de l'Expérimentation sur 
les Animaux" at the University of Montreal, in accordance with the Canadian Council 
on Animal Care. Twelve mature middle-aged (11-month old) retired fema1e breeder 
Brown Norway (Rattus norvegieus, 225.5 ± 7.9 g) rats from a single colony (Hari an 
Sprague Dawley, Netherlands), were used in this study. Brown Norway rats have been 
chosen for the following reasons: 1) rats are widely used in ovarian aging research with 
weil documented pathobiologic, cardiologic and reproductive endpoints, and 2) Brown 
Norway rats have large eyes compared to other rat species, which have made them ideal 
to use as glaucoma models. The age of Il months was chosen as it corresponds 
approximately to the time when 65% of female rats present irregular estrous cycles,343 
equivalent to the perimenopausal period in women. Rats were housed individually and 
placed in a room at 23°C with a 12-hour lîght/dark adapted photoperiod, with food and 
water provided ad libitum. 
Ovarieetomy and implantation of capsules 
After habituation to their environment, bilateral ovariectomies (OVx) were perfonned in 
rats using a posterior surgical approach under isoflurane (3.0%) in order to nonnalize 
serum estrogen concentrations to their lowest level. Silastic capsules (1.0. 0.058, 0.0. 
0.077, 0.5 cm in length, #508-006, Dow Coming, Midland, MI) filled with a crystalline 
preparation of either 25% E2 (Sigma-Aldrich, St. Louis, MO, USA) plus 75% cholesterol 
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(OVx+E2, n=7, approximately 2 mg E2 per capsule) or 100% cholesterol (placebo) 
(Sigma-Aldrich, St. Louis, MO, USA) (OVx, n=5) were implanted in the nape of the 
neck for time-release. These capsules have been validated as a means of delivering 
steady and physiologicallevels of E2 in the range of 256.9 to 319.3 pmollmL in mature 
OVx rats.344-346 Moreover, the E2 treatment administered in our OVx rats using silastic 
capsules is a representative model of HT treatment in menopausal women since the five-
fold magnitude increase seen here is within the 3.1- to 11.8-fold range of increases in E2 
levels observed in postmenopausal women using typical transdermal E2 regimens.285,287 
Following the OVx surgery, 5 mL of Ringer's lactate were subcutaneously injected for 
rehydration, while repetitive subcutaneous doses of 0.1 mL of buprenorphine 
hydrochloride (Temgesic®, Reckitt Benckiser Health Science Ltd, UK, 0.1 mg/mL) 
were injected every 12 hours over a two-day period for post-operative pain management. 
Vaginal smears were performed both to ensure effectiveness of the bilateral OVx 
surgery and to serve as an indicator of tissue responsiveness to circulating estrogens 
released from E2 capsules. Rats were exposed to E2 or placebo treatment for a period of 
six weeks. The six-week treatment has been chosen in order to permit a further study 
investigating the potential vascular protective role of estradiol in a rat glaucoma model. 
Surgical procedure for tissue perfusion investigation 
Six weeks after OVx surgery and E2 or placebo treatment, polyurethane catheters (LD. 
0.6 mm, O.D. 0.9 mm, Harvard Apparatus, Holliston, MA, USA) were inserted into the 
femoral vein and artery under 1.5% isoflurane (induction of anaesthesia with 3% 
isoflurane for 5 min). During this procedure, body temperature was monitored with a 
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rectal thermometer and maintained at 37°C by a heating pad (FHC, Bowdoinham, ME). 
Both b100d pressure and heart rate were monitored from the tai1 using a non-invasive 
b100d pressure cuff system (BPlOOO, Kent Scientific Corporation, Torrington, CT, 
USA). At the end ofthis procedure, 2 mL ofRinger's lactate were given subcutaneous1y 
for rehydration. Rats were then installed in a hammock and left under minimal restraint 
over a 2-hour period to recover from anaesthesia. Body temperature was maintained at 
37°C with a heating lamp and both blood pressure and he art rate were monitored until 
the initiation of measurement experiment for the retinal perfusion. As weU, 
cardiovascular, chemistry and hematological parameters were measured with the i-
STAT®, a veterinarian clinical blood gases and electrolytes analyzer (HESKA, Fort 
Collins, CO), from arterial blood samples collected via the arterial catheter. This was 
achieved immediately prior to the initiation of measurement experiment for the retinal 
perfusion to confirm the recovery to normal physiologie level. 
Principles of the evaluation ofretinal tissue perfusion using lMP 
In the aim of evaluating tissue perfusion in retina with a regional resolution, the 
diffusible blood flow tracer [14C]_IMP was used. The [14C]_IMP binds to the amine 
sites. IOI ,I02 It was chosen as a blood flow tracer instead of [14C]-iodoantipyrine,93 
[14C]diazepam,94 or n-[14C]butanol,95 because of three of its essential properties related 
to cerebral blood flow measurement.96 These properties avoid the primary limitation of 
the classical diffusible tracer [14C]-iodoantipyrine autoradiographie technique,99,IOO i.e. 
its time-dependent post-mortem intraparenchymal diffusion, which results in weakening 
the local tracer spatial gradients in tissues and regions. First, [14C]_IMP has a very high 
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extraction at the first pass through the microvasculature, which allows a non-restrictive 
diffusion from blood to tissue des pite the blood-retinal barrier. Second, [14C]_IMP has a 
very low clearance rate and low post-mortem diffusion,l03 due to its high affinity for 
cerebral tissue. Third, C4C]-IMP is chemically and biologically inert for the duration of 
the measurement period. 103 IMP has been successfully used in sm aIl animal 
research,96.103,I04 and in humans using Single Photon Emission Computed Tomography. 
Laser Doppler flowmetry technology using an intraocular probe could not have been 
applied to measure the retinal blood flow in rats.84-86 This technique is invasive as it 
requires to position the probe near the retinal surface while the IOP has to remain 
constant. This technique has to be performed under anaesthesia, which can alter basal 
hemodynamics and normal physiologic levels. Scanning Laser Doppler Flowmetry 
(SLDF) (HRF, Heidelberg Engineering, Germany, v1.02) technology could have been 
used as we did in postmenopausal women, but again it has been used under anaesthesia, 
and comeal dryness under anaesthesia is another limiting factor. Moreover, the SLDF 
cannot be apply in small rodents for capillary blood flow measurements as it does not 
have the ability to visualize the capillary layers and it detects blood flow signal from the 
choroid.87 
The principle of blood flow evaluation is identical to that of micrometric microspheres89 
except that this "molecular microsphere" IMP is trapped within the tissue, whereas 
micrometric microspheres are trapped inside the microvascular space. Since the goal of 
this experiment is to determine local blood flow gradients in post-mortem tissue, the 
[14C]_IMP molecular microsphere technique is more appropriate than the classical 
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microsphere technique. Moreover, the use of a diffusible tracer avoids inaccuracies of 
the retinal blood flow measurement due to axial streaming, plugging or permeability 
changes as reported with the classical microsphere technique.89,92 
Procedure of measurement of the retinal tissue perfusion 
The N-Isopropyl-[methyl-1,3- 14C]-p-iodoamphetamine (ARC, St Louis, USA) (100 
,uCi/kg) was dissolved in 600)lL of saline (injectable 0.9% NaCl solution) and infused in 
fully conscious rats over a 30 s period at a constant rate of 1.2 mL/min using an infusion 
pump (PHD 2000, Harvard Apparatus, Holliston, MA, USA) through the femoral vein. 
The amount of ,uCi/kg of injected [14C]_IMP was based on the assumption that all rats 
were proportional in size. At the end of the infusion, the rats were immediately 
sacrificed by decapitation and a blood sample was collected for serum E2 measurements. 
A small incision on the superior eyelid was made to indicate the orientation of the eyes 
and the eyes together with the attached superior eyelid were then harvested. They were 
immediately immersed in a solution of 4% paraformaldehyde for post-fixation. Two 
hours later, the anterior segment of the left eye was excised to ease the penetration of the 
paraformaldehyde toward the posterior segment. On the following day, the retina was 
removed from the eye cup, dissected in four quadrants (superior, inferior, nasal and 
temporal) and whole-mounted on a glass slide with the ganglion cells layer facing up. A 
small incision was made on the retina to indicate the superior quadrant. The who le-
mount retina was then exposed to an X-ray film (Biomax, Kodak-Eastman Inc, 
Rochester, New York) for 10 days together with a set of [14C]-standards (GE Healthcare 
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Ltd, UK). The autoradiograms were analyzed using the computerized image analysis 
MCID Basic Software (v7.0, Interfocus Imaging, Linton, England). 
Calculation of retinal tissue perjùsion 
Retinal tissue perfusion was evaluated usmg the principle of indicator-fractionation 
technique.96,I03 A local retinal uptake index (RU!) was calculated from the following 
equation,104 
RUI = [C1MP(T) / A] x BW 
where A is the injected dose (nCi), BW is the body weight (g) and CIMP (T) is the 
radioactivity measured on the autoradiogram at the time (T) of sacrifice (nCi/g). 
CIMP(T) was read from circular regions of interest of 0.8 mm2 (1 mm diameter) 
distributed at the 1, 2, 3 and 4 mm isopters away from the centre of the optic nerve head 
in all retinal quadrants (Fig. 13). The IMP uptake index in the brain has been shown to 
corre1ate well with the local cerebral blood flow (CBF), where the CBF has been 
determined by positron emission tomography.104 As the retinal vascular bed is similar to 
the cerebral vascular bed in terms of permeability (blood-tissue barrier), anatomy (non-
fenestrated capillaries) and sorne local regulatory mechanisms (without autonomie 
innervation of the vasculature),94 we considered that the IMP uptake index in the whole-
mount retina can provide an approximation ofretinal blood flow. However, it cannot be 
exc1uded that IMP may also have partly diffused from the choroid prior to retinal 
dissection. 
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Figure 13: Schematic representation of a whole-mount retina showing the regions of 
interest (ROI) measured. The retina was divided into four quadrants (the notch indicates 
the superior quadrant). A circular ROI (filled circles, area 0.8 mm2) was measured in 
each quadrant at each isopter (light circular lines at 1, 2, 3 and 4 mm away from the 
centre of optic nerve head). The four values of C1MP (T) of each quadrant were averaged 
for each isopter. 
It has been demonstrated that the amount of the beta 14C radiation energy reaching a X-
ray film decreases with thickness of the tissue being exposed up to ~100 !lm where it 
reaches a plateau leve1.347 Therefore, it can be assumed that the measured C1MP (T) from 
the whole-mount retina autoradiograms originate mainly from the first 100 !lm of the 
inner retina and is mainly representative of the blood supply of the 100 !lm inner part of 
the retina. 
Serum assays 
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Serum· E2 levels were measured using a 3rd Generation Estradiol RIA kit (Diagnostic 
Systems Laboratories, Webster, TX, USA).344 Since soy products from animal diets 
induce vasodilation on coronary arteries in vitro in combination with E2348 the 
concentration of serum equol, a metabolite of daidzein, a phytoestrogen contained in the 
rat chow used (Ralston Purina Canada Inc), was also measured on a third and distinct 
group of rats (OVx, n=4; OVx+E2, n=4) by a time-resolved fluoroimmunoassay kit 
(Labmaster diagnostic, Turku, Finland) as previously reported.349 
Statistical analysis 
The RUIs measured in each quadrant were averaged for each isopter. Unpaired Student 
t-tests were performed between the OVx group and OVx+E2 group for (1) the 
physiological parameters, (2) the E2 plasma concentrations, and (3) the RUI of each 
isopter. A significance level of p ~O.05 was chosen. A Mann-Whitney U-test was used 
to analyze equol plasma concentrations. 
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4.0 RESULTS 
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ABSIRACI 
PURPOSE: Postmenopausal hormone therapy (HI), consisting of estrogens alone or 
combined with progestagens, increases blood flow (BF) in both reproductive and non-
reproductive organs and prevents atrophy in sorne brain regions. Since both estrogen 
and progesterone receptors are present in the human retina, we investigated whether HI 
improves retinal and optic nerve head (ONH) BF, and protects ONH topography and the 
function of retinal ganglion ceUs (RGCs). 
METHODS: We investigated 65 healthy postmenopausal women of similar age, 29 who 
never used HI (0HI) and 36 who used HI (+HI) continuously since menopause onset. 
BF of the infero-temporal retinal artery (lIRA), peripapillary retina, and ONH rim were 
measured in one eye using the Canon Laser Blood Flowmeter and the Heidelberg Retina 
Flowmeter. ONH stereometrie parameters and the pattern electroretinogram (pERG) 
were measured using the Heidelberg Retina Iomograph and the VERlS™ system. 
RESUL TS: Compared to the 0HI group, the +HI group presented significantly greater 
BF of the lIRA (15.4 ± 3.4 vs 12.5 ± 2.9 ilL/min, p=0.006), greater rim volume for the 
entire ONH region (0.438 ± 0.136 vs 0.380 ± 0.143 mm3, p=0.032), and greater rim 
volume (0.066 ± 0.041 vs 0.050 ± 0.030 mm3, p=0.042), height variation contour (0.353 
± 0.099 vs 0.289 ± 0.101 mm, p=0.011), mean thickness (0.194 ± 0.053 vs 0.167 ± 
0.058 mm, p=0.033) and cross-sectional area (0.238 ± 0.068 vs 0.198 ± 0.073 mm2, 
p=0.020) of the retinal nerve fiber layer for the infero-temporal region of the ONH. Ihe 
capillary BF of the temporal peripapillary retina was greater (312.0 ± 75.1 vs 266.0 ± 
58.1 AU, p=O.181) and the latency ofP50 component of the PERG was shorter (42.2 ± 
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1.9 vs 43.3 ± 1.8 ms, p=O.063) in the +HT group compared to those of the 0HT group, 
but these differences did not reach significance level. 
CONCLUSIONS: The use of HT in postmenopausal women was associated with greater 
retinal arterial BF and thicker RNFL. 
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The menopause is the permanent cessation of ovarian foIlicular activity and subsequent 
faIl in endogenous estrogens and progesterone production in aging women. 
Postmenopausal hormone therapy (HT) consisting of estrogens alone or combined with 
progestagens, is frequently prescribed to women in order to aIleviate postmenopausal 
symptoms. 
As weIl as their role in function of many ceIls and organs, estrogens have the ability to 
influence the vascular tone and blood flow in organs and tissues. In postmenopausal 
women, HT has been shown to improve blood flow in the femoral arteryl and brain 
parenchyma,2-5 and pulsatility and/or resistivity indexes (an expression of resistance to 
flow) in the common carotid,6-8 internaI carotid,9-13 and middle cerebral arteries. IO,11 
Moreover, there is a growing body of evidence that HT has a protective effect in sorne 
regions of the brain by preventing cerebral tissue atrophy. Observational studies using 
magnetic resonance indicated that women on HT presented larger volumes of sorne 
brain regions such as the hippocampus,14-16 and the lateral prefrontal, fusiform and 
entorhinal cortex. 16 
There is a large body of evidence that impaired ocular blood flow is contributing factor 
in the etiology and progression of glaucoma and age-related macular degeneration 
(ARMD). Recently, there has been an increasing interest in investigating the possible 
protective role of HT against glaucoma and ARMD. Epidemiological population-based 
studies indicated that increased duration of exposure to endogenous estrogens (early 
menarche, late menopause onset and increasing reproductive year) significantly 
decreased the odds ratio of developing primary open-angle glaucoma 17,18 and ARNID,19 
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and that the use of HT decreased the odds ratio of advanced20 and neovascular age-
related macular degeneration.21 This possible protective role of HT may result from 
improved blood flow to the retina and optic nerve head (ONH). Interestingly, estrogen 
receptors (ERs) are present in the human retina,22-26 as are progesterone receptors 
(PRS),22-24 and postmenopausal women taking HT have shown to present improved 
pulsatility and/or resistivity indexes in the retrobulbar vessels, such as the 
ophthalmic,12,13,27,28 short posterior29 and the central retinal arteries.29-32 However, it is 
unknown as to whether HT has a vascular effect on the retinal and optic nerve head 
blood flow in postmenopausal women. AdditionaUy, as HT has a protective effect on 
sorne brain regions and ERs are present in the ganglion ceU layer and axons in human 
retinas,25,26 it is of interest to know whether HT may have a protective effect on the optic 
nerve head (ONH) topography and on retinal ganglion ceU (RGC) function. 
In an attempt to answer these two questions, we designed an observational study in 
which retinal and ONH blood flow, the ONH topography and the function of the RGCs 
were measured in healthy postmenopausal women who were HT users (+HT) since their 
menopause onset. Results were compared with those obtained from healthy 
postmenopausal women of similar age and characteristics who had never used HT 
(0HT) since their menopause ons et. The advantage of this approach over a prospective 
drug trial is that we could ascertain a potential effect of several years of estrogen 
therapy. It also would have been impossible to recruit patients for a prospective 
estrogen trial in the wake of the 2002 report of the Writing Group for the Women's 
Health Initiative Randomized ControUed Trial,33 which is when this study was being 
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initiated. Retinal blood flow measurements were obtained at three different sites: 1) in a 
major retinal vessel, the infero-temporal retinal artery (ITRA), using the Canon Laser 
Blood Flow Meter (CLBF, Japan) and in both peripapillary 2) nasal and 3) temporal 
areas using the Heidelberg Retina Flowmeter (HRF, Germany). For the ONH, the blood 
flow of the rim was also measured using the HRF. The ONH topography was assessed 
by measuring the 12 standard stereometrie parameters using the Heidelberg Retina 
Tomograph 1 (HRT 1), and the funetionality of the RGCs was measured with the pattern 
eleetroretinogram (PERG) using the VERIS™ system. 
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METHODS 
Subjects 
This study was approved by the local Institutional Review Board (IRB) of Maisonneuve-
Rosemont Hospital and adhered to the tenets of the Declaration of Helsinki. A signed 
informed consent was obtained from all subjects before enrolment in the study. Subjects 
were tested in the Ocular Blood Flow Laboratory at the Ophthalmology Research Unit, 
Maisonneuve-Rosemont Hospital Research Centre. 
Eligibility criteria 
Healthy postmenopausal women were recruited from both Notre-Dame and 
Maisonneuve-Rosemont Hospital Menopause Clinics, Montreal, Quebec by personal 
interview and by posting advertisements in both hospitals and in the local newspaper. 
To be eligible for the study, all pre-screened healthy menopausal women had to meet the 
following inclusion criteria: not HT (0HT) or HT (+HT) users (as prescribed by a 
physician) since their menopause onset, 45 years of age or older, naturally or surgically 
menopaused by ovariectomy, amenorrhea for at least one year, body mass index equal or 
less than 30 and non or former smoker. Menopausal women had to be free of systemic, 
cardiovascular and central nervous system diseases and had to present normal ocular 
histories and eye exams. Subjects on vasoactive or anti-inflammatory medications, and 
allergie to eye drops were excluded. The 0HT postmenopausal women served as a 
control group. 
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Study visit 
Twelve hours prior to the study visit, subjects were asked to avoid caffeine and alcohol 
so as not to alter their basal hemodynamic level. As weU, they were asked to avoid food 
with high fat content, which alters the serum estradiol lev el assays. AIso, so as to 
confirm the use of HT and rule out the effects of vasoactive drugs, subjects were asked 
to bring aU their medications, inc1uding any herbaI medicine with them. The type of HT 
regimen (estrogens alone or combined with progestagens) and active ingredients were 
documented for HT users. 
Medical, gynecological and ocular histories, and eye exam 
At the time of the study visit, demographic, medical, gynecological and ocular histories 
were obtained from each subject using a standardized questionnaire administered by one 
examiner (MCD), who determined the eligibility of the subjects for the study. Medical 
history inc1uded measures of the blood pressure (BP)(mmHg) at rest for 30 minutes, 
height (m), and weight (kg). These measures were used for calculating the body mass 
index (BMI=weight/height2) and mean BP ((BPdiastolic + 1/3(BPsystolic 
BPdiastolic)). Gynecological history inc1uded the foUowing variables: age at menarche, 
age at last menses (natural or induced by ovariectomy) and duration of reproductive 
years (RY) (age at last menses minus age at menarche). Menopause duration (age at 
study visit minus age at last menses) and HT duration (age at study visit minus age at 
initiation of HT) were calculated. For women who had hysterectomies, the age at last 
menses could not be determined. Therefore, age at last menses, reproductive year and 
menopause durations were tabulated as missing values. Ocular histories and eye exams 
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were obtained, which included best corrected visual acuity using the Snellen chart (VA 
expressed by its numerator divided by its denominator), refraction (expressed in 
spherical equivalent), and biometry (OcuScan, Alcon® Surgical Inc., USA v3.02). Slit-
lamp examination, evaluation of peripheral anterior chamber depth, tonometry (IOP 
mmHg), and ophthalmoscopy were performed by one ophthalm010gist (DD). Ocular 
perfusion pressure (OPP mmHg) was calculated using the following formula: OPP= 2/3 
O 34 BPrncan-I P. 
Selection of the investigated eye 
AlI retinal and ONH blood flow measurements, as well as ONH topography and PERG 
measurements were conducted in one eye only, i.e. the eye with the clearest media, 
better fixation and least lid ptosis. Wh en both eyes were eligib1e for the study, one eye 
was randomly chosen. The chosen eye was tested first undilated for the PERG testing, 
th en dilated with tropicamide (Mydriacyl® 1 %, Alcon Canada Inc.) for the HRT, SLDF 
and CLBF testing. 
Serum estradiol and progesterone assays 
A blood sample was obtained from all subjects and analyzed by the local hospital 
laboratory service for documenting the total serum estradiol (E2) and progesterone (P) 
concentrations by chemiluminescent immunoassay technique (ADVIA Centaur®, Bayer 
HealthCare Diagnostic, USA). These assays were obtained to confirm the hormonal 
status of estrogens and progestagens in all postmenopausal women. Sorne active 
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ingredients present in the HT regimens and used by postmenopausal women were not 
17~-estradiol- and/or progesterone-based. Therefore, measures of the serum estradiol 
and progesterone concentrations by the hospital laboratory service were not appropriate. 
Consequently, low serum concentrations of estradiol and progesterone not detected by 
the assay technique were tabulated as zero. As well, for sorne postmenopausal women 
who were not HT users, the endogenous serum 17~-estradiol and progesterone 
concentrations were below the level of detection by the assay technique. Consequently, 
their serum concentrations were also tabulated as zero. 
Evaluation of Retinal Blood Flow 
Infero-temporal retinal artery. Blood flow (Flow) of the infero-temporal retinal artery 
(ITRA) was measured using the Canon Laser Blood Flowmeter System (CLBF model 
100, Japan). The CLBF is a unique system that quantifies blood flow in retinal vessels 
by simultaneously measuring both diameter (D) and velocity (Vel) of the blood column 
in a vessel of interest/5 and by using eye tracking features. To achieve this, the CLBF 
system is equipped with a dual laser system mounted in an eye fundus camera and an 
acquisition/analysis software (v2.1.23). An oval (8 Mm x 50 Mm) red diode laser (675 
nm) measures the mean center line blood column velocity (Velmcan) of the vessel of 
interest by using a bidirectional laser Doppler velocimetry, the princip le of which has 
been described elsewhere.36-38 The D is measured by a rectangular (1500 Mm x 150 Mm) 
green diode laser (543 nm) manually positioned perpendicular to the vessel of interest. 
The laser measures the blood column width by transmittance profile method, the 
princip le of which has been described elsewhere.39 The D is detennined automatically 
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by computer analysis of the signal produced by the image of the vessel on a charge-
coupled device (COD) sens or using the half-height of the transmittance profile to define 
the blood column edge. It is measured for the first and last 60 ms of the 2 s velocity 
measurement period, at every 4 ms (250 Hz sampling rate). The 0 measurement is 
corrected for the axiallength of the eye ( operator input) and refractive error of the eye, 
which is measured by the CLBF itself. To compensate for microsaccade of the eye, the 
green diode laser also serves as a tracking system by scanning repeatedly and rapidly the 
intensity profile produced by the rectangular green diode laser and by analyzing the 
scanned intensity profile. Since both lasers operate simultaneously, 0 and Velmcan are 
obtained in the same time frame. 
For accuracy, the CLBF software operates by measuring two Paths (Pathl and Path2 
with each its own velocity and di ameter) , then automatically calculates the flow 
following the Poiseuille's law, according to the following equation (Eq. 1), 
Flow (IlLlmin)= VelocitYmcan(1tOiamete~/8) (Eq. 1) 
where VelocitYmcan is the time averaged center line blood velocity (mmls) during the 
cardiac cycle and 1tDiameter2/8 is the cross-sectional area of the measurement site (Ilm2) 
Since study participants underwent several tests during the study visit, retinal blood flow 
measurements were only obtained from one site, the ITRA. By inference, the blood 
flow measures from the ITRA can be used as an indicator of the overall retinal arterial 
circulation. There are two motives for choosing the main retinal artery from the infero-
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temporal region. First, it is a region that is technically accessible to obtain CLBF 
measurements, and second, the infero-temporal region is the most common site of eariy 
glaucomatous damage. The location of the measurement on the ITRA was done on a 
straight section of the vessel before the first bifurcation between 0.5 and 2.0 disc 
diameters from the edge of the optic disc. Ten consecutive high quality Path1-Path2 
pairs and calculated Flow values were obtained. After exc1uding the incomplete 
measures (the CLBF automatically rejected flow measurements when one of the two 
paths was unreplicable) and discarding the highest and lowest flow values, the three 
c10sest flow values calculated by the CLBF software were used for averaging D, Velmcan, 
and Flow. This recording protocol gave us an intra-session coefficient of variation of 
3.2+/-1.9% for D, 6.7+/-3.2% for Velmcan, and 7.1 +/-4.4% for Flow obtained from the 
ITRA in 19 normal women (manuscript in preparation). Figure 1 illustrates an example 
of a CLBF recording from a normal subject. 
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Figure 1: Example of a CLBF measurement obtained from a normal subject. The panel 
(A) illustrates the position of the red diode laser (675 nm) that measures the mean center 
line blood column velocity of the infero-temporal retinal artery (lTRA) and the 
orientation of the green diode laser (543 nm) that measures its diameter. The right panel 
(B) shows both Path measurements, Path 1 and Path 2, with their respective parameter 
windows. For one Path, the top window displays the relative velocity over a 2 s period, 
followed by a window which displays the Q-index over a 2 s period and the overall Q-
index (an indicator of the signal quality intemally determined by the software). Then a 
third window displays the stability of the vessel tracking over the 2 s period, and finally 
the last window displays the coefficient of variation of the vessel diameter. For this 
particular subject, four Flow measurements (ranging from 3. 7 to 5.2 ilL/min) were 
acquired with their respective 0 (ranging from 90.5 to 94.4 Ilm) and Vel (ranging from 
19.2 to 24.6 mmls) as shown on the bottom left ofpanel B. 
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Per;papillary rel;nas and ONH r;m areas. The capillary blood flows of the ONH rim 
and both nasal and temporal peripapillary retinal areas were measured by Scanning 
Laser Doppler Flowmetry (SLDF) (HRF, Heidelberg Engineering, Germany, v1.02). 
Briefly, the Heidelberg Retina Flowmeter combines a confocallaser scanning technique 
and laser Doppler flowmetry. It measures the amount ofback scattered light at different 
locations (pixels) in the region of interest. A parallel infrared laser beam of 3 mm 
diameter (780 nm, 180 Il W) scans line by line a two-dimensional region of the retina. 
The scan field is 100 wide by 2.50 height, corresponding to a size of2.88 mm x 0.72 mm. 
Detailed description of the instrument and measurement technique has been described 
elsewhere.40,41 During the scan along one line, the reflected light intensity at 256 
equidistant locations (pixels) is measured and digitized (pixel distance 11.2 Ilm) 
sequentially. Thus, the reflected light intensities of each pixel are obtained as a function 
of time (fluctuation time curve). The collected intensity data of each pixel was then 
analyzed by a discrete Fourier transformation, thus calculating the laser Doppler 
frequency shi ft for each pixel. The data of the laser Doppler frequency shi ft of the 64 x 
256 pixels is the base to generate the perfusion image, and the automatic full-field 
perfusion image analysis software (AFFPIA, v3.3) computes flow (distance travelled by 
all moving red blood cells per unit of times), volume (number of moving blood cells), 
and velocity (mean of blood cell speed) for each pixel, all expressed in arbitrary units 
(AU). For valid capillary blood flow measurement at each pixel, the AFFPIA uses an 
algorithm to exc1ude over- or under-exposed pixels, retinal vessel tree and eye saccades 
(which is identified by the operator). Moreover, the AFFPIA permits an interactive 
marking of the rim area of the optic nerve head allowing the output of the three 
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hemodynamic parameters, flow (Flow), volume (Vol) and velocity (Vel) for each region 
of interest, i.e. the nasal peripapillary retina (n), temporal peripapillary retina (t) and 
neuroretinal rim (r) areas. Figure 2 illustrates an example of a SLDF perfusion image 
and automatic full-field perfusion image analysis obtained trom a normal subject. 
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Figure 2: Example of a SLDF perfusion image obtained from a normal subjeet. The left 
side shows the marking eircle delimitating the rim and both nasal and temporal retina of 
the optie nerve head region from a normal subjeet. The right side shows the Flow, Vol 
and Vel values obtained with the full-field perfusion image analysis (AFFPIA). For this 
partieular subjeet, the Flow, Vel and Vol values obtained by the AFFPIA for the 
temporal retina of this SLDF image eorresponded to 271.7 AU, 0.9 AU, and 20.7 AU 
respeeti vel y. 
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Our HRF images were centered on the optic nerve head, optimizing the photodetector 
sensitivity in order to ob tain a strong signal from both nasal and temporal peripapillary 
retinas, while avoiding overexposure. Ten SLDF images were obtained from each 
subject and the five best images in tenns of focusing, ONH centration, optimum 
exposure, brightness, and lack of major eye saccades were kept for full-field perfusion 
image analysis. The obtained Flow, Vel and Vol from these 5 images for the nasal (n), 
temporal(t) and rim(r) areas were then averaged. This SLDF measurement protocol 
developed in our lab yields intra-session coefficients of reliability ranging from 0.93 to 
0.95, and coefficients of variation ranging from Il.4% to 16.4% for the Flow among the 
three regions of interest. 42 
ONH topography 
The optic nerve head topography was evaluated by measunng the 12 standard 
stereometrie parameters (i.e. dise area, cup area, cid, rim area, cup volume, rim volume, 
mean cup depth, maximum cup depth, cup shape measure, height variation contour, 
me an retinal nerve fiber layer (RNFL) thickness and the RNFL cross-sectional area) in 
all subjects. This was achieved by using the Heidelberg Retina Tomograph l (HRT l, 
Heidelberg Engineering, Heidelberg, Gerrnany, v2.0l). The HRT l is a confocallaser 
scanning ophthalmoscope operating three-dimensionally. A diode laser (670 nm) scans 
the optic nerve head (along the z-axis) in a series of 32 consecutive and equidistant two-
dimensional optical section images (x-axis and y-axis of 10° x 10° (256 x 256 pixels)). 
Each pixel is approximately 10 !lm. The reflected light at each pixel is measured by the 
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confocal optical detector system and is used for generating a topography and reflectivity 
image. The topography image is the location along the z-axis where the maximum 
reflectivity registered is assumed to be the height of the location and the reflectivity 
image is the sum of the reflectivity measurements along the z-axis. Between five to ten 
ONH images were obtained and the average of the three closest images in terms of 
alignment, brightness and clarity was obtained. With the aid of fundus pictures, the 
external contour of the optic nerve rim was manually drawn and the Heidelberg Retina 
Tomograph interactive software automatically calculated the twelve standard 
stereometrie parameters. The stereometrie parameters were obtained for the entire ONH 
(0°-360°) and for the infero-temporal reglOn (270°-360°), which is a reglOn most 
commonly affected by early glaucomatous damage. Figure 3 illustrates the topography 
and reflectivity images, and an output of the stereometrie parameters calculated by the 
HRT software from a normal subject. 
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A B 
Figure 3: Example of ONH topography measurement obtained from a normal subject 
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using the Heidelberg Retina Tomograph I (HRT I). The topography image (panel A) 
represents the maximum reflectivity registered along the z-axis at each pixel, and the 
reflectivity image (panel B) represents the sum of aU the reflectivity measurements 
along the z-axis. The 12 standard stereometric parameters from the entire ONH (0-360°, 
panel C) and the infero-temporal region (270-360°, panel D) are automatically calculated 
by the HR T software after manually marking the external contour of the optic nerve 
head rim. 
Functionality of the RGC 
The pattern electroretinogram (PERG) represents an objective and direct measure of 
retinal ganglion cell function. 43-45 It is a retinal biopotential evoked when a high contrast 
patterned stimulus (alternating stripes or checkerboards) is viewed. The PERG 
waveform signal begins with a negative deflection called N35, followed by a positive 
deflection called P50, and then a second negative deflection called N95. The PERG was 
recorded using the VERIS™ Multifocal System (Electro-Diagnostic Imaging, Inc., 
USA, v5.0) following the Guidelines of the International Society for Clinical 
Electrophysiology of Vision (ISCEV).46 Transient (4.7 reversal/s (rps)) PERGs 
(bandwidth 1-100 Hz) were evoked by a black and white reversing checkerboard stimuli 
of 50° x 38° with checksize of 0.8° generated by a 9-inch monochrome monitor (75 Hz 
frame rate). The luminance of the white squares was set at 353 cdlm2 and for the black 
squares it was set at 30 cd/m2, (of 192 cdlm2 average luminance, 84% contrast). A 
sterilized and disposable silver DTL Plus ™ (Diagnosys LLC, USA) electrode placed in 
the lower conjunctival sac served as the active electrode in reference to a gold cup 
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electrode (Grass Technologies, USA) placed at the ipsilateral outer canthus. Subjects 
were grounded through the forehead with a gold cup electrode. Electrode impedances 
were checked for 5k.O or less. The recording session was devided in segments, i.e. 32 
segments, each lasting 3.41 s for a total of 109.1 s. This corresponded to an average of 
514 responses obtained. During one segment recording, the subject was asked not to 
b1ink to minimize b1inking artifacts since there is no artifact rejection capability built 
into the system. Two repli cable PERG waveforms were obtained. The N35, P50 and 
N90 waveform components were identified, and latency (N35 lat, P50 lat, N95 lat) and 
amplitude (P50 amp, N95 amp) were measured. Figure 4 illustrates a transient PERG 
waveform and measured components obtained from a normal subject. 
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Figure 4: Example of a transient pattern electroretinogram (PERO) obtained of the right 
eye from a normal subject. The PERO was evoked by a checkerboard pattern of 50° x 
38° with a checksize of 0.8° set at a contrast of 84% (white square luminance of 353 
cd/m2, black square luminance 30 cd/m2). The PERO was recorded at 4.7 reversai/s. 
The three main waveform components were identified, N35, P50 and N90, and both 
latency (N35 lat, P50 lat, N95 lat) and amplitude (P50 amp, N95 amp) were measured as 
indicated. 
Estimation 01 sam pie size 
The calculation of the sample size was based on a power of 0.80 with an 0,=0.05 for 
comparing two means of two normally distributed samples of equal sizes using an 
unpaired two-sided !-test. The following formula to determine the sample size is: 
{ 
Deschênes et al, HT on retinal and ONH blood flow, and RNFL Page 143 
where 
cr represents a known standard deviation 
~ represents a known change ~ 11l2-1l1 1 
For our study design we used the following information to determine our sample size: 
In postmenopausal women who have been on 2 mg of micronized 17~-estradiol for 2 
months, the resistivity index in the central r~tinal artery has been shown to significantly 
decrease from 0.73 ± 0.08 to 0.66 ± 0.01.30 Although this central retinal artery 
resistivity index was not an outcome variable for this observational study, it provided 
some guidance in calculating the sample size and we predicted we would find 
approximately the same magnitude of change ofblood flow in the retina and optic nerve 
head. Therefore, 
n = (0.082 + 0.01 2)(1.96 + 0.84i 
(0.73 - 0.66/ 
n Il patients in the 0 HT (control group) 
n Il patients in the +HT (treated group) 
We decided to include 25 subjects in each group hoping to gain power analysis. 
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Statistical analysis 
Unpaired Student t-tests were perforrned for clinical, gynecological and 
ophthalmological variables between 0HT and +HT post-menopausal women. Linear 
regression analysis was perforrned for the outcome variables for the blood flow, ONH 
stereometrie parameter and PERG between 0HT and +HT post-menopausai women. As 
postmenopausal women on HT were either on estrogens alone or combined with 
progestagens, subsequent linear regression analysis was perforrned to compare the effect 
of the type of HT treatment (estrogen therapy vs 0HT, estrogen + progestagen therapy 
vs 0HT and estrogen vs estrogen + progestagen therapies) in an attempt to evaluate the 
effects of estrogen therapy only. Statistical analysis was done using STA TA/IC 
software (Stata Corp LP, Texas, vIO.O). A significance level ofa = 0.05 was chosen. 
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RESULTS 
Study population characteristics 
A total of 74 post-menopausa1 women were enrolled in the study but 9 of them were 
exc1uded for the following reasons: four presented significant media opacities that 
interfered with the testing, one was un-cooperative and presented unreliable test results, 
one also presented unreliable test results and the pupil was unable to dilate, two did not 
feel weIl before starting the study, and one patient stated she was not taking HT but her 
serum estradiol result indicated an unusually elevated level. Therefore, a total of 65 
subjects met the study criteria among whom 29 had never used HT (44.6%) since their 
menopause onset and 36 used HT (55.4%) currently and continuously since their 
menopause onset. Among 0HT and +HT women, one and two of them were surgically 
menopaused respectively (ovariectomy combined with hysterectomy), while one and ten 
of them respectively underwent through hysterectomy only. 
Clinical, gynecological, and ophthalmological characteristics for the whole study 
population are given in Table 1. The duration of HT was 8.3 ± 6.0 yr for the +HT group 
of postmenopausal women. As expected, the only significant differences between the 
0HT and the +HT subjects were the serum E2 concentration (62.2 ± 60.9 vs 258.4 ± 
159.1 pmol/L, p<O.OOl) and serum P concentration (1.9 ± 0.9 vs 11.8 ± 20.1 nmol/L, 
p=O.O 1 0). The large standard deviation for both E2 and P concentration is likely due to a 
variable endogenous source of these hormones that differs between women and with 
time. Moreover, since active ingredients present in the HT regimens used by sorne 
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postmenopausal women were not 17~-estradiol- and/or progesterone-based, this could 
also have contributed to the large standard deviation. 
Regarding their clinical, ophthalmological, and other gyneco1ogical characteristics, the 
two groups of women were not statisticaUy different, especiaUy in terms of their age, 
BMI, BP and natural menopause duration. For postmenopausal women who were 
naturaUy or surgicaUy menopaused, the sample size used for calculating the averaged 
age at last menses, natural menopause and reproductive year durations is indicated 
between parentheses below each value for the whole study population 
In the same table, the whole study population is presented in subsets of sub-populations 
A, B, C, and D that were investigated for the CLBF, SLDF, HRT and PERG testing 
respectively. Data from sorne of the tests were either not obtained or discarded for the 
foUowing reasons: sorne subjects presented fixation problems (eye movement and/or 
microsaccade), inability to open the eye wide, and unreliable data measurements for 
sorne of the tests conducted. For CLBF testing, data from sorne subjects was discarded 
because the main ITRA divided itself into second order arterioles near the outer edge of 
the ONH. Regarding the 0HT and +HT groups for aU sub-populations, they were also 
similar in aU their characteristics. The exceptions were the serum E2 and P levels that 
were statisticaUy different between 0HT and +HT groups for aU the sub-populations. 
As weU, the diastolic blood pressure (79.6 ± 9.0 vs 73.0 ± 8.8 mmHg, p=0.03), the mean 
BP (95.3 ± 8.9 vs 88.4 ± 10.1 mmHg, p=0.03), and the OPP (49.0 ± 5.9 vs 44.4 ± 6.9 
mmHg, p=0.03) were significantly higher in the 0HT group for the SLDF sub-
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population B studied. The sample size used for calculating the averaged age at last 
menses, menopause and reproductive year duration is also indicated between 
parentheses below each value for each sub-population for postmenopausal women who 
were naturally or surgically menopaused. 
Table 1: Clinical. Gynecological. and Ophthalmological Characteristics fo~ The Whole Population Study ofWomen Who Ne ver Used Cl (1) 
rn 
Postmenopausal Hormone Therapy (0HT) and Who Were HT Users (+HT) and for Sub-Population Study for CLBF (A). SLDF (B). ('") ::r (1) 
HRT (C) and PERG (D) Assessments ::s (1) 
rn 
(1) 
...... 
Whole Populotion Sub· Populotion Cl 
A B C D r 
Chanct.eristic, 0HT +HT 0HT +HT 0HT +HT 0HT +HT 0HT +HT 
1P=29) 1P=36) 1P=18) 1P=21) 1P=16) 1P=21) 1P=21) 1P=33) 1P=21) 1P=31) 
Cb'nkaJ ::c: 
~1Yr) 56.1"5.8 56.8"4.9 51.2" 5.9 56.8" 4.3 56.6" 4.1 56.5" 4.9 56.6" 5.1 56.1"4.9 56.2 .. 5,4 56.2"4.4 >-l 
BM! 26.5 .. 3.5 25.4'" 3.4 21.0"'3.1 25.9" 3.6 21.5" 3.8 25.6" 3.4 26.8'" 3.5 25.4 "'3.3 26.1" 3.9 25.9" 3.2 0 
Blood pm.".. ::s 
'"1 
5y<tolic (mmHg) 124.9 .. lB 119.9" 15.5 123.8" 13.1 120.0" 15.1 IJ1.1" Il.9 119.1" 16.4 124.6" 13.8 119.1"IH 125.2" 12.5 119.0" 15.1 (1) 
...... 
Diastolic ( .... Hg) 16.1 .8.9 13.1.8.1 16.4" 10.1 13.6" 9.3 19.6" 9.0 13.0" 8.8* 11.3. 8.2 13.2" 8.4 16.9" 8.0 13.2 .. 8.1 S' Cl 
88.4" 10.1 * -M .. n( .... Hg) 92.6" 9.1 88.6.9.4 92.1" 10.3 88.9'" 10.5 95.3 .. 8.9 92.1.9.1 88.4" 9.6 92.8" 8.4 88.3" 9.4 Cl 
Puls. omplilud> (,.,.Hg) 48.2'" 9.5 46.1'" IJ.4 41.3 "'9.1 46.4"11.5 41.5" 10.1 46.1" 13.4 41.6 "'10.0 45.8'" 12.6 48.4 "'10.4 45.8" 11.9 ::s 0.. 
0 
GJon,«oJogicaJ Z 
~ "menardu! (:;r) 12.3 .. 1.3 12.6" 1.6 12.3"1.5 lB" 1.1 Il.l'' 1.5 12.8" 1.1 12.2 "1.4 12.1" 1.6 12.3 "1.4 12.6" 1.6 ::c: 
~ "lest mens .. ()Ir) 49.3 .. 4.0 41.8 "5.1 49.4" 4.1 46.9" 6.8 49.9"4.5 41.1" 5.1 49.1" 3.1 48.0" 5.6 49.1"3.1 41.1" 5.9 rs 
-IP) (28) (26) (18) (14) (16) (18) (26) (24) (20) (22) 0 
DurUion of RY 1Yr) 31.0" 4.3 34.9" 6.3 31.1 "4.8 34.2 "1.1 31.1" 4.8 34.5" 6.6 31.5"3.9 35.1" 6.1 36.8"3.9 34.3" 6.6 0 
IP) (28) (26) (18) (14) (16) (18) (26) (24) (.10) (.Il) 0.. 
DurUion ofmenop ms. (yr) 1.6'" 6.4 8.9'" 6.3 1.8 "1.1 9.5"1.4 6.8" 5.1 8.8 "1.2 1.0"'5.6 8.6"'6.4 1.3"5.4 8.1" 6.5 ::::!:I 
IP) (28) (26) (18) (14) (16) (18) (26) (24) (20) (22) 0 
HT duntian ()Ir) 0.0" 0.0 8.3"6.0* 0.0" 0.0 8.5" 6.1* 0.0" 0.0 1.9" 6.1* 0.0 "0.0 8.3"6.1* 0.0"0.0 8.2"5.9* ~~ 
258.4" 159.1 * 25l.l'" 113.8 * 253.4 "'154.1 * 243.1" 159.8 * 262.0" 160.6* 
Cl 
Serum E, (pJoDlil) 6l.2 "60.9 10.1" 63.6 61.8'" 65,9 62.1" 64.l 51.4 .. 51.5 ::s 
11.8 "20.1* 11.1"18.1* 11.4 "'19.1* 13.9 "l2.1* lO.l .. 16.9* 
0.. 
Serum P (>malil) 1.9" 0.9 1.8" 0.1 1.6 .. 0.8 1.9 "1.0 1.9"1.0 ~ 
OphthalmoJogicaJ "Tl 
VA(r<ti<» 1.1 .. 0.2 1.0 .. O.l 1.1" 0.2 1.1" 0.2 1.0" 0.2 1.0" 0.1 1.1" O.l 1.0 "0.1 1.1 .. 0.2 1.0.0.l r 
SphBic al .quivalem 0.0" 2.9 ·0.8 .. 2.1 0.3 .. 3.4 ·0.9 .. l.5 ·0.3 "l.9 ·1.0 "2.6 ·0.2.2.8 ·0.8 "l.8 ·0.1"2.8 ·0.1" 2.1 
IOPIP>mHg) 14.5 .. 1.1 14.1" 2.l 14.1 "1.6 13.8'" 2.0 14.6 .. l.l 14.6 "'l.l 14.6" 1.6 14.2 "2.3 14.6 .. 1.4 14.0" 2.1 
OPP lP>mHg) 41.3 "6.3 44.9 "6.1 41.3 "1.0 45.5 "1.1 49.0 "5.9 44.4 "6.9* 41.2 "6.3 44.1"1.0 41.3 "5.9 44.8 .. 6.1 
'i:) 
Values are means ± standard deviations (SD). Number of subjects is in parenthesis Cl (JQ 
(l) 
* Significance level cP :s 0.05) determined by unpaired Student t-test between the +HT and 0HT for the whole and sub-populations. ...... ~ 
00 
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Table 2 shows the list of the active estrogen and progestagen ingredients present in the 
various HT regimens prescribed and used by postmenopausa1 women in this 
observational study. Table 3 indicates the frequency distribution of those active 
ingredients. In our whole study population of 65 subjects, 36 of them were +HT users 
(55.4%), 12 (18.5%) were on monotherapy (estrogens alone) and 24 (36.9%) were on a 
combined therapy (estrogens + progestagens). Of the +HT users 25 (38.5%) of them 
were taking the active ingredients 17~-estradio1 (E2), which is one of the human bio-
identica1 ingredients. 
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Table 2: Type ofPostrnenopausal Hormone Therapy and Their Active Ingredients 
Prescribed and Used by the +HT Postrnenopausal Wornen (n=36) 
HT Manufacturer 
Trade Narne 
Estrogens 
Clirnara® Bayer HealthCare 
Estradot® Norvatis Ph arma Canada 
Estrogel® Schering Canada 
Estrace® Shire Biochern 
Ogen® Pfizer Canada 
Prernarin® Wyeth Canada 
Progestagens 
Prornetriurn® Schering Canada 
Provera® Pfizer Canada 
Norlutate® Parke Davis Canada 
Mirena ® Berlex 
Estrogens + Progestagens 
Active Ingredients 
17p-estradiol 
17p-estradiol 
17p-estradiol hernihydrate 
17p-estradiol rnicronized 
estropipate 
conjugated estrogens 
progesterone rnicronized 
rnedroxyprogesterone 
norethindrone acetate 
levonorgestrel 
Estalis-Sequi® Norvatis Pharma Canada 17p-estradiol + norethindrone acetate 
Prernplus™ Wyeth Canada 
Fern HRT™ Wamer Chilcott 
conjugated estrogens + 
rnedroxyprogesterone 
ethinyl estradiol + norethindrone acetate 
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Table 3: Frequency Distribution of +HT (n=36) Categorized by Their Active 
Ingredients. 
Therapy Type Active Ingredients n (%) 
Monotherapy 17p-estradiol 10 ( 27.7) 
17p-estradiol micronized 1 ( 2.8) 
conjugated estrogens 1 ( 2.8) 
Combined 17p-estradiol + progesterone micronized 1 ( 2.8) 
Therapy 17p-estradiol + 1evonorgestrel 2 ( 5.6) 
17p-estradiol + norethindrone acetate 2 ( 5.6) 
17p-estradiol micronized + progesterone micronized 1 ( 2.8) 
17p-estradiol micronized + medroxyprogesterone 1 ( 2.8) 
17p-estradiol micronized + norethindrone acetate 1 ( 2.8) 
17p-estradiol hemihydrate + progesterone micronized 5 ( 13.9) 
17p-estradiol hemihydrate + medroxyprogesterone 1 ( 2.8) 
estropipate + progesterone micronized 2 ( 5.6) 
estropipate + medroxyprogesterone 1 ( 2.8) 
ethinyl estradiol + norethindrone acetate 3 ( 8.3) 
conjugated estrogens + progesterone micronized 1 ( 2.8) 
con jugated estrogens + medroxyprogesterone 3 ( 8.3) 
Total 36 (100.0) 
i 
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Flow of infero-temporal retinal artery 
The D, Velmean and Flow of the ITRA were obtained from 18 0HT and 21 +HT 
postmenopausal women (Table 1, sub-population A). Table 4 shows D, Velmean and 
Flow values and their significance levels obtained from linear regression models both 
unadjusted and adjusted for age ofsubject, OPP and age at menarche. In the +HT group, 
the Flow of the ITRA was significant1y greater compared to that of 0HT women (15.4 ± 
3.4 vs 12.5 ± 2.9 flLlmin, p=0.006). This significant greater Flow value was mostly due 
to a significantly larger D of the ITRA measured in the +HT group (133.2 ± 13.9 vs 
120.7 ± 11.6 vs )lm, p=0.005), while the Velmean was also greater, but not significantly 
different between the two groups (37.0 ± 6.2 vs 36.4 ± 7.6 mm/s, p=0.687). 
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Table 4: Diameter, Velocity and Flow of the Infero-Temporal Retinal Artery Measured 
in 0HT and +HT Postmenopausal Women 
0HT 
(n= 18) 
Diameter (um ± SD) 120.7 ± 11.6 
Ve10city (mm/s ± SD) 36.4 ± 7.6 
Flow (uL/min ± SD) 12.5 ± 2.9 
+HT 
(n=21) 
133.2 ± 13.9 
37.0 ± 6.2 
15.4 ± 3.4 
P value 
Unadjusted* Adjustedt 
0.005* 
0.803 
0.008* 
0.005t 
0.687 
0.006t 
Values are means ± standard deviations (SD). Number of subjects is in parenthesis. 
* Significance level determined by unadjusted linear regression model. 
t Significance level determined by adjusted linear regression for age, ocular perfusion 
pressure and age at menarche. 
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Capillary flow of the retinal peripapillary and ONH rim areas 
Table 5 represents the capillary blood Vol, Vel and Flow measurements for the rim of 
the ONH and both temporal and nasal peripapillary retina obtained from 16 0HT and 27 
+HT postmenopausal women (Table 1, sub-population B) with their significance levels 
obtained from linear regression models both unadjusted and adjusted for age of subject, 
OPP and age at menarche. In the +HT group, the capillary Vol (22.3 ± 3.9 vs 19.6 ± 3.4 
AU, p=0.120), Vel (1.11 ± 0.26 vs 0.98 ± 0.19 AU, p=0.33) and Flow (312.0 ± 75.1 vs 
266.0 ± 58.1 AU, p=0.181) of the temporal peripapillary retina were greater compared to 
the 0HT group but did not reach significance leveL A post-hoc power calculation 
indicated that the sample size was inadequately too small and under power for 
demonstrating a significance level for the Vol and Flow. Calculated power values were 
0.66 and 0.61 respectively. A sample size of 34 subjects would have been required in 
0HT and +HT groups in order to observe a significance lev el. The capillary Vol, Vel 
and Flow of the rim and nasal peripapillary retina were similar between the 0HT and 
+HT groups, although for the rim, the Vol (18.7 ± 3.2 vs 17.8 ± 3.7 AU, p=0.509), Vel 
(1.06 ± 0.20 vs 0.99 ± 0.23 AU, p=0.39l) and Flow (256.8 ± 62.6 vs 251.4 ± 68.3 AU, 
p=0.9l2) were slightly greater in the +HT group. 
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Table 5: Volume, Velocity and Flow of the Temporal Peripapillary Retinal, 
Neuroretinal Rim and Nasal Peripapillary Retinal Areas of the Optic Nerve Head 
Measured in 0HT and +HT Postmenopausal Women 
Volume (AU ± SD) 
Temporal 
Rim 
Nasal 
Ve10city (AU ± SD) 
Temporal 
Rim 
Nasal 
Flow (AU ± SD) 
Temporal 
Rim 
Nasal 
0HT 
(n=16) 
19.6 ± 3.4 
17.8±3.7 
19.1±2.9 
0.98 ± 0.19 
0.99 ± 0.23 
l.01 ±0.18 
266.0 ± 58.1 
251.4 ± 68.3 
274.3 ± 5l.7 
+HT 
(n=27) 
22.3 ± 3.9 
18.7±3.2 
19.2 ± 3.1 
1.11 ± 0.26 
1.06 ± 0.20 
l.01 ± 0.21 
312.0 ± 75.1 
256.8 ± 62.6 
274.7 ± 58.0 
P value 
Unadjusted* Adjustedt 
0.030* 
0.413 
0.947 
0.090 
0.324 
0.982 
0.042* 
0.794 
0.984 
0.120 
0.509 
0.817 
0.333 
0.391 
0.780 
0.181 
0.912 
0.697 
Values are me ans ± standard deviations (SD). Number ofsubjects is in parenthesis. 
* Significance leve1 determined by unadjusted linear regression model. 
t Significance level determined by adjusted linear regression for age, ocular perfusion 
pressure and age at menarche. 
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ONH topography 
Results of the 12 standard stereometrie parameters of ONH topography obtained for 
both the entire (0-360°) and the infero-temporal (270-360°) regions from 27 0HT and 
33 + HT subjeets (Table 1, sub-population C) are presented in Tables 6 and 7 
respeetively with their signifieanee levels obtained from linear regression models both 
unadjusted and adjusted for age of subjeet, OPP and age at menarehe. For the entire 
ONH region, the rim volume was signifieantly greater in the +HT group (0.438 ± 0.136 
vs 0.380 ± 0.143 mm3, p=0.032) eompared to those of0HT group. The mean thiekness 
and eross-seetional area of the RNFL were also greater in the +HT but did not reaeh a 
signifieanee level (0.274 ± 0.065 vs 0.256 ± 0.062 mm, p=0.100 and 1.336 ± 0.302 vs 
1.235 ± 0.302 mm2, p=0.066 respeetively). When looking at the infero-temporal ONH 
region, the rim volume (0.066 ± 0.041 vs 0.050 ± 0.030 mm3, p=0.042), height variation 
contour (0.353 ± 0.099 vs 0.289 ± 0.101 mm, p=O.Oll), the mean thiekness RNFL 
(0.194 ± 0.053 vs 0.167 ± 0.058 mm, p=0.033) and RNFL eross-seetional area (0.238 ± 
0.068 vs 0.198 ± 0.073 mm2, p=0.020) were signifieantly greater in the +HT group 
eompared to those of 0HT. The remaining stereometrie parameters for both the entire 
(Table 6) and infero-temporal (Table 7) regions of the ONH were similar between both 
groups of postmenopausal women. Although the rim area was slightly greater in the 
+HT group for both the entire (1.491 ± 0.276 vs 1.404 ± 0.267 mm2, p=0.131) and 
infero-temporal regions (0.324 ± 0.097 vs 0.302 ± 0.092 mm2, p=0.203) of the ONH, but 
these differenees did not reaeh a signifieanee level. 
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Table 6: Standard Stereometrie Parameters of the Entire Optic Nerve Head (0-360°) 
Measured in 0HT and +HT Postmenopausal Women 
0HT +HT Pva1ue 
(n=27) (n=33) Unadjusted* Adjustedt 
Disk are (mm2 ± SD) 1.855 ± 0.379 1.917 ± 0.315 0.721 0.739 
Cup area (mm2 ± SD) 0.481 ± 0.323 0.426 ± 0.297 0.501 0.318 
Cup/disk ratio 0.239 ± 0.142 0.212 ± 0.132 0.448 0.314 
Rim area (mm2 ± SD) 1.404 ± 0.267 1.491 ± 0.276 0.225 0.131 
Cup volume (mm3 ± SD) 0.105 ± 0.107 0.084 ± 0.080 0.389 0.266 
Rim volume (mm3 ± SD) 0.380 ± 0.143 0.438 ± 0.136 0.118 0.032t 
Mean cup depth (mm ± SD) 0.209 ± 0.084 0.201 ± 0.091 0.740 0.719 
Maximum cup depth 0.557 ± 0.211 0.542 ± 0.202 0.778 0.814 
(mm± SD) 
Cup shape measure -0.170 ± 0.060 -0.182 ± 0.064 0.471 0.421 
Height variation contour 0.298 ± 0.083 0.417 ± 0.093 0.409 0.210 
(mm± SD) 
Mean RNFL thickness 0.256 ± 0.062 0.274 ± 0.065 0.271 0.100 
(mm ± SD) 
RNFL cross-sectional area 1.235 ± 0.302 1.336 ± 0.302 0.201 0.066 
(mm2 ± SD) 
Values are means ± standard deviations (SD). Number of subjects is in parenthesis. 
* Significance level determined by unadjusted linear regression model. 
t Significance level determined by adjusted linear regression for age, ocular perfusion 
pressure and age at menarche. 
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Table 7: Standard Stereometrie Parameters of the Infero-Temporal Region Optic 
Nerve Head (270-360°) Measured in 0HT and +HT Postmenopausal Women 
0HT +HT Pvalue 
(n=27) (n=33) Unadjusted* Adjustedt 
Disk are (mm2 ± SD) 0.464 ± 0.115 0.493 ± 0.090 0.272 0.309 
Cup area (mm2 ± SD) 0.175 ±0.112 0.169 ± 0.100 0.822 0.497 
Cup/disk ratio 0.348 ± 0.183 0.333 ± 0.182 0.764 0.495 
Rim area (mm2 ± SD) 0.302 ± 0.092 0.324 ± 0.097 0.367 0.203 
Cup volume (mm3 ± SD) 0.037 ± 0.040 0.028 ± 0.024 0.318 0.214 
Rim volume (mm3 ± SD) 0.050 ± 0.030 0.066 ± 0.041 0.096 0.042t 
Mean cup depth (mm ± SD) 0.211 ± 0.091 0.210 ± 0.090 0.957 0.867 
Maximum cup depth 0.510 ± 0.173 0.494 ± 0.183 0.728 0.688 
(mm± SD) 
Cup shape measure -0.108 ± 0.087 -0.110 ± 0.086 0.955 0.812 
Height variation contour 0.289 ± 0.101 0.353 ± 0.099 0.015* 0.011 t 
(mm± SD) 
Mean RJ'lFL thickness 0.167 ± 0.058 0.194 ± 0.053 0.071 0.033t 
(mm± SD) 
RNFL cross-sectional area 0.198 ± 0.073 0.238 ± 0.068 0.033* 0.020t 
(mm2 ± SD) 
Values are means ± standard deviations (SD). Number of subjects is in parenthesis. 
* Significance level determined by unadjusted linear regression model. 
t Significance level determined by adjusted linear regression for age, ocular perfusion 
pressure and age at menarche. 
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Functionality of the RGC 
The PERG findings from 21 0HT and 31 +HT (Table 1, sub-population D) 
postmenopausal women are presented in Table 8 with their significance levels obtained 
from linear regression models both unadjusted and adjusted for age of subject, OPP and 
age at menarche. The P50 latency was shorter by 1.1 ms in the +HT group but this was 
borderline significant (42.2 ± 1.9 vs 43.3 ± 1.8 ms, p=O.063). The remaining PERG 
components were similar between the 0HT and +HT groups. The P50 amplitude was 
smaller by 5% in the +HT group (6.9 ± 1.5 vs 7.3 ± 1.7 IlVolt, p=O.74l), while the N95 
amplitude was greater by 3.2% (9.1 ± 1.9 vs 9.4 ± 1.6 Il Volt, p=O.867) 
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Table 8: Components of the Pattern Electroretinogram Measured in 0HT and +HT 
Postmenopausal Women 
N35 latency (ms ± SD) 
P50 latency (ms ± SD) 
N95 latency (ms ± SD) 
P50 amplitude (f.1Volt ± SD) 
N95 amplitude (J.t Volt ± SD) 
0HT 
(n=21) 
21.6± 1.9 
43.3 ± 1.8 
80.2 ± 3.3 
7.3 ± 1.7 
9.4 ± 1.6 
+HT 
(n=31) 
21.1±1.8 
42.2 ± 1.9 
80.7 ± 4.0 
6.9 ± 1.5 
9.1 ± 1.9 
Pvalue 
Unadjusted* Adjustedt 
0.332 0.233 
0.044* 0.063 
0.649 0.777 
0.400 0.741 
0.598 0.867 
Values are me ans ± standard deviations (SD). Number of subjects is in parenthesis. 
* Significance level determined by unadjusted linear regression model. 
t Significance level determined by adjusted linear regression for age, ocular perfusion 
pressure and age at menarche. 
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In a subset analysis for all outcome variables, age at menarche, reproduction year and 
menopause durations were inc1uded in the adjusted linear regression mode1 in addition 
to age, OPP and age at menarche. As age at last menses, reproduction year and 
menopause durations were unknown for sorne postmenopausal women, this subset 
analysis was therefore performed on a smaller sample size for each sub-population. 
Since age at last menses, reproduction year and menopause durations were observed not 
to be significant predictors of all the outcome variables, they were removed from the 
adjusted linear regression mode1 so as to perform the analysis on the entire sample size 
for each sub-population studied and only adjusting for age, ocular perfusion pressure and 
age at menarche. 
Effects estrogens and estrogens combined with progestestagens therapies. 
The Table 9 displays the results of linear regression analysis comparing the effect of the 
type of HT treatment (estrogen therapy vs 0HT, estrogen + progestagen therapy vs 
0HT and estrogen vs estrogen + progestagen therapies) for the significant outcome 
variables. For the infero-temporal retinal artery, postmenopausal women taking either 
estrogen therapy or estrogen combined with progestagen therapy presented significantly 
greater Diameter (p=O.16 and p=O.023) and Flow (p=O.023 and p=O.042) compared to 
the control group. The Diameter and Flow values were slightly greater in the estrogen 
therapy group than in the estrogen combined progestagen therapy group, but these 
differences were not statistically different. 
Regarding the stereometrie parameters, postmenopausal women taking either estrogen 
therapy or estrogen combined with progestagen therapy present greater rim volume for 
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the entire ONH region, and greater rim volume, height variation contour, mean thickness 
RNFL and RNFL cross-sectional area for the infero-temporal region for the ONH 
compared to the control group. However, significance leve1 was reached for both rim 
volumes of the entire and infero-temporal regions of the ONH in the estrogen user 
group, and for variation contour, mean thickness RNFL and RNFL cross-sectional area 
for the estrogen combined with progestagens user group compared to the control group. 
A post-hoc power calculation indicated that sample sizes were inadequate1y too small 
and under power for demonstrating a significance level for the variation contour, mean 
thickness and cross-sectional area of the RNFL. Calculated power values were 0.24, 
0.23 and 0.46 respectively. A sample size of at least 133 subjects in each control and 
estrogen groups would have been required. 
Table 9: Effect of Estrogens Therapy and Estrogens Combined with ~ Therapy on Different Outcome Variables 
0HT 
(n) 
CLEF (18) 
Diameter (um ± SD) 120,7 ± 11.6 
Flow (uUmin ± SD) 12,5 ± 2,9 
~ Parameters (27) 
{0-360, 
Rim volume (mm3 ± SD) 0.380 ± 0,143 
(270-360, 
Rim volume (mm3 ± SD) 0,050 ± 0,030 
Height variation contour (mm ± SD) 0,289 ± 0,100 
Mean RNFL thickness (mm ± SD) 0,167 ± 0,058 
RNFL cross-sectional area (mm2 ± SD) 0,198 ± 0,073 
+HT 
Estrogens 
(19) 
134,6 ± 19,0 
16,1 ± 4,9 
(ll) 
0,480 ± 0,185 
0,082 ± 0,063 
0.321 ± 0,078 
0,184 ± 0,039 
0,233 ± 0,059 
Estrogens + 
~ro,gestage~ 
(n) 
(12) 
132,1 ± 9.3 
14,9 ± 1.8 
(22) 
0,416±0,103 
0,057 ± 0,022 
0.370 ± 0,106 
0,198 ± 0,0,59 
0.240 ± 0,074 
Values are means ± standard deviations (SD), Number of subje cts is in parenthe sis, 
a Estrogen Therapy vs 0Hr 
b Estrogen + Progestagen Therapy vs 0HT 
c Estrogen Therapy vs Estrogen + Progestagen Therapy 
Pvalue 
Adjustedt 
a b 
0,016t 0,023t 
0,010t 0,042t 
0,028t 0,146 
0,012t 0,287 
0.377 0,003t 
0.391 0,016t 
0,170 0,022t 
t Significance level determined by adjusted line ar regression for age, ocular perfusion pressure and age at menarche, 
c 
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DISCUSSION 
This observational study in postmenopausal women provides the first clinical evidence 
that HT (estrogens alone or in combination with progestagens) has a beneficiaI effect on 
the arterial retinal circulation and a protective effect on the retinal nerve fiber layer. We 
observed a greater blood flow in the infero-temporal retinal artery, mostly caused by its 
greater diameter, and a thicker RNFL. Blood flow was also greater in the temporal 
peripapillary retina in the +HT group, but this difference did not reach statistical 
significance in the adjusted regression model, possibly due to our limited sample size. 
EtTect of HT on Retinal Circulation 
These findings of a greater blood flow observed in the infero-temporal retinal artery in 
postmenopausal women treated with HT are in agreement with other clinical studies that 
used color Doppler imaging and reported improved pulsatility and/or resistivity indexes 
in retrobulbar vessels such as the ophthalmic I3,27.28 and the central retinaI29,31,32 arteries 
in women taking HT. Moreover, our findings are in agreement with our recent findings 
observed in a ovariectomized rat model where subcutaneous administration of estradiol 
(E2) increased the tissue perfusion in whole-mount retina demonstrated by quantitative 
autoradiography using the blood flow tracer N-Isopropyl-p-[14C]-iodoamphetamine 
([14C]_IMP).47 
We demonstrated that the significantly greater blood flow measured in the infero-
temporal retinal artery in +HT group was mostly due to a significantly larger diameter of 
Deschênes et al, HT on retinal and ONH blood flow, and RNFL Page 165 
the ITRA. This finding is in contradiction with the findings reported by Leung H et al48 
on the Blue Mountains Eye Study population, and Wong TY et a1.49 on the Beaver Dam 
Eye Study population. In both studies, a computer-assisted program was used to 
measure the average arteriolar and venular diameters. In the Blue Mountain Eye 
Study,48 no statistically significant difference was found in the averaged arteriolar 
diameter between never and current HT users for women younger than age 65. There is 
no mention of the statistical results for the averaged venular diameter for these women. 
For women aged 65 or older, there were no statistically significant differences of the 
averaged arteriolar diameter in the current HT users compared to the never HT users, 
while there was a significant decrease for the averaged venular diameter. In the Beaver 
Dam Eye study,49 postmenopausal women who were HT users had significantly 
narrower averaged arteriolar and venular diameters compared to those who were never 
HT users. As weIl, there was a significant trend toward arteriolar and venular diameter 
narrowing with increasing use of HT when the administration route was oral but not 
with all combined administration routes together. However, study limitations have been 
reported by the authors of these two studies su ch as a confounding by condition bias. A 
confounding by condition is when a disease condition prompts the use of HT. The 
underlying disease or risk factor may be the causal association rather than the HT use 
itself. ln both studies, women with a history of hypertension or diabetes were included. 
These women with a history of hypertension or diabetes may have been more likely to 
use HT for its cardioprotective role and the observed narrower retinal vessel in HT users 
may simply reflect the effects of elevated blood pressure or diabetes rather than from 
HT.48-50 Moreover, women with a history of hypertension and diabetes are likely to 
have an impaired endothelium and of being on vasodilator treatment or on insulin. 
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Therefore, a potentially impaired endothelium in patients with vascular diseases may 
have not been fully responsive to the HT treatment and the endothelium of patients 
taking vasoactive medications may have not been responsive to additional vasomotor 
stimulation from HT treatment. As weIl, the au th or reported the lack of E2 assays to 
confirm the use of HT, interaction of age and elevated BP that were not fully corrected 
by the adjusted model, variations in clarity of retinal photographs, different graders, and 
slight retinal changes in vessel diameters with the cardiac cycle. In the present study, 
confounding by condition would have been less significant since women with 
hypertension or diabetes were excluded, and this may expia in why our results differed. 
In our study design, we assumed that for women who were HT users that they were 
taking HT as prescribed by their physicians. Since HT active ingredients taken by +HT 
group were not aIl 17~-estradiol and progesterone-based, the assays for quantifying 
serum 17~-estradiol and progesterone could not have been used to establish patient 
compliance. It would have been too costly to perform assays for aIl possible active 
ingredients that exist in different HT formulations. The digitized technique used in both 
Blue Mountains Eye Study and the Beaver Dam Eye Study populations to document 
vessel diameter from photographs has not been directly compared with the vessel 
diameter obtained with the CLBF system, but since the diameter measurement by the 
CLBF accounts for cardiac pulsation, the CLBF system may have provided a more 
accurate vessel diameter measurement. 
Systemic action of HT in postmenopausal women cannot be ruled out due to a number 
of reports of vasomotor effect of estrogens on various vascular beds.2,6,9,IO,27 A 
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longitudinal study monitoring the blood pressure changes in HT users and nonusers 
indicated that systolic blood pressure increased less in HT users than non users over a 
period of ten years, while the diastolic blood pressure remained stable. These findings 
are somewhat in agreement with ours where the systolic blood pressure was greater in 
women who were not HT users, but the diastolic blood pressure and mean blood 
pressure were also greater in these women compared to HT users. These differences 
reached a significance level for only the sub-population C. The resulting ocular 
perfusion pressure was also higher in the women who were not HT users compared to 
those who were HT users reaching a significance level for only the sub-population C. 
Higher ocular perfusion pressure has a beneficial vascular effect by providing a better 
blood flow. However, although higher ocular perfusion pressure was greater in 
postmenopausal women not on HT, their infero-temporal retinal artery and temporal 
peripapillary retinal blood flow observed was smaller. Based on these observations, it is 
most likely that the increased blood flow we observed in the retina results from a local 
action of HT on retinal circulation and not from a systemic action. 
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Possible Vasomotor Pathways of Estrogens on Retinal Circulation 
The beneficial effect of HT on retinal blood flow is most likely caused by the 
vasodilating properties of estrogens mediated by the endothelium-derived relaxing 
factors, primarily nitric oxide (NO) and prostacyclin (PGh) pathways, which have been 
identified in the retinal vascular bed.51 -54 This effect could be mediated through ERa or 
ERj3, expressed in the retina.22-26,55 Both ERa and ERj3 have been shown to be 
implicated in the increase of NO synthase (NOS) expression56,57,57 or NO production. 58 
With regards to the prostacyclin pathway, several studies have shown that the 
stimulating action of estrogens on PGh synthesis,59,60 can increase retinal blood flow.53 
Finally, studies have indicated that estrogens also antagonize the effects of endothelium-
derived contracting factors61 such as endothelin-l, which has been documented to be a 
potent vasoconstrictor on the ophthalmic and retinal arteries.62 
Possible Vasomotor Pathways of Progestagens on Retinal Circulation 
Progestagens are prescribed as a combined HT to menopausal women with an intact 
uterus so as to regulate the action of estrogens on endometrial cells and to prevent 
endometrial cancer. In our whole study population of sixty-six subjects, 36 subjects 
(55.4%) were HT users, among which 24 (36.9%) were on estrogens/progestagens 
combined therapy. The type of progestagen regimen used was heterogeneous in terms 
of active ingredients, where 11 (18.5%) subj ects were using progesterone (P), 6 (9.2%) 
were using norethindrone acetate (NETA), 5 (7.7%) were using medroxyprogesterone 
(MPA), and 2 (3.1%) were using levonorgestrel. 
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However, divergent vasomotor effects of progestagens have been reported. In animal 
mode1s, P has been shown to either induce vasodilation,63-66 increase BF67,68 or have no 
effect69.70 when given alone, and to antagonize the estrogen-induced BF in a combined 
therapy.69-71 When given alone MPA was shown to have no effect on the hypothalamic 
blood flow,n but to antagonize73,74 or not antagonize75 the vasodilating effects of 
estrogens in a combined therapy. In clinical trials, P administration has been shown to 
decrease the endothelium-dependent flow mediated vasodilatation (FMD) of the brachial 
artery,76 have no effect77 or increase FMD78 when given alone. In a combined therapy, P 
administration was shown to antagonize79 or noe8,80 the estrogen-induced FMD 
compared to estrogen administration alone. MPA was shown to antogonize the 
estrogen-induced FMD.81 Therefore, possible beneficial or antagonizing vascular 
interactions of progestagens on estrogens in our study population cannot be ignored in 
our findings. In our study population, we observed that when only estrogen therapy was 
used, the Diameter and Flow of the infero-temporal were slightly greater than in the 
estrogen combined progestagens therapy, but these differences were not statistically 
different. 
Like estrogens, the vasomotor effects of progestagens can result from an interaction with 
both N082-84 and PGh pathways85 present in the retinal vascular bed51 ,54 mediated 
through the progesterone receptors,22-24 which have been identified in the retina. 
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Regional Effect of HT on ONH Blood Flow 
Using the Scanning Laser Doppler Flowmetry technique, we demonstrated greater 
capillary blood flow in the +HT group the temporal peripapillary retina to a lesser extent 
in the rim area, but these did not reach statistical significance level. Possible vasomotor 
effects of HT on the capillary blood flow on the nasal peripapillary retina in 
postmenopausal +HT cannot be ruled out for the following reasons. The brightness 
optimization of the laser beam we used in our sampling method may have preferentially 
generated a stronger signal by the photodetector for the temporal retinal than the rim and 
nasal peripapillary area signal. Also, the capillary density is higher in the temporal 
compared to the nasal peripapillary retinas for similar distance from the disc.86 
Therefore, the nasal peripapillary are a may be less sensitive to blood flow changes. 
HT Effects on ONH Topography 
In the +HT group, we observed that the rim volume, height variation contour, mean 
thickness of the RNFL and RNFL cross-sectional area were greater compared to that of 
the 0HT group. For the rim volume, this was significant for both the entire and the 
infero-temporal region of the ONH, while for the height variation contour, mean 
thickness and cross-sectional area of the RNFL they reached significance level for the 
infero-temporal region. The differences observed in these stereometrie parameters 
indicate a thinner retinal nerve fiber layer, in postmenopausal women not on HT 
compared to those on HT. This finding is similar to the sparing of sorne brain regions 
observed in post-menopausal women using HT. 14-16 A sparing of the retinal nerve fiber 
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layer may result from the vascular properties of estrogens and progestagens, as described 
eartier, by providing a better blood flow and nutrients to the ROC and the NFL. ln 
addition, sparing of the retinal nerve fiber layer may result from the protective properties 
of estrogens on neurons independent of blood flow. 87 These protective effects have been 
documented to increase neuron survival in several toxicity models of cultured neurons, 
such as glutamate, ~-amyolid, hydrogen peroxide, and excitatory amino acid toxicity 
models. 87 Interestingly, recent studies have reported a protective effect of estrogens on 
retinal ganglion cells in glutamate toxicity88 and axotomized optic nerve rodent 
models.89 
Similar to its vasomotor effects, progestagens also present divergent effects in terms of 
protective effects on neurons. When given alone, P has been shown to increase neuron 
survival in glutamate toxicity models of neurons from the hippocampus,9o and cerebral 
cortex,91 and in a spinal cord genetic model92 in rodents. However, an increase of 
neuron survival in presence of progesterone has not been observed in the axotomized 
optic nerve model in rodents.89 In combined therapy, P has been shown to increase 
neuron survival beyond that of E2 alone in the hippocampal glutamate toxicity modeL90 
With regards to MP A, it has shown not to have a neuroprotective effect on neurons 
when given al one or in combined therapy,90 or to potentiate neuronal loss93 in a 
hippocampal glutamate toxicity model. Therefore, possible beneficial or antagonizing 
protective effects of progestagens in combined therapy cannot be ruled out in our 
findings. In our study population, we observed that when only estrogen therapy was 
used, the rim volume, height variation contour, mean thickness and cross-sectional area 
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of the RNFL measurements were greater than in those in the estrogen combined 
progestagen therapy. These differences reached significance level only for the rim 
volume but not for the height variation contour, mean thickness and cross-sectional area 
of the RNFL. This likely resulted from under power analysis for those specifie 
variables. 
For the height variation contour, mean thickness and cross-sectional area of the RNFL, 
the 0HT group of post-menopausal women presented a decrease of 4.6%, 6.7% and 
7.6% respectively compared to +HT group for the entire optic nerve region, while for 
the infero-temporal quadrant, this decrease was 18.1 %, 13.9% and 16.8% respectively. 
Preferential thinning of infero-temporal neural structures is also seen in early glaucoma, 
and several causes for this have been proposed.94,95 It is interesting to speculate that the 
vulnerability of this region may explain sorne of our findings. 
Since our findings on the optic nerve head topography related to RNFL differences 
between the two groups of postmenopausal women, we could have chosen a test to 
specifically assess the RNFL, such as the optical coherence tomography. However, we 
were interested in investigating the ONH topography, which was obtained with the HRT 
1. 
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Effect of HT on the functionality of RGC 
The exact origins of the PERG components have not been identified, but current data 
suggest that the N95 is a contra st related component of the RGC function and that P50 is 
partly RGC derived with sorne contribution from structures distal to RGc.96 Smaller 
PERG amplitudes and de1ayed latencies are indicative of RGC loss. Clinical studies 
where loss of RGCs occur such as in OHT and OAG, have demonstrated that N95 
amplitude is reduced and P50 latency is increased,97 and that N95 amplitude 
significantly and positively correlates with RNFL thickness while P50 latency 
negatively correlates.98,99 
We observed a borderline significantly shorter P50 latency in the +HT group by only 1.1 
ms. Although a shorter P50 latency may indicate an improvement in the function of 
ganglion cells, it is unlikely that such a small improvement would be c1inically 
significant. Interestingly, our findings are somewhat consistent with the pattern visual 
evoked potential (PVEP) findings observed in postmenopausal women, where the use of 
Tibolone over a period of 3 months, a synthetic steroid with prominent estrogen effects, 
was shown to significantly improve the PI 00 latencies by 4 ms (5%). As well as a 
significant increase by 31% in the PI00 amplitude. lOo Yilmaz et al. (2000)100 
hypothesized that increasing sensitivity of the central nervous system to catecholamines 
by changing the opening frequency of voltage-related L-type calcium channels,lol 
increasing effects of glutamate 102 and decreasing formation of y-aminobutyric acid 
(GABA)103 induced by estrogens might be the responsible mechanisms in shortening 
PI00 latency and increasing PI00 amplitude. So far, it is unknown how estrogens might 
improve the P50 latency of the PERG. The same mechanisms may apply in shortening 
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P50 latency in postmenopausal women who were HT users. This remains to be 
investigated. We also observed a small increase in the N95 amplitude by 3% and a 
small decrease in P50 amplitude by 6% in the +HT group. However, the magnitude of 
amplitude changes were not in the 31 % magnitude change of the P100 amplitude as 
reported by Yilmaz al. (2000), and they did not reach statistical significance. Since N95 
amplitude correlates with the amount of RNFL, the difference in the RNFL thickness we 
observed between the two groups of postmenopausal women may not be large enough to 
induce a significant change in the PERG amplitudes. 
Study Limitations 
As part of our exclusion criteria, postmenopausal women had to be free of systemic and 
cardiovascular diseases. Potentially impaired endothelium in patients with systemic and 
cardiovascular diseases may not be fully or partly responsive to the HT treatment. 
Moreover, these patients may likely be on vasodilator treatments and their endothelium 
may not be responsive to additional vasomotor stimulation from HT treatment. If we 
had included postmenopausal women with systemic and cardiovascular diseases, it is 
possible that the differences we observed in blood flow and RNFL thickness might have 
been different. 
In this heterogeneous population of postmenopausal women we investigated, the type of 
HT regimens in terms of their active ingredients, routes of administration, dosage and 
duration of administration was heterogeneous and may have yielded different degrees of 
vasomotor effects on the retina and protective effects on the retinal nerve fiber layer. In 
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addition, women were at variable postmenopausal times. As well, the outcome variables 
measured were collected at a single time point, which does not provide any information 
on the progress on the outcome variables in both groups of postmenopausal women. 
Finally, postmenopausal women may not exhibit similar cardiovascular characteristics 
and risks which could interplay with the efficacy of HT. The ideal study design would 
be to randomize women to HT at the time of the onset of menopause with documented 
cardiovascular characteristics and risks, and establish a baseline for blood flow, structure 
and function before beginning therapy. Then monitor blood flow, structure and function 
changes at intervals over a five- to ten-year period. Such a protocol could be part of a 
larger HT study. 
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CONCLUSION 
This is the first observational study that investigated the long-term effects of estrogens 
depletion compared to the use of postmenopausal hormone therapy on the retina and 
nerve fiber layer in a population of women. The findings of this study indicated that 
compared to postmenopausal women who had never used HT, postmenopausal women 
who have used HT since their menopause onset presented 1) a better retinal blood flow 
as observed in the infero-temporal retinal artery and capillary blood flow of the temporal 
retina and 2) a greater rim volume, height variation contour, and mean thickness and 
cross-sectional area of the RNFL. These findings likely reflect the vasomotor and 
protective properties of estrogens or estrogens and progestagens combined, and may 
explain the link between the hormonal status of estrogen and progestagen. levels 
throughout a woman's life and the risk of developing glaucomal7,18 and age-related 
macular degeneration. 19-21 
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Abstract 
Background: Estrogens, used as postmenopausal hormone therapy, have been shown to 
improve pulsatility and/or resistivity indexes in the retrobulbar arteries in women. In 
this study, we investigated whether retinal perfusion could be improved by a chronic 
treatment of estradiol in a menopausal rat model. Methods: Mature female Brown 
Norway rats were ovariectomized and silastic capsules containing either l7p-estradiol 
(E2) or placebo were implanted subcutaneously. Six weeks later, retinal tissue perfusion 
was measured in four concentric isopters of aH quadrants of whole-mount retina by 
quantitative autoradiography usmg the diffusible tracer N-Isopropyl-p-[14C]-
iodoamphetamine ([14C]-IMP). ResuUs: The results showed that the E2 treatment 
significantly induced an increase in local retinal uptake index (22% to 45% according 
the concentric isopter analyzed) compared to placebo animaIs. Interpretation: These 
findings demonstrate that long term E2 treatment in ovarian hormone deficient rats 
enhances retinal tissue perfusion, which may play a protective role in age-related ocular 
blood flow dysfunction. 
Keywords: estrogens, retina, blood flow, iodoamphetamine, ovariectomy 
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BACKGROUND 
The menopause is the permanent cessation of ovarian follicular activity and subsequent 
fall in endogenous estrogens and progesterone production in women. Postmenopausal 
hormone therapy (HT) consisting of estrogens al one or combined with progestagens, is 
frequently prescribed to women in order to alleviate c1imacteric symptoms. As well as 
their role in protection of structure and function of many cens and organs, estrogens 
have the ability to influence the vascular tone and blood flow. ln postmenopausal 
women, HT improves blood flow in the femoral arteryl and brain parenchyma,2-5 and 
pulsatility and/or resistivity indexes in the carotid,6.7 internaI carotid,8.9 and middle 
cerebral arteries.9.IO These blood flow indexes are also decreased in the retrobulbar 
arteries, such as the ophthalmic,II-l3 the short posterior,14 and the central retinal 
arteries. 14-16 
Recently, there has been an increasing interest in investigating the possible vascular 
protective role of estrogens in age-related retinal blood flow dysfunction, such as 
glaucomal7.18 and age-related macular degeneration. 19-21 However, although estrogen 
receptors (ERs) are present in the retina in the human,22-24 as well as in the rat,22.25 it has 
not been directly determined wh ether chronic estrogen administration can increase blood 
tissue perfusion in the retina. In this study, we addressed this question using 1 7~­
estradiol (E2) treatment in a menopause rat mode!. In vivo retinal tissue perfusion was 
quantified by autoradiography using the diffusible tracer N-Isopropyl-p-[14C]-
iodoamphetamine (C 4C]-IMP) in the conscious rat. This methodological approach 
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provided the ability to distinguish the local effects of E2 on tissue perfusion in different 
isopters and quadrants of whole-mount retinas. 
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METHODS 
Animais 
AlI experimental methods and animal care procedures adhered to the ARVO Statement 
for the Use of AnimaIs in Ophthalmic and Vision Research and were approved by the 
local institutional animal care committee, "le Comité de Déontologie de 
l'Expérimentation sur les Animaux" at the University of Montreal, in accordance with 
the Canadian Council on Animal Care. Twelve mature middle-aged (11-month old) 
retired female breeder Brown Norway (Rattus norvegicus, 225.5 ± 7.9 g) rats from a 
single colony (Harlan Sprague Dawley, Netherlands), were used in this study. This age 
in rats corresponds approximately to the time when 65% of female rats present irregular 
estrous cycles, equivalent to the peri-menopausal period in women. Rats were housed 
individually and placed in a room at 23°C with a 12-hour light/dark adapted 
photoperiod, with food and water provided ad libitum. 
Ovariectomy and implantation of capsules 
After habituation to their environment, bilateral ovariectomies (OVx) were performed in 
rats using a posterior surgical approach under isoflurane (3.0%) in order to normalize 
serum estrogen concentrations to their lowest level. Silastic capsules (I.D. 0.058, O.D. 
0.077, 0.5 cm in length, #508-006, Dow Coming, Midland, MI) filled with a crystalline 
preparation of either 25% E2 (Sigma-Aldrich, St. Louis, MO, USA) plus 75% cholesterol 
(OVX+E2, n=7, approximately 2 mg E2 per capsule) or 100% cholesterol (placebo) 
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(Sigma-Aldrich, St. Louis, MO, USA) (OVx, n=5) were implanted in the nape of the 
neck for time-release. These capsules have been validated as a means of delivering 
steady and physiological levels of E2 in mature OVx rats.26,27 Following the OVx 
surgery, 5 mL of Ringer's lactate were subcutaneously injected for rehydration, while 
repetitive subcutaneous doses of 0.1 mL of buprenorphine hydrochloride (Temgesic®, 
Reckitt Benckiser Health Science Ltd, UK, 0.1 mg/mL) were injected every 12 hours 
over a two-day period for post-operative pain management. Vaginal smears were 
performed both to ensure effectiveness of the bilateral OVx surgery and to serve as an 
indicator of tissue responsiveness to circulating estrogens released from E2 capsules. 
Rats were exposed to E2 or placebo treatment for a period of six weeks. A six-week 
treatment was chosen in order to permit a further study investigating the potential 
vascular protective role of estradiol in a rat glaucoma model. 
Surgical procedure for tissue perfusion investigation 
Six weeks after OVx surgery and E2 or placebo treatment, polyurethane catheters (I.D. 
0.6 mm, O.D. 0.9 mm, Harvard Apparatus, Holliston, MA, USA) were inserted into the 
femoral vein and artery under 1.5% isoflurane (induction of anaesthesia with 3% 
isoflurane for 5 min). During this procedure, body temperature was monitored with a 
rectal thermometer and maintained at 37°C by a heating pad (FHC, Bowdoinham, ME). 
Both b100d pressure and heart rate were monitored from the tail using a non-invasive 
blood pressure cuff system (BP1000, Kent Scientific Corporation, Torrington, CT, 
USA). At the end ofthis procedure, 2 mL of Ringer's lactate were given subcutaneously 
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for rehydration. Rats were then installed in a hammock and left under minimal restraint 
over a 2-hour period to recover from anaesthesia. Body temperature was maintained at 
37°C with a heating lamp and both blood pressure and heart rate were monitored until 
the initiation of measurement experiment for the retinal perfusion. As well, 
cardiovascular, chemistry and haematological parameters were measured with the i-
STAT®, a veterinarian clinical blood gases and electrolytes analyzer (HESKA, Fort 
Collins, CO), from arterial blood samples collected via the arterial catheter. This was 
achieved immediately prior to the initiation of measurement experiment for the retinal 
perfusion to confirm the recovery to normal physiologic level. 
Principles of the evaluation ofretinal tissue perfusion using lMP 
In the aim of evaluating tissue perfusion in retina with a regional resolution, the 
diffusible blood flow tracer [14C]-IMP was used. The [14C]-IMP binds to the amine 
sites.28,29 It was chosen as a blood flow tracer instead of [14C]iodoantipyrine/o 
[14C]diazepam/ 1 or n-[14C]butanoV2 because of three of its essential properties related 
to cerebral blood flow measurement.33 These properties avoid the primary limitation of 
the classical diffusible tracer [14C]-iodoantipyrine autoradiographic technique/4 i.e. its 
time-dependent post-mortem intraparenchymal diffusion, which results in weakening the 
local tracer spatial gradients in tissues and regions. First, [14C]_IMP has a very high 
extraction at the first pass through the microvasculature, which allows a non-restrictive 
diffusion from blood to tissue despite the blood-retinal barrier. Second, [14C]-IMP has a 
very low clearance rate and low post-mortem diffusion,35 due ta its high affinity for 
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cerebral tissue. Third, [14C]_IMP is chemically and biologically inert for the duration of 
the measurement period.35 IMP has been successfully used in small animal 
research,33,35,36 and in hum ans using Single Photon Emission Computerized 
Tomography. 
The principle of blood flow evaluation is identical to that of micrometric microspheres37 
except that this "molecular microsphere" IMP is trapped within the tissue, whereas 
micrometric microspheres are trapped inside the microvascular space. Since the goal of 
this experiment is to de termine local blood flow gradients in post-mortem tissue, the 
[14C]-IMP molecular microsphere technique is more appropriate than the c1assical 
microsphere technique. Moreover, the use of a diffusible tracer avoids inaccuracies of 
the retinal blood flow measurement due to axial streaming, plugging or permeability 
changes as reported with the c1assical microsphere technique.37,38 
Procedure of measurement of the retinal tissue perfusion 
N-Isopropyl-[methyl-l,3- 14C]-p-iodoamphetamine (ARC, St Louis, USA) (100 .uCi/kg) 
was dissolved in 600).lL of saline (injectable 0.9% NaCl solution) and infused in fully 
conscious rats over a 30 s period at a constant rate of 1.2 mL/min using an infusion 
pump (PHD 2000, Harvard Apparatus, Holliston, MA, USA) through the femoral vein. 
At the end of the infusion, the rats were immediate1y sacrificed by decapitation and a 
blood sample was collected for serum E2 measurements. A small incision on the 
superior eye1id was made to indicate the orientation of the eyes and the eyes together 
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with the attached supenor eyelid were then harvested. They were immediately 
immersed in a solution of 4% paraformaldehyde for post-fixation. Two hours later, the 
anterior segment of the left eye was excised to ease the penetration of the 
paraformaldehyde toward the posterior segment. On the following day, the retina was 
removed from the eye cup, dissected in four quadrants (superior, inferior, nasal and 
temporal) and whole-mounted on a glass slide with the ganglion cells layer facing up. A 
small incision was made on the retina to indicate the superior quadrant. The who le-
mount retina was then exposed to an X-ray film (Biomax, Kodak-Eastman Inc, 
Rochester, New York) for la days together with a set of [14C]-standards (GE Healthcare 
Ltd, UK). The autoradiograms were analyzed using the computerized image analysis 
MCID Basic Software (v7.0, Interfocus Imaging, Linton, England). It has been 
demonstrated that the amount of the beta 14C radiation energy reaching a X-ray film 
decreases with increasing thickness of the tissue being exposed up to 2: 1 00 !lm where it 
reaches a plateau leve1.39 Therefore, it can be assumed that the measured C1MP (T) from 
the whole-mount retina autoradiograms originate mainly from the first 100 /-lm of the 
inner retina and is mainly representative of the blood supply of the 100 !lm inner part of 
the retina. 
Calculation of retinal tissue perfusion 
Retinal tissue perfusion was evaluated using the principle of indicator-fractionation 
technique.33 ,35 A local retinal uptake index (RUI) was calculated from the following 
equation,36 
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RUI [C1MP(T) / A] x BW (Eq. 1) 
where A is the injected dose (nCi), BW is the body weight (g) and C1MP (T) is the 
radioactivity measured on the autoradiogram at the time (T) of sacrifice (nCi/g). 
C1MP(T) was read from circular regions of interest of 0.8 mm2 (1 mm diameter) 
distributed at the l, 2, 3 and 4 mm isopters away from the center of the optic nerve head 
in an retinal quadrants (Fig. 1). The IMP uptake index in the brain has been shown to 
correlate weIl with the local cerebral blood flow (CBF), where the CBF has been 
determined by positron emission tomography.36 As the retinal vascular bed is similar to 
the cerebral vascular bed in terms of permeability (bIood-tissue barrier), anatomy (non-
fenestrated capillaries) and sorne local regulatory mechanisms (without autonomic 
innervation of the vasculature),31 we considered that the [MP uptake index in the whole-
mount retina can provide an approximation of retinai blood flow. However, it cannot be 
excluded that IMP may aiso have partI y diffused from the choroid prior to retinal 
dissection. 
Deschênes et al, 17~-estradiol effect on retinal perfusion 204 
Figure 1: Schematic representation of a whole-mount retina showing the regions of 
interest (ROI) measured. The retina was divided into four quadrants (the notch indicates 
the superior quadrant). A circular ROI (fi lIed circles, area 0.8 mm2) was measured in 
each quadrant at each isopter (light circular lines at 1, 2, 3 and 4 mm away from the 
center of optic nerve head). The four values of C1MP (T) of each quadrant were averaged 
for each isopter. 
Serum assays 
The total serum E2 levels were measured using a 3rd Generation Estradiol RIA kit 
(Diagnostic Systems Laboratories, Webster, TX, USA)?6 Since soy products from 
animal diets induce vasodilation on coronary arteries in vitro in combination with E2,4o 
the concentration of total serum equol, a metabolite of daidzein, a phytoestrogen 
contained in the rat chow used (Ralston Purina Canada Inc), was also measured on a 
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third and distinct group of rats (OVx, n=4; OVx+E2, n=4) by a time-resolved 
fluoroimmunoassay kit (Labmaster diagnostic, Turku, Finland) as previously reported.41 
Statistical analysis 
The RUIs measured in each quadrant were averaged for each isopter. Unpaired Student 
t-tests were perforrned betweeIi the OVx group and OVx+E2 group for (1) the 
physiological parameters, (2) the E2 plasma concentrations, and (3) the RUI of each 
isopter. A significance level of p :<::;0.05 was chosen. A Mann-Whitney U-test was used 
to analyze equol plasma concentrations. 
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RESULTS 
Effect of ovariectomy and E2 treatment on the physiological parameters and serum E2 
and equol levels 
Cardiovascular, blood gas and haematological parameters in the OVx and OVX+E2 
groups are summarized in Table 1. The E2 treatment did not alter most physiological 
parameters, except body weight and hematocrit level. As expected, OVx rats gained 
weight (p = 0.005) since estrogens play a role in food intake and energy expenditure.42 
The hematocrit level was reduced by 15% in OVx+E2 group (p = 0.01) corresponding to 
a haemoglobin value of l2.l ± 0.7 g/dL as compared to 14.2 ± l.3 g/dL in OVx rats, yet 
the hematocrit level in OVX+E2 rats remained within the physiological range (35-
57%).43 
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Table 1: Effects of l7~-estradiol (E2) treatment on the physiological parameters 
monitored in the conscious OVx rats after two hours of recovery from anaesthesia and 
prior to the injection of [14C]-IMP. 
Weight (g ± SD) 
Body temperature (OC ± SD) 
Blood pressure 
systolic (mmHg ± SD) 
diastolic (mmHg ± SD) 
mean (mmHg ± SD) 
Arterial pH (±SD) 
Arterial p02 (mmHg ± SD) 
O2 saturation (% ± SD) 
Arterial pC02 (mmHg ± SD) 
Arterial HC03 (mmollL ± SD) 
Hematocrit (% PVC ± SD) 
OVx 
(n=5) 
247.4 ± 7.5 
37.3 ± 0.3 
12l.0 ±12.6 
95.8 ± 6.2 
104.2 ± 8.3 
7.44 ± 0.03 
80.4 ± 5.6 
96.2 ± 0.8 
37.1 ± l.8 
25.4 ± 1.1 
41.4 ± 4.6 
OVX+E2 
(n=7) 
224.0 ± 13.0 
37.7 ± 0.5 
130.2 ± 7.9 
102.6 ± 9.5 
11l.5 ± 8.4 
7.44 ± 0.02 
80.3 ± 5.6 
96.1 ± 0.6 
37.8 ± l.2 
25.6 ± 1.4 
35.3 ± 2.1 
p 
value 
0.005* 
0.77 
0.50 
0.50 
0.27 
0.70 
0.97 
0.89 
0.44 
0.83 
0.01 * 
p02, pC02, partial gas pressure of oxygen and carbon dioxide, respectively; HC03, 
bicarbonate. Values are means ± SD. Number of animaIs in parentheses. 
* p<O.O l, significantly different from OVx placebo (Student t-test). 
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After six weeks of treatment, serum E2 levels were approximately five-fold higher (p < 
0.01) in OVx rats treated with Ez as compared to OVx rats treated with placebo silastic 
capsules (71.1 ± 7.6 vs 370.4 ± 57.0 pmol/L) (Fig. 2A). Serum equol levels were not 
statistically different (p = 0.14) between OVx and OVx+E2 rats (511.1 ± 165.2 vs 748.3 
± 217.5 nmol/L) (Fig. 28). 
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Figure 2: Serum 17~-estradiol (E2) (A) and equol (B) level in the ovariectomized 
feinale rats treated with silastic capsules either containing placebo (OVx, white bars) or 
E2 (OVx+E2, black bars). The E2 concentrations were five-fold higher in OVx+Ez rats 
compared to OVx rats (A), but serum equol levels were similar in both groups (B). * 
p<0.05, significantly different from OVx placebo for the estradiol concentration 
(Student t-test). 
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Retinal uptake index of ['4 CJ-IMP in ~egions of whole-mount retina 
Pseudocolour autoradiograms of whole-mount retinas generated by the MeID Image 
analysis system (Fig. 3) display a decreasing gradient of tracer from the centre to the 
periphery of the retina, and a fairly homogeneous distribution throughout each isopter. 
Visually, the tracer concentration in the OVx+E2 group appeared higher than that in the 
OVx group. Quantified data expressed in RUIs show significantly elevated values in the 
OVX+E2 rat in the three furthermost peripheral isopters compared tocontrol rats (Table 
2, Fig. 4). This increase in the RUI ranges from 22% to 45%, reaching 45% in the third 
isopter. 
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Figure 3: Representative whole-mount retina autoradiograms displayed in pseudocolour 
from an ovariectomized rat treated with placebo silastic capsules (OYx, left panel) and 
an OYx+E2 rat treated with E2 silastic capsules (right panel). The tissue concentration of 
[14C]-IMP was higher in the OYx+E2 rat, indicating that the retinal blood perfusion was 
greater in E2 treated animais than in placebo treated animais. The correspondence 
between pseudocolour scale and C1MP (T) values (nCi/g) is represented on the right side 
of the figure. 
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Table 2: Effects of E2 treatment on local retinal uptake index of [14C]_IMP in OVx 
conscious rats at different isopter distances from the center of the optic nerve head. 
[14C]_IMP local retinal uptake index 
Isopter OVx OVX+E2 P 
1 mm 
2mm 
3mm 
4mm 
(n=5) 
8.0± 0.7 
6.9 ± 0.8 
5.2 ± 0.6 
3.5 ± 0.4 
(n=7) 
9.8±0.6 
9.7± 0.8 
7.5 ±0.6 
4.6 ± 0.3 
RUI values are mean ± SD. Number of animaIs in parentheses. 
* p<O.Ol, significantly different from OVx placebo (Student t-test). 
value 
0.11 
0.03* 
0.04* 
0.04* 
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Figure 4: Percent of changes (OVx+E2 versus OVx) of the local retinal uptake index 
(RUI) of [14C]_IMP for each isopter. The RUI was increased in OVx+E2 versus OVx 
group at each isopter, although only the three farmost peripheral isopters showed 
statistical significance. * p<O.05, significantly different from OVx placebo (Student t-
test). 
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INTERPRETATION 
These results provide the first evidence that a chronic treatment with E2, mimicking HT 
treatment under menopausal physiological conditions, increases retinal tissue perfusion. 
Our quantitative autoradiographie investigation using [14C]_IMP showed that both the 
central and peripheral areas of the retina presented a significant blood flow 
improvement. 
Estradiol treatment paradigm 
At the time of sacrifice, serum E2 levels were nearly five-fold higher in OVx rats 
receiving the E2 capsules as compared to rats receiving the placebo capsules. The serum 
E2 levels for both groups were consistent with values reported in other studies.27,44 The 
E2 treatment administered in our OVx rats using silastic capsules is a representative 
model of HT treatment in menopausal women since the five-fold magnitude increase 
seen here is within the 3.1- to l1.8-fold range of increases in E2 levels observed in 
postmenopausal women using typical transdermal E2 regimens. 8,10 Also the 
subcutaneous release of E2 from silastic capsules is sirnilar to transdermal application of 
E2 as both approaches bypass the hepatic degradation of estradiol. 
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Effect of E2 on local retinal tissue perfusion 
This study provides the first evidence demonstrating that E2 treatment increased the 
blood perfusion in all quadrants of rat retina with higher RUI increases in the peripheral 
retinaI. As se en in other species,45 blood tissue perfusion was higher in the central as 
compared to peripheral retina, yet E2 treatment elevated blood flow in the peripheral to a 
greater degree than in the central retina. This finding may indicate a local effect of 
estrogens at this level allowing a better uptake of [14C]-IMP. One explanation for a 
higher response in the peripheral regions is that the capillary network in the peripheral 
retina is denser than in the central retina, as shown in corrosion casts in rats,46 thereby 
allowing a better tissue perfusion. A second explanation could relate to the regional 
distribution of estrogen receptors or downstream target enzymes in the retina, which 
remains to be investigated. Increases in the uptake of [14C]-IMP after the administration 
of most likely indicate an increase in retinal blood flow, in accordance with our 
clinical laser Doppler flowmetry findings showing that menopausal women on HT 
presented a significantly higher blood flow from the infero-temporal retinal artery 
compared to age-matched non-us ers women (paper in preparation). Our resillts are also 
in agreement with those reporting improved pulsatility and/or resistivity indexes 
observed in various retrobulbar vessels, such as the ophthalmic ll . 13 or central retinal 
arteries,14-16 in women taking HT: However, due to the dual vascular supply of the 
retina, a fraction [14C]_IMP entrapped in the retina could have diffused through the 
retinal epithelium from the choroidal circulation. 
j , 
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This regional change of blood tissue perfusion supports a local action of estrogens, 
although the possibility of a systemic action could not be discarded due to a number of 
reports of the vasomotor effect of estradiol on various vascular beds.2,8,9,11,47 In addition, 
the significance of reduced hematocrit in the OVx+E2 group on systemic blood flow, 
and corisequently the retinai blood flow, shouid be taken into consideration. Similar 
Iower hematocrit has been observed in rats48 and women49,50 following the 
administration of ethinyl estradiol. This reduced hematocrit (1) may decrease blood 
viscosity as seen in women after HT treatmentl3 ,51 and may favour increases in blood 
flow, or (2) may decrease oxygen delivery and favour local metabolic autoregulation. 
However, a 6.1 decrease in hematocrit in the OVx+E2 rats, reflecting approximately 
2 g/dL change in haemoglobin, is likely insufficient to induce a 22 to 45% increase in 
the retinal tissue perfusion. 
The effect of E2 on the retinal blood flow is most likely related to the vasodilator 
properties of especially in relation to the endothelium-derived relaxing factors, 
mostly nitric oxide (NO) and prostacyclin (PGI2) pathways, which have been identified 
in the retinal vascular bed.52.54 This effect could be mediated through ERa or 
ER~, since both receptors are expressed in the vascular system ofrats,55 and that ERs are 
aiso expressed in their retinas.22.25 The same mediation may occur in humans.23,24 Both 
ERa and ER~ are implicated in the increase of NO synthase (NOS) expression56,57 or 
NO production.58 With regards to the prostacyclin pathway, several studies have shown 
the stimulating action of estrogens on the PGI2 synthesis,59,6o and PGI2 has been shown 
to increase retinal blood flOW. 54 Finally, studies have indicated that estrogens aiso 
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antagonize the effects of endothelium-derived contracting factors. 61 It seems improbable 
that equol, the metabolite of phytoestrogens from the rat chow, had a direct effect on the 
retinal tissue perfusion in our rat model since a vasomotor action of equol has been 
shown only at elevated concentrations (10 ~g/mL), but not at lower concentrations (0.1 
~g/mL)62 su ch as detected in our rats. Moreover, the low binding affinity of equol to 
both ERs is between 1/250th and 1/1000th ofthat for E2.63 
In conclusion, our findings demonstrate for the first time that estradiol influences the 
posterior segment ocular blood flow as observed by a significant increase in retinal 
tissue perfusion ranging from 22% to 45% in this menopausal rat model. The molecular 
vascular mechanisms of E2 and its potential vasculoprotective role against age-related 
retinal blood flow dysfunction remain to be investigated. 
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5.0 DISCUSSION 
The observational study conducted on postmenopausal women provided the first clinical 
evidence that the long-term effects of estrogen depletion compared to the use of 
hormone replacement therapy (estrogens alone or in combination with progestagens) has 
a negative effect on the retinal arterial circulation and the optic nerve head topography. 
5.1 Effects of HT on retinai blood flow 
We observed that postmenopausal women on HT presented significantly greater blood 
flow in the infero-temporal retinal artery, which was mostly due to a significantly larger 
diameter of the ITRA compared to those of women who never used HT since their 
menopause onset. These data are in agreement with other clinical studies that used color 
Doppler imaging and reported improved pulsatility and/or resistivity indexes in 
retrobulbar vessels such as the ophthalmic289,322,323 and the central retinae24,326,327 
arteries in women taking HT. Blood flow was also greater in the temporal peripapillary 
retina in the +HT group, but this difference did not reach statistical significance in the 
adjusted regression model, possibly due to our limited sample size. Our findings of 
improved retinal blood flow observed in postmenopausal women on HT were confirmed 
in a menopause rat model by quantitative autoradiography technique using the blood 
flow tracer [14C]_IMP. In menopaused rats, chronic treatment with E2, mimicking HT 
treatment under menopausal physiological conditions, increased retinal tissue perfusion 
in whole-mount retina. 
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We demonstrated that the significantly greater blood flow measured in the infero-
temporal retinal artery in +HT group was mostly due to a significantly larger diameter of 
the ITRA. This finding is in contradiction with the findings reported by Leung H et 
a1.350 on the Blue Mountains Eye Study population, and Wong TY et a1.351 on the Beaver 
Dam Eye Study population. 
In both studies, a computer-assisted program was used to measure the average arteriolar 
and venular diameters. In the Blue Mountain Eye Study,350 for postmenopausal women 
older than age 65, there was a significant decrease for the averaged venular diameter for 
HT users compared to those who never used HT. ln the Beaver Dam Eye study,35 1 
postmenopausal women who were HT users had significantly narrower averaged 
arteriolar and venular diameters compared to those who were never HT users. However, 
study limitations have been reported by the authors of these two studies such as a 
confounding by condition bias, lack ofE2 assays to confirm the use of HT, interaction of 
age and elevated BP that were not fully corrected by the adjusted model, variations in 
c1arity of retinal photographs, different graders, and slight retinal changes in vessel 
diameters with the cardiac cycle. 
In the present study, confounding by condition would have been less significant since 
women with systemic and cardiovascular diseases were excluded, and this may explain 
why our results differed. Also, the measurements of the infero-temporal retinal artery 
diameter were obtained with the CLBF system, which accounts for cardiac pulsations, it 
may have provided more accurate vessel diameter measurements than the computer-
assisted program used in both studies. 
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5.2 Vasomotor mechanisms of estrogens on retinai blood flow 
The beneficial effect of E2 and HT on retinal blood flow in postmenopausal women and 
ovariectomized rats is most likely caused by the vasodilating properties of estrogens 
mediated by the endothelium-derived relaxing factors, primarily nitric oxide (NO) and 
prostacyc1in (PGh) pathways, which have been identified in the retinal vascular 
bed.35.352-354 This effect could be mediated through ERa or ER~, expressed in the 
retina.'79.180.185-188 Both ERa and ER~ have been shown to be implicated in the increase 
of NO synthase (NOS) expression195.212 or NO production. '94 With regards to the 
prostacyc1in pathway, several studies have shown that the stimulating action of 
estrogens on PGh synthesis,355.356 and intravitreal injection of prostacyc1in have shown 
increased retinal blood flow in an animal mode1.35 Finally, studies have indicated that 
estrogens also antagonize the effects of endothelium-derived contracting factors such as 
endothelin,'91 which has been documented as potent vasoconstrictor on the ophthalmic 
and retinal arteries.34 
5.3 Vasomotor mechanisms of progestagens on retinai blood flow 
Progestagens are prescribed as a combined HT to menopausal women with an intact 
uterus so as to regulate the action of estrogens on endometrial cells and to prevent 
endometrial cancer. In our whole study population of sixty-five subjects, 36 of them 
(55.4%) were HT users, ofwhich 24 (36.9%) were on estrogens/progestagens combined 
therapy. The type of progestagen regimen used was heterogeneous in terms of active 
ingredients, where Il (16.9%) subjects were using progesterone (P), 6 (9.2%) were 
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using norethindrone acetate (NETA), 5 (7.7%) were using medroxyprogesterone (MPA) 
and 2 (3.1%) were using levonorgestrel. However, divergent vasomotor effects of 
progestagens have been reported. In animal models, P has been shown to either induce 
vasodilation,252-255 increase BF256,257 or have no effect258,259 when given al one, and to 
antagonize the estrogen-induced BF in a combined therapy.258,259,263 When given alone 
MPA was shown to have no effect on the hypothalamic blood flOW,l92 but to 
. 357358 . 359 h d'l' f'" f . antagomze' or not to antagomze t e vasa 1 atmg e lects 0 estrogens m a 
combined therapy. In clinical trials, P administration has been shown to decrease the 
endothelium-dependent flow mediated vasodilation (FMD) of the brachial artery,260 to 
have no effect261 or to increase FMD262 when given alone. In a combined therapy, P 
d ... h . 264 . 262 265 h . d d a mmlstratlOn was s own to antagomze or not antagomze ' t e estrogen-m uce 
FMD compared to estrogen administration alone. MP A was shown to antagonize the 
estrogen-induced FMD.360 Therefore, possible beneficial or antagonizing vascular 
interactions of progestagens on estrogens in our study population cannot be ignored in 
our findings. Similar to estrogens, the vasomotor effects of progestagens can result from 
an interaction on both N0266-268 and PGI2 pathways267,269 present in the retinal vascular 
bed.35,352-354 This vasomotor effect is likely mediated through the progesterone receptors, 
which have been identified in the hum an retina. 179,180,185 
5.4 Possible vasomotor effect of equol on retinal blood flow 
Vasomotor effects of equol, a metabolite of daidzein, a phytoestrogen present in soy 
products also cannot be excluded in our study results. The conversion of daidzein into 
equol occurs in the intestinal flora. Equol has been shown to induce vasodilation on 
231 
coronary arteries in vitro in combination with E2.348 In both studies, postmenopausal 
women and ovariectomized rats likely ingested soy products. However, effects of equol 
resulting from the ingestion of soy products is likely negligible for the following 
reasons. Only 27%361 of women excrete equol and we can assume that both +HT and 
0HT postmenopausal women groups were equally exposed to the effect of equol. 
Moreover, the vasomotor effect of equol has been shown only at elevated concentrations 
(10 !J.g/mL), but not at lower concentrations (0.1 !J.g/mL)362 such as those levels detected 
in our rats. Finally, equol has a low binding affinity to both ERs, between 1I250th and 
l/lOOO'h ofthat for E2.363 
5.5 Effect of 17p-estradiol on weight, hematocrit and blood pressure 
The changes in weight, Hct, blood pressure on systemic blood flow and consequently on 
retinal tissue perfusion should be taken into consideration. 
First of aIl, the OVx rats gained weight. The amount of C4C]-IMP injected was based 
on the rat weight to account for smaller and bigger proportional rats. The weight gain 
likely resulted from higher amounts of adipose tissue, in response to higher food intake 
and less energy expenditure364 white the retinal volume does not change with weight. 
This could have biased the amount ofinjected [14C]-IMP, which may not have been fully 
corrected by the formula to determine the RUI index, leading to possible higher RUI 
values in the OVx rats. A negative relationship exists between weight and SHBG.365-369 
It is possible the SHBG level may have decreased in the OVX rats and this may have led 
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to a reduced amount of estradiol bounded to SHBG. Consequently, more available free-
estradiol could have induced sorne vasodilating effect in the OVx rats. As well, estrone 
is produced by adipose tissue from androstenedione. In the OVx rats that gained weight, 
inereased estrone production could have also induced sorne vasodilating effeet, although 
estrone is less biologically active than estradiol. In our observational study, 
postmenopausal women had to have and BMI ::;30 as part of our inclusion criteria and 
the BMI in the 0HT group were similar to those of the +HT group. Therefore, the 
absence of weight gain effect on the SHBG should not have modified the bioavailability 
of estrogens in the 0HT postmenopausal women. 
Secondly, the OVx+E2 rat presented lower Het level by 6.1 (14.7%). Similar lower 
hematocrit levels have been observed in rats (a 14.3% decrease)370 and in women «5% 
decrease)371,372 following the administration of ethinyl estradiol. This reduced 
hematocrit level (1) may decrease blood viscosity as seen in women after HT 
treatment289,373 and may favour increases in blood flow, or (2) may deerease oxygen 
delivery and favour local metabolic autoregulation, necessitate to increased flow of 
blood to meet the 02-delivery demands. However, a decrease of 6.1 in hematocrit level 
in the OVx+E2 rats, reflecting approximately 2 g/dL change in haemoglobin, is likely 
insufficient to induce a 22% to 45% increase in the retinal tissue perfusion. 
Additionally, IMP is freely exchangeable between red cells and plasma with a 
differential concentration of approximately a 1.8/1 with the plasma.374 Reduced 
amounts of Hct observed in our treated group of rats may have caused greater IMP 
availability to bind to the amine sites in the retina and induced higher RUIs (retinal 
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uptake indexes). In the menopause rat model, the clinical significance of reduced 
hematocrit in the OVx+E2 group on systemic blood flow, and consequently the retinal 
blood flow, as well as on the availability of the [14C]-IMP used to measure RUI is 
unknown. A future study investigating the vasomotor effect following a short exposure 
time to estradiol, while avoiding changes in the hematocrit level, is required to narrow 
down the direct effects of estradiol on retinal circulation. In our postmenopausal women 
observational study, we have not documented the hematocrit level. Hematocrit, blood 
viscosity and plasma volume should be documented in future studies investigating 
ocular blood flow in postmenopausal women. 
Finally in our postmenopausal study, we observed lower systolic, diastolic and mean 
blood pressure in women who were +HT users compared to 0HT users. The differences 
for the diastolic and me an blood pressure reached a significance level for only the sub-
population C. Our findings are somewhat in agreement with the findings of a 
longitudinal study monitoring the blood pressure changes In normotensive 
postmenopausal women?75 Seventy-seven women used both estrogen and progestagen 
therapy and 149 women used neither. Over time, it was observed that the systolic blood 
pressure increased less in HT users than in non HT users over a period of ten years, 
while the diastolic blood pressure remained stable. Systemic blood pressure (BP) and 
ocular perfusion pressure (OPP = mean BP-IOP), (systolic BP-IOP and diastolic BP-PP) 
are important hemodynamic factors in providing normal blood perfusion to the retina. 
The resulting calculated ocular perfusion pressure was lower in the women who were 
+HT users compared to those who were 0HT users reaching a significance level for 
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only the sub-population C. A high ocular perfusion pressure has a beneficial vascular 
effect by providing a better blood flow. However, the +HT postmenopausal women 
with lower ocular perfusion pressure presented greater infero-temporal retinal artery and 
temporal peripapillary retinal blood flow. This indicates that the increased retinal blood 
flow we observed was not affected by the systemic blood pressure and that it most likely 
results from a local action of HT on retinal circulation. In our menopaused rat mode l, 
systolic, diastolic and mean blood pressures were slightly higher in the OVx+E2 rats, 
although they were not statistically significant. We did not measure the intraocular 
pressure in rats to determine the OPP. A small increase in systemic blood pressure may 
have provided a better retinal tissue perfusion in the OVX+E2 rats. Intraocular pressures 
should be measured in further studies in rats for determining the OPP. 
5.6 Possible effect of 17p-estradiol on vascular density 
In addition to the vasomotor effects of estrogens on improving the retinal circulation, 
angiogenesis may also contribute to increased capillary blood flow in the retina. 
Estradiol is being recognized as having the ability to induce angiogenesis by stimulating 
endothelial cell proliferation via the vascular endothelial growth factor (VEGF), as seen 
in microvascular development in uterus and vascular tissue.376 In a female rat model, a 
significant reduction in the capillary density (30%) in the frontal cortex accompanied by 
a decrease in VEGF level (49%) has been observed following ovariectomy.377 
Administration of 17p-estradiol in the OVx rats has reversed VEGF levels back to 
similar levels in intact female rats.377 A possible decreased capillary density in the retina 
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may have occurred in postmenopausal women who were not usmg UT and in 
ovariectomized rats and possible increased capillary retinal blood flow in both studies 
following estrogen treatment may reflect the retinal capillary density levels being 
restored. This remains to be investigated. 
5.7 Effects of UT on ONU Topography 
ln the +UT group, we observed that the rim volume, height variation contour, mean 
thickness of the RNFL and RNFL cross-sectional area were greater compared to that of 
the 0UT group. For the rim volume, this was significant for both the entire and the 
infero-temporal regions of the ONU, while for the height variation contour, mean 
thickness and cross-sectional are a of the RNFL, they reached significance level for the 
infero-temporal region. The differences observed in these stereometrie parameters 
indicate a thinner retinal nerve fiber layer, in postmenopausal women not on UT 
compared to those on UT. This finding is similar to the sparing of sorne brain regions 
observed in post-menopausal women using UT.312-314 A sparing of the retinal nerve 
fiber layer may result from the vascular properties of estrogens and progestagens, as 
described earlier, by providing a better blood flow and nutrients to the RGC and the 
NFL. ln addition, sparing of the retinal nerve fiber layer may result from the protective 
properties of estrogens on neurons independent of blood flOW. 226 These protective 
effects have been documented as increasing neuron survival in several toxicity models 
of cultured neurons, su ch as glutamate, ~-amyolid, hydrogen peroxide, and excitatory 
amino acid toxicity models.226 lnterestingly, recent studies have reported a protective 
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effect of estrogens on retinal ganglion ceUs in glutamate toxicity378 and axotomized 
optic nerve rodent models.273 
Similar to its vasomotor effects, progestagens also present divergent effects in tenns of 
protective effects on neurons. When given alone, P has been shown to increase neuron 
survival in glutamate toxicity models of neurons from the hippocampus,270 and cerebral 
cortex,271 and in a spinal cord genetic modef72 in rodents. However, an increase of 
neuron survival in the presence of progesterone has not been observed in the axotomized 
optic nerve model in rodents.273 ln combined therapy, P has been shown to increase 
neuron survival beyond that of E2 alone in the hippocampal glutamate toxicity model.270 
With regards to MPA, it has shown to have no protective effect on neurons when given 
alone or in combined therapy,270 or to potentiate neuronal loss379 in a hippocampal 
glutamate toxicity mode!. Therefore, possible beneficial or antagonizing protective 
effects of progestagens in combined therapy cannot be ruled out in our findings. In our 
study population, we observed that when only estrogen therapy was used, the rim 
volume, height variation contour, mean thickness and cross-sectional area of the RNFL 
measurements were greater than in those with the estrogen combined progestagen 
therapy. These differences reached significance level only for the rim volume but not 
for the height variation contour, mean thickness and cross-sectional are a of the RNFL. 
This likely resulted from under power analysis for those specifie variables. 
For the height variation contour, mean thickness and cross-sectional area of the RNFL, 
the 0HT group of post-menopausal women presented a decrease of 4.6%, 6.7% and 
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7.6% respectively compared to +HT group for the entire optic nerve region, while for 
the infero-temporal quadrant, this decrease was 18.1 %, 13.9% and 16.8% respectively. 
Preferential thinning of infero-temporal neural structures is also seen in early glaucoma, 
and several causes for this have been proposed.380,381 It is interesting to speculate that 
the vulnerability of this region may explain some of our findings. 
Since our findings on the optic nerve head topography related to RNFL differences 
between the two groups of postmenopausal women, we could have chosen a test to 
specifically assess the RNFL, such as the optical coherence tomography. However, we 
were interested in investigating the ONH topography, which was obtained with the HRT 
1. As well, time-domain OCT only became available in our centre after this project was 
well underway. 
5.8 Effect of HT on the functionality ofRGC 
The exact origins of the PERG components have not been identified, but current data 
suggest that the N95 is a contrast related component of the RGC function and that P50 is 
partI y RGC derived with some contribution from structures distal to RGc.382 Smaller 
PERG amplitudes and delayed latencies are indicative of RGC loss. Clinical studies 
where loss of RGCs occur such as in OHT and OAG, have demonstrated that N95 
ainplitude is reduced and P50 latency is increased,339 and that N95 amplitude 
significantly and positively correlates with RNFL thickness while P50 latency 
negatively correlates.340,341 
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We observed a borderline significantly shorter P50 latency in the +HT group by only 1.1 
ms. Although a shorter P50 latency may indicate an improvement in the function of 
ganglion celts, it is unlikely that such a smalt improvement would be c1inically 
significant. Interestingly, our findings are somewhat consistent with the pattern visual 
evoked potential (PVEP) findings observed in postmenopausal women, where the use of 
Tibolone over a period of 3 months, a synthetic steroid with prominent estrogen effects, 
was shown to significantly improve the PIOO latencies by 4 ms (5%), as weIl as a 
significant increase by 31 % in the Pl 00 amplitude.383 Yilmaz et al. (2000)383 
hypothesized that increasing sensitivity of the central nervous system to catecholamines 
by changing the opening frequency of voltage-related L-type calcium channels,384 
increasing effects of glutamate385 and decreasing formation of y-aminobutyric acid 
(GABA)386 induced by estrogens might be the responsible mechanisms in shortening 
PIOO latency and increasing Pl 00 amplitude. So far, it is unknown how estrogens might 
improve the P50 latency of the PERG. The same mechanisms may apply in shortening 
P50 latency in postmenopausal women who were HT users. This remains to be 
investigated. We also observed a small increase in the N95 amplitude by 3% and a 
small decrease in P50 amplitude by 6% in the +HT group. However, the magnitude of 
amplitude changes were not in the 31 % magnitude change of the PIOO amplitude as 
reported by Yilmaz al. (2000), and they did not reach statistical significance. Since N95 
amplitude correlates with the amount of RNFL, the difference in the RNFL thickness we 
observed between the two groups of postmenopausal women may not be large enough to 
induce a significant change in the PERG amplitudes. 
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5.9 Possible effect HT on the functionality of other retinal neurons 
While the VEP assesses the functionality of the ON and the visual pathways, and the 
PERG asses ses the RGCs, the electroretinogram (ERG) assesses the functionality of the 
entire retina evoked by a standardized flash of light. The b-wave is the main component 
of the ERG and represents the Müller cell response to an increase in extracellular 
potassium generated by the retinal neuron activity. The OPs are a series of successive 
wavelets of the ERG with a frequency range of 200 Hz. The exact cellular origin of the 
OPs is still unidentified but they are believed to originate within the inner nuclear and 
outer plexiform layers.387 
Since estrogen receptors are present throughout the different retinal layers in human 
retina,186,187 estrogens are likely modulating the activity of all retinal neurons and 
consequently the entire retinal functionality. A study published by Verit et al. (2007)388 
indicated that the use of Tibolone over a 6-month period in postmenopausal women did 
not significantly affect the Pl 00 amplitude and latencies, but the oscillatory potentials 
(OPs) of the ERG were overall significantly smaller in the Tibolone user group. In 
cyclical women, hormonal the variation of estrogens and progesterone have shown to 
modulate OPs and b-wave amplitudes.389 
GABA and glutamate are two important neurotransmitter in the retina and particpiate in 
the generation of the OPs and b-wave amplitude. Increasing effects of glutamate385 and 
a decreasing formation of y-aminobutyric acid (GABA)386 in the presence of estrogens 
may have a mixed effect on the b-wave and OP amplitudes. Therefore, the use of HT in 
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postmenopausal women may have affected the functionality of the retina. This remains 
to be investigated. 
5.10 Possible effect HT on visu al function 
Although we have shown improved retinal blood flow and greater RNFL thickness in 
our postmenopausal women on HT, it is unknown how these beneficial effects translate 
to potentially improved performance on the visual function in these women. Very few 
studies have reported the use of postmenopausal HT on the visual function. 
Postmenopausal women using equine conjugated estrogens and dydrogesterone for 1 
year or Tibolone for 6 months have demonstrated better performance on the contrast 
sensitivity tese90 and blue-on-yellow Humphrey visual field tests.391 This improved 
performance in postmenopausal women on HT can result from several combined factors 
such as better blood flow to the visual pathways and protective effect on neurons, as 
weIl as an increase in the tear film production392 and break-up time393 and better 
neuronal response along the visual pathways as documented by enhanced pattern VEP 
signa1.383 Longitudinal effects of HT on visual function assessed by contrast sensitivity 
and visual field testing in postmenopausal women is warranted. 
5.11 Possible neurotrophic effect of HT 
Experimental studies have demonstrated that estrogens have a neurotrophic property by 
increasing dendritic spines density,230-232 which are the post-synaptic sites of excitatory 
input to a wide variety of neurons in the mammalian brain and stimulating cell 
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proliferation.233.234 These neurotrophic effects are thought to be mediated by the brain-
derived neurotrophic factor (BDNF).235,236 Such neurotrophic activity could also occur 
in our observational study and menopausal rat model. 
5.12 Study Limitations 
As part of our exclusion criteria, postmenopausal women had to be free of systemic and 
cardiovascular diseases. Clinical studies have reported that the use of HT in patients 
who suffer from diabetes or coronary artery disease did not improve the FMD compared 
to baseline values.394.395 In hypertensive patients, the pulsatility indexes of the uterine, 
carotid and ophthalmic arteries were shown to be higher compared to those of 
normotensive patients after starting HT?96 As previously mentioned, potentially 
impaired endothelium in patients with systemic and cardiovascular diseases may not be 
fully or partly responsive to the HT treatment. Moreover, these patients may likely be 
on vasodilator treatment and their endothelium may not be responsive to additional 
vasomotor stimulation from HT treatment. If we had included postmenopausal women 
with systemic and cardiovascular diseases, it is possible that the differences we observed 
in blood flow and RNFL thickness might have been different. 
In this heterogeneous population of postmenopausal women we investigated, the type of 
HT regimens in terms of their active ingredients, routes of administration, dosage and 
duration of administration was heterogeneous and may have yielded different degrees of 
vasomotor effects on the retina and protective effects on the retinal nerve fiber layer. In 
addition, women were at variable postmenopausal times. As weU, postmenopausal 
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women may not exhibit similar cardiovascular characteristics and risks, which could 
interplay with the efficacy of HT. Finally, the outcome variables measured were 
collected at a single time point, which does not pro vide any information on the progress 
on the outcome variables in both groups of postmenopausal women. Since HT off ers 
cardioprotective effects, potmenopausal women who are not HT users are at greater risk 
of developing cardiovascular diseases over time. Consequently, a longitudinal study 
wou Id bring additional information of the retinal blood flow and ONH changes and 
functionality over time in postmenopausal women. The ideal study design would be to 
randomize women to HT at the time of the ons et of menopause with documented 
cardiovascular characteristics and risks, and establish a baseline for blood flow, structure 
and function before beginning therapy. Then monitor bloodflow, structure and function 
changes at intervals over a five- to ten-year period. Such a protocol could be part of a 
larger HT study. 
We successfully developed a menopaused rat model in which retinal tissue perfusion 
was assessed by quantitative autoradiography technique. This menopaused rat mode! is 
a valuable tool in providing a better understanding of our findings of improved retinal 
blood flow and protective effects on the RNFL. First, the type of estrogens, dose and 
route of administration as weIl as the type of progestagen used in combined therapies 
can be investigated. The longitudinal effect of estrogen depletion and HT can be 
monitored in different groups of menopaused rats. Finally, possible vasomotor 
pathways such as nitric oxide, prostacyclin and endothelin, and effect on RGCs and 
axons can be extensively studied. 
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We conducted our studies in postmenopausal women and ovariectomized rats, in whom 
the gonadal source of endogenous estrogens production was either minimalized or 
eliminated respectively. However, a possible source of endogenous estrogens in the 
retina could not be excluded. Recently, Cascio and al. (2007)171 found P450 aromatase 
mRNA and expression in the adult male rat retina and confirmed that the biosynthesis of 
17~-estradiol occurs. Similarly, P450 aromatase mRNA and expression are found in 
several regions of the brain in different species l68 and biosynthesis of 17~-estradiol also 
occurs in the brain. 169,170 It is unknown what role local estrogen biosynthesis plays in 
the retina. In the brai n, the proposed role is believed to be involved in the trophic and 
protective effects on neurons. 168 The possible impact of retinal estrogen biosynthesis in 
the retina relating to our findings in postmenopausal women and menopaused rat model 
is unknown. However, we assumed that both postmenopausal women and 
ovariectomized rat groups were equally exposed to retinal estrogen biosynthesis. 
Intravitreal injection of estrogen receptor antagonists in a rat model may help to narrow 
down the role of retinal estrogen biosynthesis on retinal circulation and neurons. 
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6.0 CONCLUSION 
This is the first observational study that has investigated the long-term effects of 
estrogen depletion compared to the use of hormone replacement therapy on the retina 
and nerve fiber layer in a population of postmenopausal women. The findings of this 
study indicated that compared to postmenopausal women who never had used HT, 
postmenopausal women who have used HT since their menopause onset presented 1) a 
significantly better retinal blood flow as observed in the infero-temporal retinal artery 
and 2) greater rim volume, height variation contour, mean and cross-sectional area of the 
RNFL of their optic nerve head. Blood flow was also greater in the temporal 
peripapillary retina in the +HT group and the latency of the P50 component of the PERG 
were shorter by 1 ms, but these difference did not reach statistical significance in the 
adjusted regression model, possibly due to our small sample size. Our results of 
improved retinal blood flow and protective effect on the ONH topography provided 
direct evidence that estrogens al one or in combination with progestagens have a 
vasomotor effect on the retinal circulation and a protective effect on the RNFL. 
So as to investigate the vasomotor mechanisms on the retinal circulation and protective 
effect on retinal nerve fiber layer and function of the RGCs in the near future, a 
successful menopaused rat model was developed. ln this model we demonstrated that 
chronic subcutaneous treatment of 17~-estradiol significantly improved retinal blood 
flow as observed by an increase of the retinal uptake index, following the injection of a 
blood flow tracer, the N-Isopropyl-[methyl-l,3- 14C]-p-iodoamphetamine, in whole-
mount rat retina. 
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As mentioned in the introductory section, recent epidemiological population-based 
studies have reported that early men arche, late menopause onset and increased 
reproductive year duration, significantly decreased the odds ratio of developing open-
angle glaucoma and ARMD and that the use of HT protects against glaucoma and 
ARMD. These observations strongly suggest that an hormonal component is involved in 
the aetiology of glaucoma and ARMD possibly linked to the depletion of estrogen level 
in postmenopausal women. 
Glaucoma and ARMD are multifactorial eye diseases and clinical evidence indicates that 
impaired ocular blood flow is thought to be involved in the aetiology and progression of 
these two eye diseases. Improved retinal blood flow and protective effects on the RNFL 
may explain the link between the hormonal status of estrogen and progestagen levels 
throughout a woman's life and the risk of developing glaucoma317,318 and age-related 
macular degeneration.319-321 by providing a protective effect via improved ocular blood 
flow and neuronal protection. Rats are often used as glaucoma and ARMD mode!. 
Therefore, the application of a menopaused rat model in which glaucoma or ARMD is 
induced, could bring answers on the possible protective mechanisms of estrogens and 
HT against glaucoma and ARNID in the postmenopausal women. 
These findings of our observational study are a stepping stone for designing studies to 
further understand the role of estrogens and the consequences of estrogen withdrawal on 
the retina and optic nerve in postmenopausal women. A clinical trial investigating 
retinal and optic nerve head blood flow, tomography and functionality (visual field and 
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visual evoked potentials) in postmenopausal women over a period of time is warranted, 
where HT will be prescribed to postmenopausal women following the recommendations 
of the Society of Obstetricians and Gynaecologists of Canada and International 
Menopause Society. 
In the interim, while the science progresses on this, particular attention should be given 
to postmenopausal women's eyesight. As mentioned earlier, our findings in menopausal 
women may explain the link between the hormonal status of estrogen and progestagen 
levels throughout a woman's life and the risk of developing glaucoma317.318 and age-
related macular degeneration.319-321 Women with early menopause onset or premature 
ovarian failure caused by chemo/radiotherapy, genetic disorders, auto immune disease 
and hypopituitarism397 should be closely monitored by their eye specialists. 
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7.0 FUTURE DIRECTIONS 
The findings of our observational study in postmenopausal women and ovariectomized 
rats only reveal a small piece of the puzzle on the role of estrogens in the eye. The 
possibilities for further research are countless. Here are a few suggestions of what can 
be undertaken. 
lntravitreal injection of agonists and antagonists of estrogens in an ovariectomized 
animal model, which will avoid possible systemic effects from oral or transdermal 
treatment, will provide answers to the local role of estrogens and progesterone on retinal 
and optic nerve head blood flow, tomography and functionality. 
The laminar beams composing the lamina cribrosa, are made up of long fibers of elastin 
and collagen.398 It is believed that elastin is involved in the optic nerve head compliance 
to changes in the intraocular pressure. The depletion of estrogens during menopause 
could likely impair the collagen and elastin in the lamina cribrosa as seen on the skin 
d . 399 urmg menopause. Consequently, the optic nerve head might be less compliant to 
intraocular pressure changes. This remains to be investigated. 
The trabecular meshwork in the eye is responsible for normal flow of aqueous of the eye 
and prevents increases in the intraocular pressure. Elastin and collagen are also present 
in the trabecular meshwork.4oo Again, the depletion of estrogens during menopause 
could likely impair the collagen and elastin in the trabecular meshwork and compromise 
the aqueous flow. This remains to be investigated. 
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Selective estrogen receptor rnodulators (SERMs) for treating rnenopausal syrnptorns are 
being developed. SERMs avoid sorne side effects frorn conventional HT use, such as 
breast cancer. SERMs are synthetic cornpounds that behave like estrogens in sorne 
tissues but block the action of estrogen in others. For exarnple, the SERM raloxifene has 
been developed to prevent osteoporosis in postrnenopausal wornen. In the Multiple 
Outcornes of Raloxifene Evaluation (MORE) randomized trial, ra]oxifene was reported 
to not significantly affect the risk of cardiovascular events after four years of treatment 
in postrnenopausal wornen.401 It also contributed to a 40% reduction ofnewly diagnosed 
invasive breast cancer.402 However, adverse events such as hot flashes and leg crarnps 
and rare venous thromboernbolic events have been reported.403 The development of 
SERMs is still ongoing to find better rnolecules with the least side and adverse effects. 
Since the eye is a window of the body, retinai and optic nerve head blood flow, 
tomography and functionality assessment in postrnenopausal women and ovariectomized 
animal models can monitor the activity of SERMs and help in designing better 
rnolecules. 
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ABSTRACT 
Objective: To provide guidelines for health care providers on the 
management of menopause in asymptomatic healthy women as 
weil as in women presenting with vasomotor symptoms, urogenital, 
sexual, and mood and memory concerns and on specifie medical 
considerations, and cardiovascular and cancer issues. 
Keywords: 
Menopause, estrogen, progestin, androgen, complementary therapies, vasomotor 
symptoms, urogenital symptoms, mood, memory, estrogen replacement therapy, 
hormone replacement therapy, cardiovascular diseases, cancer 
Outcomes: Prescription medications, complementary and alternative 
medicine (CAM), and lifestyle interventions are presented 
according to their efficacy in treating menopausal symptoms. 
Evidence: MEDLINE and the Cochrane database were searched for 
articles from March 2001 to April 2005 in English on subjects 
related to menopause, menopausal symptoms, urogenital and 
sexual health, mood and memory, hormone therapy, CAM, and on 
specifie medical considerations that affect the decision of which 
intervention to choose. 
Values: The quality of evidence is rated using the criteria described in 
the report of the Canadian Task Force on the Periodic Health 
Examination. Recommendations for practice are ranked according 
to the method described in this report (see Table 1). 
Sponsors: The development of this consensus guideline was 
supported by unrestricted educational grants from Berlex Canada 
Inc, Lilly Canada, Merck Frosst, Novartis, Novogen, Novo Nordisk, 
Proctor and Gambie, Schering Canada, and Wyeth Canada. 
RECOMMENDATIONS 
1. General Recommendations 
1. Health care providers should discuss and encourage initiation of 
healthy lifestyle choices in menopausal women. (1I·2A) 
2. The primary indication for hormone therapy (HT) should be for the 
management of moderate to severe menopausal symptoms. (lA) 
3. HT should not be prescribed for primary or secondary prevention 
of cardiovascular disease (CVD) or for primary prevention of . 
dementia. (lA) 
4. Local estrogen therapy (ET) is recommended if HT is prescribed 
for vulvovaginal symptoms alone. (lA) 
5. HT should be prescribed for the appropriate duration to achieve 
treatment goals while taking into consideration risks and benefits 
and the woman's quality of life. (IIIB) 
6. HT should be prescribed at the lowest effective dose, although the 
long-term risklbenefit ratio of lower dose HT has not been 
demonstrated. (IIIC) 
7. The primary indication for progestin use should be endometrial 
protection in women using systemic estrogen therapy who have 
an intact uterus. (lA) 
8. HT may be prescribed for an extended period, following proper 
counselling, if the woman decides that for her the benefits 
outweigh the risks (1I-2A). Periodic re-evaluation is strongly 
recommended (IIIC). 
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Criteria for quality of evidence assessment and classification of recommendations 
Level of evidence* 
1: Evidence obtained from at least one properly designed 
randomized controlled trial. 
11-1: Evidence from well-designed controlled trials without 
randomization. 
11-2: Evidence from well-designed cohort (prospective or 
retrospective) or case-control studies, preferably from 
more than one centre or research group. 
11-3: Evidence from comparisons between times or places with 
or without the intervention. Dramatic results from 
uncontrolled experiments (such as the results of treatment 
with penicillin in the 19405) could also be included in this 
category. 
III: Opinions of respected authorities, based on clinical 
experience, descriptive studies, or reports of expert 
committees. 
Classification of recommendations* 
A. There is good evidence to support the recommendation that 
the condition be specifically considered in a periodic health 
examination. 
B. There is fair evidence to support the recommendation that 
the condition be specifically considered in a periodic health 
examination 
C. There is poor evidence regarding the inclusion or exclusion 
of the condition in a periodic health examination. 
D. There is fair evidence to support the recommendation 
that the condition not be considered in a periodic health 
examination. 
E. There is good evidence to support the recommendation that 
the condition be excluded from consideration in a periodic 
health examination. 
·Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W. Canadian Task Force on the Periodic Health Exam. Ottawa: Canadian Communication Group; 
1994. p. xxxvii. 
·The quality of evidence reported in the se guidelines has been adapted from the Evaluation of Evidence criteria described in the Canadian Task Force 
on the Periodic Health Exam. 
tRecommendations included in these guidelines have been adapted from the Classification of Recommendations criteria described in the Canadian 
Task Force on the Periodic Health Exam. 
9. Androgen therapy may be considered for selected women with 
acquired sexual desire/interest disorders after comprehensive 
assessment, systemic estrogen therapy and appropriate 
counselling (11-1 B) Androgen therapy is still investigational and 
long-term safety data are lacking (1IIB). 
10. Health care providers may offer identified complementary and 
alternative medicine with demonstrated efficacy for mild 
menopausal symptoms. (lB) 
II. Specifie Recommendations 
Chapter 1: Introduction: 
No Recommendations 
Chapter 2: Menopause and Age-Related Concems 
1. Lifestyle modifications, including reducing core body temperature, 
regular exercise, weight management, smoking cessation, and 
controlled breathing may be recommended to reduce mild 
vasomotor symptoms. (lC) 
2. Health care providers should offer HT (ET/estrogen-progestin 
therapy) as the most effective therapy for the medical 
management of menopausal symptoms. (lA) 
3. Progestins alone or low-dose oral contraceptives can be offered 
as alternatives for the relief of menopausal symptoms especially 
during the transition phase. (lA) 
4. Non-hormonal prescription therapies, including antidepressant 
agents, gabapentine, clonidine, and bellergal, can be prescribed 
as alternatives to HT to reduce vasomotor symptoms. (lB) 
5. Complementary and alternative medicine, including black cohosh, 
red clover (derived isoflavone, and vitamin E) may be 
recommended for the reduction of mild vasomotor symptoms (lB). 
Long-term efficacy and safety data are still lacking. 
6. Any unexpected bleeding that occurs after 12 months of 
amenorrhea is considered postmenopausal bleeding and should 
be investigated. (lA) 
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7. If prescribing HT to older postmenopausal women, low or ultra-Iow 
dose ET is preferred. (lB) 
Chapter 3: Urogenital Concems 
1. Conjugated estrogen (CE) cream, an intravaginal 
sustained-release estradiol ring, or estradiol vaginal tablets are 
recommended as effective treatment for vulvovaginal atrophy. (lA) 
2. Routine progestin co-therapy is not required for endometrial 
protection in women receiving vaginal estrogen therapy in 
appropriate dose. (IIIC) 
3. Vaginallubricants may be recommended for subjective symptom 
improvement of dyspareunia. (IIIC) 
4. Health care providers can offer polycarbophil gel (a vaginal 
moisturizer) as an effective treatment for symptoms of 
vulvovaginal atrophy including dryness and dyspareunia. (lA) 
5. Effective surgical treatment options, including Burch 
colposuspension and the TVT procedure, are recommended for 
the treatment of stress urinary incontinence. (lA) 
6. Effective non-surgical treatment options, such as weight 1055 (in 
obese women), pelvic floor physiotherapy with or without 
biofeedback, weighted vaginal cones, functional electrical 
stimulation, and/or intravaginal pessaries, can be recommended 
for the treatment of stress urinary incontinence. (11-1 B) 
7. Lifestyle modification, bladder drill (11-1 B), and antimuscarinic 
therapy (lA) are recommended for the treatment of urge urinary 
incontinence. 
8. ET should not be recommended for the treatment of 
postmenopausal urge or stress urinary incontinence. (lA) 
9. Vaginal estrogen therapy can be recommended for the prevention 
of recurrent urinary tract infections in postmenopausal women. 
(lA) 
Chapter 4: Sexual Concerns 
1. A biopsychosexual assessment of preferably both partners (when 
appropriate), identifying intrapersonal, contextual, interpersonal, 
and biological factors, is recommended prior to treatment of 
women's sexual problems. (iliA) 
2. For women with vaginal atrophy, local estrogen should be 
prescribed to improve vulvovaginal atrophy-associated 
dyspareunia. (lA) 
3. Routine evaluation of sex hormone levels in postmenopausal 
women with sexual problems is not recommended. Available 
androgen assays neither reflect total androgen activity, nor 
correlate with sexual function. (iliA) 
4. Any investigational testosterone therapy included in the 
management of selected women with acquired sexual 
desire/interest disorder, typically associated with an arousal 
disorder, should only be initiated by clinicians experienced in 
women's sexual dysfunction and with informed consent from the 
woman. The investigational nature, lack of long-term safety data, 
need for systemic estrogen therapy, and careful follow-up must be 
explained. (IC) 
Chapter 5: Mood and Memory 
1. Estrogen alone may be offered as an effective treatment for 
depressive disorders in perimenopausal women and may 
augment clinical response to antidepressant treatment, 
specifically SSRls (lB). The use of antidepressant medication, 
however, is supported with the most research evidence (lA). 
2. Estrogen can be prescribed to enhance mood in women with 
depressive symptoms. The effect appears to be greater for 
perimenopausal symptomatic women th an for postmenopausal 
women. (lA) 
3. Estrogen therapy is not currently recommended for reducing the 
risk of developing dementia in postmenopausal women or for 
retarding the progression or deterioration in women with 
diagnosed Alzheimer's disease. (lB) . 
Chapter 6: Prescription Drugs 
No Recommendations 
Chapter 7: Complementary and Alternative Medicine 
No Recommendations 
Canadian Consensus Conference on Menopause, 2006 Update 
Chapter 8: Specifie Medical Considerations 
1. HT should be offered to women with premature ovarian failure 
(POF) or early menopause (lA), and its use can be recommended 
until the age of natural menopause (IIIC). 
2. ET can be offered to women who have undergone surgical 
menopause for the treatment of endometriosis. (lA) 
3. Menopausal women undergoing pelvic surgery should be given 
appropriate thromboembolic prophylaxis. (lA) 
4. Health care providers may prescribe HT to diabetic women for the 
relief of menopausal symptoms. (lA) 
Chapter 9: Cardiovascular Disease (CVD) 
1. Health care providers should not initiate or continue HT for the 
sole purpose of preventing CVD (coronary artery disease and 
stroke). (lA) 
2. Health care providers should abstain from prescribing HT in 
women at high risk for venous thromboembolic disease. (lA) 
3. Health care providers should consider other evidence-based 
therapies and interventions to effectively reduce the risk of CVD 
events in women with or without vascular disease. (lA) 
Chapter 10: Cancer 
1. Ali unscheduled uterine bleeding should be investigated because 
no estrogen-progestin regimen is completely protective against 
endometrial carcinoma. (lA) 
2. Estrogen-progestin therapy may be offered to women with 
low-grade adenocarcinoma of the endometrium who have 
moderate to severe menopausal symptoms. (lB) 
3. Health care providers should periodically review the risks and 
benefits of prescribing HT to a menopausal woman in light of the 
association between duration of use and breast cancer risk. (lA) 
4. Health care providers may prescribe HT for menopausal 
symptoms in women at increased risk of breast cancer with 
appropriate counselling and surveillance (lA) (in women in the 
Women's Health Initiative [WHI) study with high Gael scores were 
at no greater risk of breast cancer than women with low risk 
scores). 
5. Health care providers should clearly discuss the uncertainty of 
risks associated with HT after a diagnosis of breast cancer in 
women seeking treatment for distressing symptoms. (lB) 
J Obstet Gynaecol Can 2006;28(Special Edition 1):S7-S94 
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IMS Updated Recommendations on 
postmenopausal hormone therapy 
Issued on behalf of the Board of the International Menopause Society by Amos Pin es 
(President), David W. Sturdee (General Secretary), Martin H. Birkhauser (Treasurer), 
Hermann P. G. Schneider, Marco Gambacciani and Nick Panay 
INTRODUCTION 
The past decade has seen marked fluctuations in 
opinions concerning the merits and risks of 
postmenopausal hormone therapy. In July 2002, 
menopause management faced a major turning 
point when the first data from the Women's 
Health Initiative (WHI) trial were released. The 
study was categorized as a primary prevention 
trial for coronary heart disease, although the fact 
that me an age at recruitment was 63 years was not 
given enough importance at that time. WHI 
investigators conduded that hormone therapy 
(HT) was not cardioprotective, and, in fact, its 
risk-benefit ratio did not favor the use of 
postmenopausal hormones for prevention of 
chronic diseases. As a result, there was a dramatic 
change in prescription habits following recom-
mendations to reserve HT for very symptomatic 
women, and ta limit its use to the 'shortest 
duration needed' and 'to the lowest effective 
dosage'. This was the atmosphere in which the 
International Menopause Society (IMS) initiated 
the IMS Workshop held in Vienna (December 
2003) and the IMS Position Paper that was based 
on the Workshop discussions. Looking at global 
perspectives, and being independent of local or 
regional constraints imposed by official health 
authorities, this IMS Statement called for a more 
balanced approach in the Interpretation of the 
scientific data on hormone use that were available 
in 2003. Since then, additional information has 
been accumulated from both arms of the WHI 
study, observational trials and from other studies, 
allowing a more comprehensive review on ail 
issues related to the use of hormones in the 
postmenopausal period. In view of the above, the 
IMS Board decided that it is time to update the 
2004 Statement and to enlarge its sc ope to 
menopause management and adult women's 
health in general. More than 30 experts from the 
various fields of menopause medicine reviewed the 
latest information in a Workshop held in Budapest 
in February 2007. 
The following Recommendations express the 
views of the IMS on the principles of hormone 
therapy in the peri- and postmenopausal periods. 
Throughout the Recommendations, the term HT 
will be used to coyer ail therapies induding 
estrogens, progestogens, combined therapies and 
tibolone. 
The previous IMS Statement in 2004 is still 
valid and serves as a basis for the current Updated 
Recommendations. 
We are aware of the geographical variations 
related to different priorities of medical care, 
different prevalence of diseases, and country-
specific attitudes of the public, the medical 
community and the health authorities toward 
menopause management, which may ail impact 
on hormone therapy. The following recommenda-
tions, therefore, give a global and simple overview 
that serves as a common platform on issues related 
ta the various aspects of hormone treatment.· 
These Recommendations were reviewed and dis-
cussed by representatives of more than 60 
National and Regional Menopause Societies from 
ail continents. These Recommendations can be 
easily adapted and modified according to local 
needs. 
nrcp<"n,vlc.nr,p· Prof essor A. Pines, l"r..~rtrn,,,nt of Internai Medicine 1: Ichilov Hospital. 6 Weizman Street. Tel Aviv 
64239, Israel 
© 2007 International Menopause Society 
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GOVERNING PRINCIPLES 
Hormone therapy should be part of an ove rail 
strategy including lifestyle recommendations 
regarding diet, exercise, smoking and alcohol 
for maintaining the health of postmenopausal 
women. HT must be individualized and tailored 
according to symptoms and the need for preven-
tion, as weil as personal and family history, results 
of relevant investigations, the woman's prefer-
ences and expectations. The risks and benefits of 
HT differ for women around the time of meno-
pause compared to those for older women. 
HT includes a wide range of hormonal products 
and routes of administration, with potentially dif-
ferent risks and benefits. Thus, the term 'class 
effect' is confusing and inappropriate. 
Women experiencing a spontaneous or iatro-
genic menopause before the age of 45 years and 
particularly before 40 are at higher risk for car-
diovascular disease and osteoporosis. They will 
benefit from hormone replacement, which should 
be given at least until the normal age of menopause. 
Counselling should con vey the benefits and 
risks of HT in simple terms, e.g. absolute numbers 
rather than as percentage changes from baseline 
expressed as a relative risk. This allows a woman 
and her physician to make a well-informed deci-
sion about HT. 
HT should not be recommended without a clear 
indication for its use. 
Women taking HT should have at least an 
annual consultation to include a physical exam-
ination, update of medical history, relevant la bora-
tory and imaging investigations and a discussion 
on lifestyle. 
There are no reasons to place mandatory limi-
tations on the length of treatment. 
Whether or not to continue therapy should be 
decided at the discretion of the well-informed 
hormone user and her health professional, depen-
dent upon the specific goals and an objective esti-
mation of benefits and risks. 
Dosage should be titrated to the lowest effective 
dose. Lower doses of HT than have been used 
routinely can maintain quality of life in a large 
proportion of users. Long-term data on lower 
doses regarding fracture risk and cardiovascular 
implications are still lacking. 
In general, progestogen should be added to 
systemic estrogen for ail women with a uterus to 
prevent endometrial hyperplasia and cancer. 
However, natural progesterone and sorne proges-
togens have specific beneficial effects that could 
justify their use besides the expected actions on 
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the endometrium. Low-dose vaginal estrogens 
administered for the relief of urogenital atrophy 
do not require progestogen co-medication. Direct 
delivery of progestogen ta the endometrial cavity 
from the vagina or by an intrauterine system is 
logical and may minimize systemic effects. 
Androgen replacement should be reserved for 
women with clinical signs and symptoms of 
androgen insufficiency. In women with bilateral 
oophorectomy or adrenal failure, androgen repla-
cement has significant beneficial effects, in parti-
cular on health-related qua lit y of life and sexual 
function. 
BENEFITS OF HORMONE THERAPY 
General 
HT remains the most effective therapy for vaso-
motar and estrogen-deficient urogenital symptams . 
Other menopause-related complaints, such as joint 
and muscle pains, mood swings, sleep disturbances 
and sexual dysfunction (including reduced libido) 
may improve during HT. Quality of life and 
sexuality are key factors ta be considered in the 
management of the aging individual. The adminis-
tration of individualized HT (including androgenic 
preparations when appropriate) improves both 
sexuality and overall quality of life. 
Postmenopausal osteoporosis 
HT is effective in preventing the bone loss asso-
ciated with the menopause and decreases the 
incidence of ail osteoporosis-related fractures, 
including vertebral and hip, even in patients at 
low risk. Although the magnitude of decline in 
bone turnover correlates with estrogen dosage, 
even lower than standard-dose preparations main-
tain a positive influence on bone indices in most 
women. Based on updated evidence on effective-
ness, cost and safety, HT is an appropria te first-
line therapy in postmenopausal women presenting 
with an increased risk for fracture, particularly 
under the age of 60 years and for the prevention of 
bone loss in women with premature menopause. 
The protective effect of HT on bone minerai den-
sity declines after cessation of therapy at an 
unpredictable rate, although sorne degree of frac-
ture protection may remain after cessation of HT. 
The initiation of standard-dose HT is not recom-
mended for the sole purpose of the prevention of 
fractures after the age of 60 years. Continuation 
of HT after the age of 60 years for the sole purpose 
of the prevention of fractures should take into 
Climacteric 
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account the possible long-term effects of the specifie 
dose and method of administration of HT, com-
pared to other proven therapies. 
Cardiovascular disease 
Cardiovascular disease is the principal cause of 
morbidity and mortaJity in postmenopausal wo-
men. Major primary prevention measures (besides 
smoking cessation and diet control) are weight 
10ss, blood pressure reduction, and diabetes and 
lipid control. There is evidence that HT may be 
cardioprotective if started around the rime of 
menopause and conrinued long-rerm (often re-
ferred to as the 'window of opportunity' concept). 
HT markedJy reduces the risk of diabetes and, 
through improved insulin resistance, it has posi-
tive effects on other risk factors for cardiovascular 
disease such as the Iipid profile and metabolic 
syndrome. 
In women less than 60 years old, recently 
menopausal and without prevalent cardiovascular 
disease, the initiation of HT does not cause early 
harm and in fact reduces cardiovascular morbidity 
and mortality. Continuation of HT beyond the 
age of 60 should be decided as a part of the ove rail 
risk-benefit analysis. 
Other benefits 
HT has benefits for connective tissue, skin, joints 
and intervertebral disks. HT may reduce the risk 
of colon cancer. HT initiated around the time 
of menopause or by younger postmenopausal 
women is associated with a reduced risk of 
Alzheimer's disease. 
POTENTIAL SERIOUS ADVERSE 
EFFECTS OF HORMONE THERAPY 
Studies on the risks of postmenopausal hormone 
use have mainly focused on breast and endo-
metrial cancer, venous thromboembolism (pul-
monary embolism or deep vein thrombosis), 
stroke and coronary events. 
Breast cancer 
The incidence of breast cancer varies in different 
countries. Therefore, currently available data 
cannot necessarily be generalized. The degree of 
association between breast cancer and postmeno-
pausaI HT remains controversial. 
Women should be reassured that the possible 
risk of breast cancer associated with HT is small 
CIi m acte rie 
(less than 0.1 % per annum). For combined HT, 
observational data from the Million Women 
Study suggested that breast cancer risk was 
increased as early as the first year, raising serious 
reservations on possible methodologic flaws. On 
the contrary, randomized controlled data From the 
Women's Health Initiative (WHI) study indicate 
that no increased risk is observed in women 
initiating HT, for up ta 7 years. It should be noted 
that the majority of subjects in the WHI study 
were overweight or obese. 
Data from the WHI and Nurses' Health Study 
suggest that long-term estrogen-only administra-
tion for 7 and 15 years, respectively, does not 
increase the risk of breast cancer in American 
women. Recent European observational studies 
suggest that risk may increase after 5 years. 
There are insufficient data to evaluate the 
possible differences in the incidence of breast 
cancer using different types and routes of estro-
gen, natural progesterone and progestogens, and 
androgen administration. 
Baseline mammographie density correlates with 
breast cancer risk. This does not necessarily apply 
to the increase in mammographie density induced 
byHT. 
The combined estrogen-progestogen therapy-
related increase in mammographie density may im-
pede the diagnostie interpretation of mammograms. 
Endometrial cancer 
Unopposed estrogen administration induces a 
dose-related stimulation of the endometrium. 
Women with a uterus should have progestogen 
supplementation. 
Continuous combined estrogen-progestogen 
regimens are associated with a lower incidence 
of endometrial hyperplasia and cancer than occurs 
in the normal population. 
Direct intrauterine delivery systems may have 
advantages. Regimens containing low-/ultra-Iow-
dose estrogen and progestogen cause less endo-
metrial stimulation and less bleeding. 
Thromboembolism and cardiovascular 
events 
The HT-related risk for serious verrous throm-
boembolic events increases with age (although 
minimal urrtil age 60), and is also positively asso-
ciated with obesity and thrombophilia. By avoid-
ing first-pass hepatic metabolism, transdermal 
estrogen may avert the risk associated with oral 
HT. The impact on the risk of a thromboembolic 
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event may also be affected by progestogen, 
depending on the type. Late starters of standard-
dose HT may have a transient slightly increased 
risk for coronary events. The risk of stroke is cor-
related with age. HT may increase the risk of 
stroke after the age of 60. 
Safety data from studies of law-dose and ultra-
law-dose regimens of estrogen and progestogen 
are encouraging. 
ALTERNATIVE TREATMENTS 
The efficacy and safety of complementary alter-
native medicines have not been demonstrated and 
further studies are required. 
Selective serotonin reuptake inhibitors, selective 
noradrenaline reuptake inhibitors and gabapentin 
are effective in reducing vasomotor symptoms in 
short-term studies. Their long-term safety needs 
further evaluation. 
There are no medical or scientific reasons to 
recommend unregistered 'bioidentical hormones'. 
The measurement of hormone levels in the saliva 
is not clinically usefuL These 'customized' hormo-
nal preparations have not been tested in studies 
and their purity and risks are unknown. 
RESEARCH 
There is urgent need for further research especially 
into the relative merits of lower doses, regimens 
and routes of administration. 
CONCLUSION 
The safety of HT largely depends on age. Women 
younger than 60 years old should not be concerned 
about the safety profile of HT. New data and re-
analyses of older studies by women's age show that, 
for most women, the potential benefits of hormone 
therapy given for a clear indication are many and 
the risks are few when initiated within a few years 
of menopause. In view of the new data, Regulatory 
Authorities should review their current recommen-
dations as a priority. 
The original IMS Position Statement was pub-
lished in Climacteric 2004; 7:8-1.1. 
APPENDIX: Key messages from the lectures, abstracted by the speakers, on adult 
women's health presented at the IMS Budapest Workshop, February 2007 
HEAL THY LIFESTYLE 
Exercise in the menopause - an update 
• Any physical activity is better than being 
sedentary. 
• Regular exercise reduces total and cardiovas-
cular mortality. 
• Better metabolic profile, balance, muscle 
strength, cognition and quality of life are 
observed in physically active persons. Heart 
events, stroke, fractures and breast cancer are 
significantly less frequent. 
• Benefits far overweigh possible adverse con-
sequences: the more, the better, but too much 
may cause harm. Iniury to the musculo-
articulo-skeletal system should be avoided. 
• Optimal exerdse prescription is at least 
30 minutes of moderate-intensity exercise, at 
least three times weekly. Two additional 
weekly sessions of resistance exercise may 
provide further benefit. 
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Healthy lifestyle 
• Obesity (body mass index> 30 kg/m2) affects 
over 20% of the population and is becoming 
an increasing problem in the lower sodo-
economic sectors and also among children. 
• Weight loss of only 5-10% is sufficient to 
improve many of the abnormalities associated 
with the insulin resistance syndrome. 
• The basic components of a healthy diet are: 
four to five servings/day of fruits and vegeta-
bles, whole grain fibers, fish twice a week, and 
low total fat (but the use of olive ail is 
reèommended). Consumption of salt should 
be limited and the daily amount of aIcohol 
should not exceed 30 g for men and 20 g for 
women. Smoking should be prohibited. 
• Lifestyle modifications include socializing, and 
being physically and mentally active. 
• The public health approach to lifestyle pro-
motion requires a multidisciplinary approach, 
Climacteric 
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starting from schools through to work places, 
involving the food and advertising industry, as 
weil as medical insurers and health authorities. 
A new paradigm in the doctor-patient relations 
is required, where the doctor becomes more of 
an advisor and the patient has to take the 
responsibility for his own health. 
UROGYNECOLOGY 
• Symptoms such as vaginal dryness, soreness, 
dyspareunia, urinary frequency and urgency 
are extremely common in postmenopausal 
women. Incontinence in women seems to 
increase with age, from 3-5% at age 20, 
8-9% at age 30 and 12-15% at age 50. 
• However, there is a huge inter-individual as 
weil as intra-individual sensitivity to these 
changes, and symptoms and signs of urogenital 
aging are therefore highly variable within an 
individual as weil as between individuals. 
• The loss of lubrication and glandular func-
tions severely impairs sexual desire. Treatment 
of this condition improves quality of life, not 
only for the woman but also for her partner. 
• Urogenital symptoms respond weB to estro-
gens. Long-term treatment is often required as 
symptoms can recur on cessation of therapy. 
Systemic risks have not been identified with 
local low-potency/low-dose estrogens. 
• Use of systemic hormone therapy does not 
seem to prevent urinary incontinence. 
• Antimuscarinic drugs combined with local 
estrogens constitute first-line treatment in 
women with urge incontinence and/or over-
active bladder. 
• Surgery remains the prime option for peri-
menopausal women with pure stress incon-
tinence in whom hormone therapy may even 
worsen the situation. 
OSTEOPOROSIS 
Hormonal therapy (HT) 
• HT is effective in preventing the bone loss 
associated with the menopause. 
• HT decreases the incidence of ail osteoporosis-
rela ted fractures, including vertebral and hip frac-
tures, even in patients at low risk for fractures. 
• HT is indicated for the prevention of bone loss 
in women with premature menopause and 
secondary amenorrhea. 
• HT is indicated in postmenopausal women in 
the age group 50-60 years presenting with a 
risk for fracture. 
C1imacteric 
• Potential adverse effects of HT can be limited 
by using lower than standard doses or by 
avoiding oral administration, without com-
promising the beneficial effect of HT on bone. 
• The protective effect of HT on bone minerai 
density is lost after cessation of therapy at an 
unpredictable rate. Although sorne degree of 
fracture protection may remain after cessation 
of HT, the patient at risk for fracture should 
receive additional therapy with proven bone-
sparing medication. 
• The continuation of HT after the age of 60 for 
the sole purpose of the prevention of fractures 
should take into account the possible side-
effects in the individual of the specifie dose and 
method of administration of HT, compared to 
other proven therapies. 
• The initiation of HT for the sole purpose of the 
prevention of fractures is not recommended 
after the age of 60 years . 
Non-hormonal therapy 
• Calcium and vitamin D: Sorne studies suggest 
that the combination of calcium and vitamin 0 
is able to reduce the risk of falling, and 
decreases the hip fracture risk, provided the 
dose of vitamin 0 is more than 700 lU per 
day. Other data suggest that the efficacy of the 
combined calcium and vitamin 0 regimen 
primarily relies on the component calcium. 
• Bisphosphonates: With bisphosphonates, bone 
turnover normalizes within weeks and no further 
suppression is seen during long-term use with 
up to 10 years of continuo us administration. 
Both vertebral and non-vertebral antifracture 
efficacies are detectable after 6 months of treat-
ment. The antifracture efficacy seems to last 
more than 5 years after cessation of treatment. 
• SERMs: The selective estrogen receptor mod-
ulator (SERM) raloxifene reduces the risk of 
vertebral fracture in postmenopausal women 
with or without prevalent vertebral fracture. 
New SERMs and a SERMlHT combination 
are in final stages of development. 
• Parathyroid hormone (PTH) produces a sig-
nificant reduction in the risk of vertebral and 
non-vertebral fracture. There is no indication 
that combining PTH with a bone resorption 
inhibitor has any additional benefit to giving 
either drug alone. 
• Strontium ranelate is a new agent for the 
treatment of osteoporosis, combining mild 
decreased bone resorption and maintained 
bone formation. It significantly decreases the 
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risk of new vertebral fracture and also reduces 
the relative risk of non-vertebral fractures. 
• New therapeutic possibilities such as the 
humanized monoclonal antibody to the recep-
tor activator of nuclear factor-kappa B (RANK) 
ligand (RANKL) denosumab are under investi-
gation. First results are promising. 
Guidelines on osteoporosis 
• Optimal skeletal health is dependent on 
an appropriate Iifelong balance of calcium! 
vitamin D nutrition and exercise. 
• Bone minerai density (BMD) assessment by D XA 
is the basis for the diagnosis of osteoporosis. 
• The various bone assessment techniques, 
including DXA, ultrasound and computed 
tomography, offer complementary 100ls for 
the assessment of fracture risk, but the most 
important single measure is total hip DXA. 
• Site-specific assessments provide the best guide 
to future fracture risk at that site. 
• A large proportion of fractures occur in 
individuals who do not have BMD-defined 
osteoporosis. 
• BMD is not a cost-effective population screen-
ing tool but is best applied on a selective basis, 
based on age and other risk factors, sorne of 
which have an influence on fracture risk that is 
independent of BMD. 
• The goal of management in osteoporosis is the 
prevention of fracture. 
• Ten-year fracture probability is the most 
useful estimate for therapeutic intervention. 
• Individual fracture probability should be based 
on the combination of bone minerai density, 
age and other clinical risk factors. 
• Hip fracture is responsible for a large propor-
tion of the financial burden of osteoporosis to 
health-care systems but other osteoporosis-
related fractures, particularly vertebral frac-
tures, cause considerable morbidity which can 
be long-standing. 
• Choice of therapy should be based on a 
balance of effectiveness, risk and cost. 
SKIN, CARTILAGE AND OTHER 
CONNECTIVE TISSUES 
Skin, the earotid artery and intervertebral 
dises 
• Menopause inflicts a negative effect on the 
connective tissue in the dermis of the skin. 
Such an effect is prevented and in sorne cases 
reversed with estrogen therapy. 
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• Similar changes in connective tissue are 
observed at the arterial media layer. 
• Apart from its positive effect on the bone, it 
was recently found that estrogen induces 
favorable changes at the intervertebral 
discs. The menopause, on the other hand, has 
a negative effect on discs, just Iike in bone. 
• Estrogen deprivation, on the one hand, and 
estrogen therapy, on the other, probably leads 
to changes in the connective tissue matrix at 
many other sites and organs in addition to the 
aforementioned tissues. 
Articulated joints and the menopause 
• The marked predominance of polyarti-
cular osteoarthritis in women and, in particu-
lar, the marked increase of osteoarthritis in 
women after the menopause both point to a 
likely involvement of female sex steroids in the 
maintenance of cartilage homeostasis. 
• In postmenopausal women treated with 
levormeloxifene, the urinary excretion of 
C-telopeptide of type II (CTX-II), a biomarker 
for cartilage turnover, is decreased by approx-
imate1y 50%. CTX-II levels are restored to the 
premenopausal range. Bone resorption is 
similarly restored to premenopausal levels. 
• Timely initiated estrogenJSERM treatment 
can effectively prevent both bone and cartilage 
loss accompanying the menopause, involving 
both direct and indirect mechanisms. 
CARDIOVASCULAR PROBLEMS 
Gender-specifie eharaeteristies of 
atherosclerosis in menopausal women 
• The clinical course of cardiovascular disease 
has gender-specific characteristics. 
• Menopause may be considered a risk factor for 
coronary artery disease in women due to the 
potential effects of ovarian senescence on cardiac 
function, blood pressure and various metabolic 
parameters (glucose tolerance, lipid profile). 
• Arterial hypertension and diabetes are more 
important cardiovascular risk factors in wo-
men than in men. 
• Preventative strategies should be focused in 
women on reducing blood pressure and con-
trolling weight and glucose metaboIism. 
• Women often have angina with normal cor-
onary arteries but, when they develop an 
infarct, their prognosis is significantly worse 
than that of men. 
Climacteric 
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Postmenopausal hormones and coronary 
artery disease 
• The majority of preclinical data and observa-
tional studies support the potential HT benefits 
in reducing risk of coronary artery disease 
(CAO). 
• Randomized controlled trials (RCTs) reported 
mixed results. RCTs exploring possible asso-
ciation between cardioprotection and hormone 
use mainly included women with known CAO 
or potentially having subclinical atherosclero-
sis. Those RCTs had insufficient power to 
assess the effects of hormones on coronary risk 
in younger symptomatic women initiating 
therapy at the onset of menopause. 
• In both the randomized and observational 
WHI hormonal trials, although the overall 
data were not significant for benefit or harm, 
over the course of the studies there was a 
significant trend for decreasing coronary dis-
ease with time. 
• Patient selection and timing of initiation may 
explain these apparently conflicting results. 
Evidence from the major randomized and 
observational trials point to the importance of 
age at initiation of hormone use. A coronary 
benefit has been shown to be confined to 
women < 10 years from the onset of meno-
pause. 
• Initiation of hormone therapy has been related 
to more coronary events (termed 'early harm') 
during the first year of use. However, this 
increased risk appears to be applicable only to 
elderly women with prevalent coronary disease. 
• Emerging data strongly suggest a possible 
coronary benefit in younger healthy women 
who also do not experience early harm. These 
suggestions remain to be confirmed in pro-
spective trials. 
• Whether there is a difference in the coronary 
effects of added progestogen compared to 
estrogen alone has not been established, but 
effects may be more favorable with the use of 
estrogen alone. 
• Based on currently available evidence, it is clear 
that hormonal therapy has no place in the treat-
ment of older women with coronary disease, 
and this indudes recent data on raloxifene. 
Menopause and stroke: special features 
and impact of HT 
• Although both CAO and stroke are arterial 
vascular diseases, the effects of postmeno-
Climacteric 
pausai hormones on those very common 
conditions are not necessarily similar. 
• Hormone therapy has been listed as a 
risk factor for stroke, although the data in 
menopausal women are not consistent. The 
existence of hypertension was shown to 
significantly increase the risk. 
• The increased risk for ischemic stroke in 
the WHI population was in the order of 1 
additional casel1000 women-years, which 
makes it by definition a rare event. However, 
the risk was not increased in the 50-59-year-
old age group, which is in keeping with data 
from recent observational trials in younger, 
normotensive cohorts. 
• Subanalyses of observational cohorts suggested 
the risk to be less with lower doses of estrogen, 
particularly when lower doses are prescribed 
soon after menopause. In addition, the risk is 
possibly even lower with non-oral therapy. 
• There is a body of evidence from basic science 
studies which reaffirms the neuronal and 
stroke-protective effects of estrogen. Thus, 
the discrepancy between these data and 
clinical data showing no bene fit or increased 
risk of stroke remains to be explained. 
• Data on progestogen use versus unopposed 
estrogen use have not been consistent. 
COAGULATION 
Venous thromboembolism safety 
• Venous thromboembolism (VTE) is one of the 
major adverse events during HT. The risk 
increases with age and body mass index, but is 
also particularly increased during the first 
years of therapy. 
• Oral estrogens reduce fibrinolysis. 
• Non-oral estrogens, by avoiding the hepatic 
first-pass effect, have minimal effect on coa-
gulation, and may be preferable for those at 
increased risk of VTE. 
• Specifie progestogens are capable of reducing 
the impact of oral estrogens on anticoagulant 
factors. 
• Population screening for thrombophilia is 
not indicated. Selective screening can be in-
dicated on the basis of personal and familial 
history. 
Arterial disease safety 
• HT induces both pro-inflammatory (liver 
biomarkers) and anti-inflammatory (vascular 
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biomarkers) effects. Modification of inflam-
mation in either direction can be good or bad 
for arterial disease depending upon the in-
dividual status of inflammation in the vascular 
wall. 
• The liver-derived pro-inflammatory effects of 
estrogen may be avoided by a non-oral route 
of administration. Using low doses of oral 
estrogen potentially decreases these changes, 
but the dose-response curve is close to the 
dose-response curve for efficacy. 
• Limitation of vascular anti-inflammatory ef-
fects is a target not yet achieved. Both oral and 
non-oral HT exhibit vascular-derived anti-
inflammatory actions, although possibly with 
different magnitude. 
• There is limited evidence that different pro-
gestogens modulate liver and vascular inflam-
matory effects. 
CENTRAL NERVOUS SYSTEM! 
PSYCHIATRY 
Cognition and cognitive aging 
• For younger women, observational evidence 
suggests no substantial cognitive sequelae 
from the natural menopausal transition; lim-
ited evidence from clinical trials suggests 
that HT has no substantial cognitive effect 
after natural menopause, at least in the short 
term. 
• For younger women, there is limited evidence 
from clinical trials that estrogen therapy may 
be of short-term cognitive benefit in the setting 
of surgical menopause. 
• For older women, HT started in the late 
postmenopause probably does not have a 
substantial impact on cognitive abilities. 
• The long-term cognitive consequences of 
HT initiated during the menopausal transi-
tion or early postmenopause are unknown. 
The need for further research in this area is 
urgent. 
Alzheimer's disease and other 
neurological disorders 
• During development and adulthood, the hu-
man brain is a target for estrogen and other 
steroid hormones. Estrogen influences neural 
function and neurological disease directly, 
through effects on neurons and glia, and 
indirectly, through effects on the cerebral 
vasculature and immune system. 
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• With menopause, the cessation of ovarian 
estrogen production and the initiation of HT 
have the potential to influence processes in the 
central nervous system relevant to a variety of 
neurological disorders. 
• For women with Alzheimer's disease (AD), 
limited evidence from clinical trials indicates 
that HT does not improve symptoms or slow 
disease progression. 
• There is limited evidence from clinical trials 
that HT increases dementia risk when initiated 
after the age of 64. 
• Observational evidence implies that HT used 
by younger women around the time of 
menopause is associated with lower risk of 
AD. However, findings may be biased, and 
further research is needed to determine 
whether there might exist an early window 
during which the effects of HT on AD risk are 
beneficial rather than harmful. 
• Potential effects of HT on the incidence or 
symptoms of Parkinson's disease are largely 
unknown. 
• Based on evidence from a single clinical trial, 
combined HT may increase seizure frequency 
in postmenopausal women with epilepsy. 
Estrogen: effects on normal brain 
function, and neuropsychiatric disorders 
• Many women complain of memory and 
other cognitive/emotional difficulties at times 
that are associated with changes in estrogen 
levels. 
• However, the biological mechanisms through 
which estrogen may exert these effects remain 
poorly understood. Also, the effect of estrogen 
treatment on cognition and brain function in 
healthy women and those with Alzheimer's 
disease is controversial. 
• There is evidence that, in healthy women, 
estrogen affects the dopaminergic, serotoniner-
gic and cholinergic systems, and brain regions 
crucial to higher cognitive function and mood. 
• New results from recent in vivo randomized, 
controlled neuroimaging experiments demon-
strate that, in young females and those in mid-
life: 
o brain function is modulated by normal 
variation in ovarian function; 
o acute loss of ovarian hormones increases 
neuronal membrane breakdown; 
o acute suppression of ovarian function is 
associated with reduced activation of brain 
regions critical to memory. 
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ONCOLOGY 
Breast cancer prevention 
• The lobular breast attains its maximum devel-
opme nt during pregnancy and lactation 
(Lob. 4). After menopause, mammary lobules 
in both nulliparous and parous women regress 
to structures designated Lob. 1. 
• Undifferentiated lobules (Lob. 1) in the breast 
of nulliparous women retain a high concen-
tration of epithelial cells (Stem ce Ils 1) that are 
targets for carcinogens and therefore suscep-
tible to undergo neoplastic transformation. 
• Early first full-term pregnancy imprints in the 
breast epithelial cells a genomic signature 
(Stem ce Ils 2), making them refractory to 
transformation. 
• The Stem cell 2 con tains specific genes control-
ling transcription, RNA processing, immune 
response, apoptosis, DNA repair and DNA 
recombination. Their coded proteins may serve 
as biomarkers for breast cancer protection. 
• Clinical studies are under way to induce in the 
human breast a genomic signature of Stem cell 
2 and thereby confer cancer protection. This 
concept may pave the way to long-term 
oncological prevention. 
Hormone therapy and breast cancer 
• Estrogen associated with breast cancer devel-
opme nt is not circulating estrogen but rather 
that produced locally within the breast. 
• Excessive formation of catechol estrogen 
quinones initia tes a series of events leading 
to breast cancer, by reacting with DNA. 
Endogenous estrogen is detrimental primarily 
in those women with genetic susceptibility. 
• The WHI study demonstrated that 7.1 years of 
treatment with estrogen only did not increase 
the risk of breast cancer in hysterectomized 
women. The prospective cohort in the Nurses' 
Health Study also reported that unopposed 
estrogen did not increase the risk of breast 
cancer until after 15 years of estrogen exposure. 
• Data from the estrogen plus progestogen arm 
of the WHI showed an increase in breast 
cancer risk at an average follow-up of 5.6 
years. However, women who had not used HT 
prior to the study were not at a higher risk for 
breast cancer for up to 7 years after initiation 
of therapy. 
• Micronized progesterone or dydrogesterone 
used in association with oral or percutaneous 
Climacteric 
estradiol may be associated with no increase in 
risk or lower risk than use of synthetic pro-
gestogens for at least 4 years, and perhaps even 
8 years, of treatment. 
• The risk of breast cancer decreases rapidly 
after cessation of HT; by 5 years, the risk may 
not be greater than that in women without any 
history of exposure. 
Endometrial safety, bleeding, hormone 
therapy and endometrium 
• Progestogen prevents the endometrial prolif-
eration of estrogen. 
• Continuous combined regimens are associated 
with a lower risk of endometrial cancer than in 
the untreated population. 
• New lower-dose regimens cause less endome-
trial stimulation and less bleeding. 
• Intrauterine delivery of progestogen is a 
suitable and logical route of administration. 
• The protective effect of progestogen on the 
endometrium has to be balanced against the 
apparent adverse effect on breast cancer risk. 
• Data on the effect of tibolone on the endome-
trium from randomized, controlled trials 
suggest a similar effect to continuous com-
bined regimens. 
NEW ATTITUDES TO SEXUALITY 
AND QUALITY OF LIFE IN THE 
MENOPAUSE 
Clinical evaluation/ diagnosis 
• A complex interplay of biological, psycholo-
gical and socio-relational factors determines 
women's sexual health. This may negatively 
affect the entire sexual response cycle, indu-
cing significant changes in desire, arousal, 
orgasm and satisfaction at menopause and 
beyond. 
• Both age and declining sex hormones have 
detrimental effects on sexual functioning, with 
a significant increase in vaginal dryness/dys-
pareunia and a significant decrease in desire 
and sexual responsiveness. 
• Desire difficulty is the most common sexual 
complaint experienced by women and the 
proportion of women with low desire increases 
with age. However, there are age-related 
changes in sexually related personal distress, 
which are especially evident in surgically meno-
pausai women. These women are at increased 
risk for hypoactive sexual desire disorder. 
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• Women may not be willing to initiate a 
conversation on sexual interest, behavior and 
activity themselves, but they usually appreciate 
being questioned by doctors. 
• Validated tools (self-administered question-
naires/daily diaries and event logs/semi-
structured interviews) may be used pro-
perly to diagnose sexual symptoms and to 
gain information on sexual constructs and 
relationships, while hormonal assays are pre-
sently not considered a standard of routine 
practice. 
• An accurate sexual history and a focused 
clinical evaluation may help clinicians in the 
management of sexual symptoms that are 
causing significant distress. Hormonal and 
non-hormonal treatments, and/or psycho-
sexual strategies should be individualized and 
tailored according to a woman's history and 
current needs. 
Meno1?ause and aging, quality of life and 
sexuality 
• Healthy status represents a major determinant 
of quality of life, particularly in elderly people, 
but sexuality is an important factor at ail ages 
as weil. 
• Sexuality is less often a problem for women 
than for men. 
• Hormonal changes which are associated with 
aging or menopause may deeply affect quality 
of life. 
• Therapeutic interventions such as hormonal or 
non-hormonal treatments, targeting selected 
diseases or components of the aging process, 
may improve quality of life and sexuality in 
both sexes. 
NEW HORMONAL THERAPIES AND 
REGIMENS 
Regulatory authorities' statements 
• Regulatory Authorities are constituted in the 
interests of Public Health and not the indivi-
dual patient. 
• The composition of the committees is of 
paramount importance in determining out-
come. 
• Publications since 2003 have not impacted 
much on either Recommendations or informa-
tion published. 
• Further review by an independent organization 
is to be recommended. 
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New products and regimens since 2003 
• New products are being developed which 
maintain benefits and minimize risks. How-
ever, some use fuI products have been with-
drawn by ph arma companies through 
profita bil it y decisions. 
• New ultra-Iow-dose oral preparations appear 
to maintain benefits for symptom relief and 
osteoporosis whilst minimizing side-effects 
and risks. 
• New progestogens can minimize progestogenic 
side-effects through anti-androgenic and anti-
mineralocorticoid effects, e.g. drospirenone. 
• Endometrial protection may not be needed 
with the ultra-Iow-dose transdermal system 
(1411g/day). 
• A new female androgen patch will be licensed 
for treatment of female androgen deficiency 
causing di stress (hypoactive sexual desire 
disorder). 
• A non-hormonal option, selective noradrena-
line reuptake inhibitor, for vasomotor symp-
tom management is currently in development 
in phase III clinical trials. 
• A SERMlestrogen therapy combination is in 
phase III clinical trials and showing encoura-
ging data for efficacy/risks. 
Route of administration and timing of 
initiation 
• Non-oral estradiol and progestogens circum-
vent the first-pass metabolism and therefore 
have the potential for a lesser stimulation of 
the Iiver proteins and a relevant neutral 
metabolic profile, which might be more favor-
able in terms of cardiovascular and venous 
thromboembolism risk. 
• The risk of venous thromboembolism has 
been shown to dîffer significantly when trans-
dermal estradiol was compared with oral 
estradiol. However, whether this is related to 
a differential impact of estradiol on clotting 
factors synthesized in the liver has not been 
confirmed. 
• It is assumed that lower circulating levels of 
progestogens will have less negative impact on 
breast cancer risk, if any. 
• First uterine pass of vaginal delivery of 
progestogens leads to adequate local concen-
trations and good endometrial protection, but 
with very low systemic progestogen levels. 
• Combination of non-oral administration of 
estradiol and direct intrauterine delivery 
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of progestogen may improve compliance 
and minimize the risks of hormone replace-
ment. However, long-term, good-quality stu-
dies to confirm this hypothesis are still needed. 
• Further analysis of randomized, controlled and 
prospective studies indicates that early admin-
istration of hormone therapy in younger 
postmenopausal women can afford protection 
against cardiovascular disease, while initiation 
of therapy at an older age, after 10 years 
without endogenous estrogen, is harmful. 
Androgens 
• Androgen production is usually preserved in 
the menopause, and therefore, postmenopau-
sai women usually do not suffer from andro-
gen deficiency and do not require routine 
androgen replacement. 
• The definition of female androgen deficiency is 
not precise enough and may lead to over-
diagnosis. 
• Androgen replacement in healthy postmeno-
pausaI women has shown no beneficial effect 
in published trials and currently cannot be 
recommended. 
• Androgen replacement should be reserved for 
women with severe androgen deficiency due to 
an established cause and matching c1inical 
signs and symptoms. 
• Randomized, controlled trials on androgen 
replacement in women with bilateral ooph-
orectomy or adrenal failure have shown 
significant beneficial effects, in particular on 
health-related quality of life and sexual func-
tion, which were impaired at baseline in the 
participating cohorts. 
Non-estrogenic approaches to the 
management of menopausal symptoms 
• Lifestyle and diet modifications may improve 
both hot flushes and mood. Regular exercise, 
weight reduction, avoiding too much caffeine 
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and cessation of smoking appear to improve 
hot flushes. Relaxation techniques, meditation, 
and pace respiration may help too, although 
there is relatively very Iittle support for that 
effect from good c1inical trials. 
• Plant-derived compounds (i.e. isoflavones, 
evening primrose, black cohosh and ginseng) 
are very popular as remedies for vasomotor 
symptoms, sleep disturbances and bad 
mood. Although sorne studies found those 
products to be helpful, the magnitude of the 
effect - when present - is small and not 
much greater than that of placebo. 
• The most tested pharmacological alternatives 
to estrogens are serotonin reuptake inhibitors 
(SSRI). At their best, SSRIs reduce hot flushes 
by 50-60% and their effect appears only 
short-term. The more positive results were 
seen in breast cancer survivors, whereas the 
chance for negative results was greater in 
healthy women. SSRIs improve mood inde-
pendently of their effect on hot flushes. When 
used for the treatment of the c1imacteric 
syndrome, SSRIs do not adversely affect libido. 
Withdrawal symptoms may occur after long-
term usej thus, SSRIs should not be stopped 
abruptly. 
GENE FINGERPRINTING - ITS ROLE 
INHT 
• Genetic variability may be important in 
determining efficacy of therapy as weil 
as susceptibility for adverse events. Clinical 
implications of genomic medicine have 
been investigated also in menopause medicine. 
• Enzyme activity may depend on single nucleo-
tide polymorphism. This was demonstrated in 
regard to steroid synthesizing enzymes and 
estrogen metabolizing enzymes (i.e. strains of 
the cytochrome P system). 
• Factor 5 and factor 2 polymorphisms are 
recognized as strong risk predictors for throm-
bosis in hormone users. 
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